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ABSTRACT
Age-related alterations in each component of the circadian system are well 
documented but the way these alterations translate into the observed changes in 
circadian rhythmicity and whether they contribute to the sleep problems reported by 
elderly are still not known. Therefore, one of the aims of this thesis was to examine 
the differences in spectral sensitivity between young and elderly people. In addition, 
studying the differences in spectral sensitivity between elderly with and elderly 
without sleep problems aimed to investigate whether these changes contribute to 
reported sleep problems. Adapting and evaluating the protocol used in this study 
aimed to investigate differences in spectral sensitivity between patients suffering 
from type 1 diabetes mellitus. Further aims of this thesis were to investigate age- 
related changes in the amplitude and timing of the melatonin rhythm and the 
relationship of these parameters to sleep in the elderly. In addition the phase 
relationship between melatonin and sleep in the elderly was assessed in order to 
study their contribution to the sleep disturbances reported. A final aim was to 
investigate the effectiveness of exogenous melatonin administration compared with 
placebo on sleep in elderly women with self-reported sleep problems.
2
Following exposure to short wavelength light (Xmax 456: 3.8 and 9.8 pW/cm for 30 
mins), a significantly reduced melatonin response was noted in elderly compared to 
young women. By contrast no age-dependent difference in the degree of melatonin 
suppression was seen following exposure to medium wavelength light (Xmax 548 nm: 
28 and 62 jiW/cm2). The response to short and medium wavelength light did not 
differ between elderly women with and without sleep problems. The protocol used in 
this study was adapted and evaluated for use with young type 1 diabetic patients in 
order to investigate the effectiveness of short wavelength light to suppress nocturnal 
melatonin in these subjects.
Significantly reduced urinary 6-sulphatoxymelatonin (aMT6s) production (pg/24 h) 
and an advance in the timing of the urinary aMT6s rhythm and plasma dim light 
melatonin onset (DLMO) were noted in elderly compared to young women.
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However, no difference was seen in these parameters between elderly women with 
and those without self-reported sleep problems. Overall, no relationship was found 
between the melatonin parameters and subjectively and objectively assessed sleep. 
However, some differences in the timing of the melatonin rhythm compared to the 
sleep rhythms were observed. The time interval between DLMO and sleep onset 
was significantly longer in the elderly women with sleep problems. The time interval 
between the peak of the aMT6s rhythm and sleep offset was reduced (but not 
significantly, p=0.08) in women with sleep problems. Finally, exogenous melatonin 
(5 mg) taken 30 mins before bedtime for 4 weeks failed to improve subjectively and 
actigraphically assessed sleep, compared to placebo in 11 postmenopausal women 
with self-reported sleep problems.
For the first time an age-related reduction in sensitivity to short wavelength light has 
been demonstrated, probably due to age-related changes in lens density. However, 
the findings suggest that it is unlikely that this reduced response contributes in a 
major way to the sleep problems of otherwise healthy and mobile elderly women. 
Neither the amplitude nor the timing alterations observed in the melatonin rhythm in 
the elderly seem to associate with the reported sleep disturbances. However, 
alterations in the phase relationship between melatonin and sleep timing may 
underlie some of the sleep problems. Better understanding of the cause of the sleep 
problem may aid in finding a therapeutic agent that improves sleep quality in the 
elderly, since melatonin administration failed to improve sleep in most of the studied 
subjects.
® Mirela Herljevic 
2007
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Chapter 1
  2
1.0 INTRODUCTION
In our world, which rotates around its axis and revolves around the sun, light and 
temperature change daily and over the course of the year. Evolution is exceedingly 
advanced, such that even the lowest creatures anticipate the daily changes in solar 
energy by scheduling many activities to occur at approximately 24-hour intervals.
One of the most predominant endogenous clocks, controls rhythmic biological 
outputs in phase with the light-dark cycle of the 24 h society we live in. These 
biological rhythms are known as circadian rhythms from the Latin "circa" about and 
"dies" day. The endogenous period of the circadian clock (tau - t ), when all the 
environmental time cues are removed, persists but varies slightly from 24 h, driving 
all the rhythms at the same period. Therefore, the circadian clock requires daily 
synchronization (entrainment) by environmental time stimuli (zeitgebers) 
(Pittendrigh, 1960; Aschoff, 1969). This means that resetting mechanisms of the 
circadian clock are constantly at work, in the presence of the external time clues, 
ensuring that circadian rhythms (e.g. core body temperature, activity, sleep - wake 
cycle, blood pressure, electrolyte levels, clock genes, melatonin, cortisol secretion) 
do not drift out of phase with the 24 h day. The most potent entraining zeitgeber of 
the circadian clock is light and its use to entrain is referred to as photoentrainment. 
In organisms where t  is longer than 24 h a daily advance is needed, whereas in 
organisms where t  is shorter than 24 h daily delay is required to ensure that the 
organism is entrained to the 24 h light-dark cycle (Section 1.2).
With ageing many aspects of the circadian outputs show changes (Section 1.3). 
Reduced amplitude in circadian functioning of arousal, body temperature, hormones 
and many other circadian variables is well documented in the literature (Reviewed in 
Van Someren, 2000). Changes in several other aspects of the circadian timing 
system, such as endogenous period, synchronization with the environment, rate of 
entrainment, sensitivity to environmental cues and phase relationship between 
different circadian rhythms (Reviewed in Dijk et al., 2000) have been studied. These 
changes may be due to the changes in the circadian system including the site of the
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main circadian pacemaker, the suprachiasmatic nuclei (SCN) of the hypothalamus 
(Section 1.3.2).
1.1 The Circadian System
The circadian system is comprised of input pathways (that transmit environmental 
information and endogenous feedback information to the circadian clock), the clock 
itself which generates circadian oscillations and output pathways that transmit the 
circadian signal to the rest of the organism.
1.1.1 Input Pathways
1.1.1.1 The Eye
The eye is an organ specialized in the detection, localization and analysis of visible 
(400 -  700 nm) wavelengths of light. Light is electromagnetic radiation usually 
described as a wave of energy. Only a small part of the electromagnetic spectrum is 
detected by our visual system (400 -  700 nm).
The light enters the eye through the cornea, a transparent external surface. Once 
past the cornea, the light enters the aqueous humour passing through its fluid. The 
cornea lacks blood vessels and is nourished from the outside by tears and by the 
aqueous humour from the inside (Reviewed in Bonnel et al., 2003). Light is refracted 
before passing through the aqueous humour, the pupil and the lens, where it is 
further refracted towards the fovea of the retina. Before reaching the back of the 
retina light passes through the vitreous humour. The vitreous humour is more 
viscous than the aqueous humour and keeps the globe of the eye spherical 
(Reviewed in Bloemendal et al., 2004). The light is then focused onto the retina, the 
light sensitive layer of the eye, which contains light detecting cells called 
photoreceptors. The human cornea, aqueous humour and vitreous humour are clear 
tissues that transmit nearly 100% of visible wavelengths. The crystalline lens and 
macular pigment of the macula lutea located around the fovea region of the retina 
absorb light especially at the short wavelength end of the spectrum and reduce the 
amount of light reaching the retina (Reviewed in Asbell et al., 2005) (Fig. 1.1). The
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age-related changes in the size of the pupil and the characteristics of the lens 
influence the amount of light reaching the retina (Section 1.3.2.1).
Fig. 1.1 Anatomy of the eye.
Taken from Bear et al., 2001
Light is received in its least distorted form at the retinal fovea but other parts of the 
retina are also illuminated. On reaching the retina the light passes through the inner 
retinal membrane, ganglion cell layer, inner plexiform layer (containing synapses 
between ganglion, bipolar and amacrine cells), inner nuclear layer (containing 
bipolar and amacrine cells), outer plexiform layer (containing synapses of bipolar, 
horizontal and photoreceptor cells) and outer nuclear layer (containing rod and cone 
photoreceptors). The light that is not absorbed by the photoreceptors in the outer 
nuclear layer is absorbed by the retinal pigment epithelium. This means that light 
passes through the retinal membrane and 4 different cell layers before it reaches the 
photoreceptors. The light that passes through these layers is not absorbed due to 
the unmyelineted structure of the layers and their relatively transparent nature (Fig
foveo Ipoinr of 
central (ocusj
Moculn
V itreoui
humor
Ciliary rmiscie 
(control* the lens} Opsic
Retmo (rods nerve
eiiTrtl cones}
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Fig. 1.2 Ocular anatomy of the retina.
Taken from Foster, 2005
1.1.1.1.1 Visual Photoreception
The mammalian retina contains two types of photoreceptors that are responsible for 
image formation, namely the rods and cones. Both types are composed of three 
regions: synaptic terminals, inner region containing the cell body and an outer 
segment with membranous disks that contain photopigment. The photopigment is 
composed of an opsin protein molecule that absorbs light. The opsin protein is a 
membrane bound G -  protein coupled receptor with 7 transmembrane domains and 
a lysine residue needed for linkage of the retinoid chromophore. The structural 
difference between rods and cones is in the outer segment where rods have a 
longer outer region with many disks of photopigment whiles cones have a shorter 
outer region with few membranous disks. This structural difference between the two 
photoreceptors explains their functional difference. Cones are adapted to photopic 
(day time) conditions, permitting the perception of colour. Conversely, rods are 
sensitive to dim light, allowing night (scotopic) vision, with the input perceived only in
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gray tones. The concentration of cones is maximal at the fovea region of the retina, 
an area associated with the ability to visualize fine details. The density of the cones 
decreases rapidly from the fovea to the peripheral retina. The fovea does not 
contain any rods (Reviewed in Bonnel et al., 2003), which are the major component 
of the peripheral retina (Curcio et al., 1990).
There are three types of cones differing in the specific properties of the opsin protein 
to which the retinal chromophore is bound. They are divided according to the 
wavelength of light they absorb into blue cones (short wavelength absorbers; S -  
cones), green cones (medium wavelength absorbers; M-cones) and red cones (long 
wavelength absorbers; L-cones). With the difference in their absorption abilities they 
are responsible for our ability to see color.
When the light that passes through the retina reaches the outer region of the 
photoreceptors, the retinaldehyde chromophore absorbs a photon of light triggering 
phototransduction. The chromophore changes its form from the 11-cis isomer to the 
all-trans isomer by the process of photoisomerization. This change in the
chromophore results in the detachment of the chromophore from the opsin, resulting 
in opsin activation. Activated opsin enzymatically catalyzes activation of the G-
protein transducin. Transducin catalyses activation of the enzyme
phosphodiasterase (PDE), which in turn detaches cyclic guanosine monophosphate 
(cGMP) from the sodium channels hydrolyzing it to GMP. Once cGMP is detached 
from the sodium channels they close preventing Na+ entry causing hyperpolarization 
that prevents neurotransmitter glutamate release at the outer plexiform layer where 
photoreceptors and bipolar cells synapse (Reviewed in Bonnel et al., 2003). The 
photoreceptors do not generate action potentials but they generate graded potential 
that is transmitted to bipolar cells and from the bipolar cells to other retinal cells, 
which then generate an action potential. The all-trans retinal is converted back to the 
11-cls retinal chromophore during the dark in the pigmented epithelium of the retina 
(Bloemendal et al., 2004) requiring the isomerase enzyme and adenosine
triphosphate (ATP). When retinal is converted back to its 11-cis form it travels back 
from the pigmented epithelial region of the outer nuclear layer to the outer segment 
of the photoreceptor cells and rejoins to opsin (Bloemendal et al., 2004).
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Action potentials generated by the retinal ganglion cells propagate down the optic 
nerve via the optic chiasm where the optic nerves from the two eyes cross over to 
the opposite sides projecting further to synapse with neurons in the thalamus. Axons 
of the thalamic neurons then project to the primary visual cortex in the occipital 
lobes where perception of vision occurs.
1.1.1.1.2 Circadian Photoreception
The visual system encodes visual images of the environment whilst the circadian 
system is affected by alterations in the quantity (irradiance) and quality (spectral 
distribution) of environmental light. The fact that these two systems detect and 
process different information from the environment implies the existence of two 
different detection mechanisms and processing pathways.
Until recently only rod and cone photoreceptor cells of the retina were known to be 
directly light sensitive. When rodless coneless (rd/rd cl) mice which lacked any 
cones and rods together with the outer and most of the inner nuclear layer of the 
retina were investigated, it was demonstrated that normal circadian responses, such 
as entrainment of circadian behavior (Freedman et al., 1999), suppression of pineal 
melatonin production (Lucas et al., 1999) and persistence of the pupillary light reflex 
(Lucas et al., 2001) were retained. Upon bilateral enucleation of these transgenic 
mice (Freedman et al., 1999) all circadian light responses were abolished. These 
findings suggested the presence of a novel photoreceptor involved in the circadian 
response to light but distinct from photoreceptors involved in visual photoreception. 
The fact that circadian responses were maintained upon removal of the whole outer 
and most of the inner nuclear layer of the retina suggested that the circadian 
photoreceptors are likely to be located in the ganglion cell layer. These animal data 
are also supported by studies done on visually blind humans. Czeisler et al. (1995) 
has shown that some visually blind people with no light perception are able to 
entrain to 24 h environment and display nocturnal melatonin suppression by light.
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1.1.1.1.2.1 Melanopsin
Recently, melanopsin has been identified as a functionally sensitive photopigment in 
the retinal ganglion cell photoreceptors (Mclyan et al., 2005, Panda et al., 2005, Qiu 
et al., 2005). When non-photosensitive cells are transfected with the human or 
mouse melanopsin genes, they become light sensitive (Mclyan et al., 2005, Panda 
et al., 2005, Qiu et al., 2005). These studies also showed that specific forms of 
retinaldehyde (especially 11-cis-retinaldehyde) are required indicating that 
melanopsin acts as a photopigment. Data on melanopsin absorption spectra 
revealed that the peak sensitivity of the melanopsin-transfected cells is 479 nm 
where the mouse melanopsin gene was transfected into human kidney cells (Qiu et 
al., 2005) and 480 nm where the gene was transfected into Xenopus oocytes 
(Panda et al., 2005). These two recent studies identified peak sensitivities of 
melanopsin which are very similar to the results from recent action spectra of 
different circadian responses in both humans A,max 459 -  464 nm (Brainard et al., 
2001; Thapan et a., 2001) and animals ^max481 and 498 nm (Lucas et al., 2001; 
Hattar et al., 2003). However, Mclyan et al. (2005) suggests the peak sensitivity of 
melanopsin is closer to 420 -  430 nm. The differences in the peak sensitivity of 
melanopsin between Mclyan et al. (2005) and Panda et al./Qiu et al. (2005) studies 
were proposed to be related to the immediate environment of the expressed 
photopigment, such as pH conditions and differences in the mouse (Panda et al., 
2005; Qui et al., 2005) and human (Mclyan et al., 2005) melanopsin used. Future 
studies are needed to resolve this discrepancy.
First isolated from frog melanophores (Provencio et al., 1998) melanopsin is an 
atypical vertebrate opsin found in the cell bodies, dendrites and axons of retinal 
ganglionic cells. Melanopsin shares structural similarities with all known opsins, 
including 7 transmembrane domains and an a lysine residue for binding the retinoid 
chromophore. However, melanopsin has a greater sequence homology to 
invertebrate opsins than vertebrate opsins (Provencio et al., 2000). Invertebrate 
opsins have a different mechanism for photopigment regeneration. The 
retinaldehyde chromophore all trans state, after the light pulse, remains in that form 
to reisomerise to 11-cis by a second wavelength of light. Therefore melanopsin does
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not require chromophore regenerating tissue as rods and cones do. Mclyan et al. 
(2005) and Panda et al. (2005) also showed some evidence that melanopsin 
exhibits bistability with the ability to bind alternately to 11-cis and all-trans- 
retinaldehyde, and to act as both a sensory pigment and an isomerase for 
photopigment regeneration. However, the mechanism of how melanopsin initiates a 
phototransduction cascade is still not clear. Some of the evidence suggests that light 
ultimately triggers the release of calcium ions inside the ganglion cells (Mclyan et al., 
2005; Panda et al., 2005; Qiu et al., 2005).
Dacey et al. (2005) have examined the photosensitivity of melanopsin expressing 
ganglion cells and showed that the peak spectral sensitivity of these cells was near 
480 nm. They also showed that the short wavelength detecting cones attenuate the 
light responses of melanopsin expressing ganglion cells, whereas the rods and 
medium and long wavelength detecting cones provide an excitatory input (Dacey et 
al., 2005). They also show that melanopsin containing ganglion cells project to the 
lateral geniculate nuclei, the brain structure that relays image forming information to 
the visual cortex, supporting the idea that the non-image forming system also 
contributes to aspects of visual perception and vice versa.
Melanopsin is distributed in the inner retina, more precisely in the subset of 
amacrine and ganglion cells (Provencio et al., 2000). The retinal ganglion cells that 
contain melanopsin are known as type III cells that project and make up retinal 
hypothalamic tract (RHT) innervating the SCN. Berson et al. (2002) demonstrated 
that these cells are photosensitive to stimuli over a prorogated light stimuli that 
matches to a light response required for circadian entrainment. No response was 
noted to brief stimuli (Berson et al., 2002).
However, the evidence indicates that melanopsin on its own does not control all of 
the circadian responses (Fig. 1.3). Melanopsin knock out mice (Opn4 -/-) exhibit 
attenuated phase shifting (Panda et al., 2002; Ruby et al., 2002) and diminished 
pupillary responses to bright light (Lucas et al., 2003). However, in mice lacking 
rods, cones and melanopsin, all major non-image forming visual capabilities are lost
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Light
Fig. 1.3 The rods (R) and cones (C) convey visual information to the ganglion cells (G) 
through the bipolar cells (B). Horizontal cells (H) allow lateral connections between rods and 
cones. Amacrine cells (A) allow lateral connections between bipolar and ganglion cells. The 
optic nerve is formed from the axons of all the ganglion cells. A subset of ganglion cells (MG 
cells) also detects light directly (Berson et al., 2002); for this, they require the photopigment 
melanopsin, as now confirmed (Panda et al., 2003; Qiu et al., 2005).
Adapter from Foster, 2005
(Panda et al., 2003; Hattar et al., 2003). Therefore, the current evidence suggests 
that melanopsin and the rods and cones can fully account for all circadian light 
responses.
1.1.1.2 Retinohypothalamic Tract -  RHT
Anatomically and functionally distinct from the optic nerve is the monosynaptic 
pathway called the retinohypothalamic tract that convey non-image forming 
information directly to the SCN. The RHT is essential for maintaining entrainment as 
destruction of all visual pathways beyond the RHT does not affect stable 
entrainment (Klein and Moore, 1979), whereas destruction of the RHT abolishes 
entrainment (Johnson et al., 1988). The RHT originates in the retina, specifically as 
a small set of type III retinal ganglion cells that are distributed across the entire
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retina with slightly more cells on the periphery of the retina (Pickard, 1980). Their 
wide distribution and large receptive field allow the RHT to transduce photic 
information about environmental irradiance from a large area of the retina mainly to 
the core of the SCN (Moore et al., 1995). The RHT also projects to other regions of 
the brain, such as the lateral hypothalamic area, the anterior hypothalamic area and 
the retrochiasmatic area (Johnson et al., 1988). The retinal ganglionic cells 
projecting to the SCN also project to the intergeniculate leaflet (IGL) of the thalamus, 
pretectal area (PTA), subparaventricular zone (SPZ) and ventrolateral preoptic 
nucleus of the hypothalamus (Pickard, 1985) (Fig. 1.4).
There is accumulating evidence that glutamate is a neurotransmitter of the RHT. In 
addition to glutamate, RHT terminals also release two peptide co-transmitters, 
substance P and pituitary adenyl cyclase-activating peptide (PACAP) (Reviewed in 
Ebling, 1996).
Eye
Light
- >  VLPO
t
- >  vSPZ
t
>  SCN
t G
PTA “FT
t T
IGL -----
Sleep/wake state
Circadian regulation of 
sleep and locomotor activity 
Circadian rhythms
Pupilary light reflex >
Photic and non-photic
regulation of SCN
>
Fig. 1.4 Input pathways from the retinal ganglionic cells (RGCs) to different regions of the 
brain.
Adapted from Moore, 1993
VLPO-ventro lateral preoptic nucleus; vSPZ-subparaventricular zone; SCN-suprachiasmatic 
nucleus; PTA-pretectal area; IGL-intergeniculated leaflet; GHT-geniculohypothalamic tract
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1.1.1.3 The Intergeniculate Leaflet (IGL) -  Geniculohypothalamic Tract (GHT)
The IGL is characterized by a population of neuropeptide Y (NPY) neurons, 
coexisting with GABA (y-Aminobutyric acid) containing neurons that project to the 
SCN core and a population of enkephalin-containing neurons that project to the 
contralateral IGL (Card and Moore, 1989). Lesions of the IGL in animals alter the 
period of locomotor activity under constant light conditions (Pickard, 1989) but the 
animals are able to entrain to a light-dark cycle suggesting that the IGL plays a 
modulatory, rather than principal role in the regulation of photic entrainment and 
rhythm generation.
The geniculohypothalamic tract (GHT) is a neuronal projection from the IGL to the 
SCN. The IGL also receives input from the SCN (Moore and Card, 1994). The 
integrity of the GHT is not necessary for photic entrainment of circadian rhythms 
(Pickard et al., 1987) although lesions of the GHT cause changes in circadian 
rhythmicity by slowing the rate of entrainment after a phase shift, reducing the 
magnitude of phase advance and reducing the free-running period (t) under 
constant light conditions (Johnson et al., 1989).
1.1.1.4 Other Afferent Inputs to the SCN
Another major afferent system that innervates the SCN core and IGL originates from 
the serotonergic midbrain raphe nucleus (Meyer-Bernstein et al., 1996). Extensive 
research has implicated serotonergic projections to the SCN and IGL to have two 
different functions. Nocturnal modulation of photic effect on the SCN was shown by 
administration of a 5-HT agonist leading to activation of the raphe nuclei and 
subsequent attenuation of the photic effect on the SCN (Moga and Moore, 1997). 
The second function of serotonergic projections is mediation of non-photic effects on 
the SCN during the subjective day (Rea and Pickard, 2000). Arousal, wakefulness 
and motor activity are associated with increased serotonin release, which in turn 
acts on the SCN and causes phase shift-like effects (Reviewed in Turek et al., 
2001).
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There are several other less characterized afferent pathways projecting to the SCN 
shell, acetylcholine (ACh) containing neurons from the basal forebrain (BF) and 
pons, medullary (locus coeruleus) noradrenergic (NA) and histamine (HA) 
containing projections from the posterior hypothalamus (Moga and Moore, 1997). 
The function these pathways are not understood.
1.1.2 The SCN
Today, it is known that circadian clocks control physiology at many levels from gene 
expression to complex behaviors such as sleep, activity and performance. The 
central oscillator function of the SCN has been established by lesion and transplant 
studies (Moore and Eichler, 1972; Ralph and Lehman, 1991). These experiments 
have demonstrated that the SCN is essential for circadian regulation. SCN-lesioned 
animals lose their circadian rhythmicity and become arrhythmic (Moore and Eichler, 
1972) while transplantation of the wild-type SCN restores circadian rhythms with the 
period length of the donor animal (Ralph and Lehman, 1991).
Overall, the gross anatomical structure and major neuronal projections from the 
SCN are conserved from rodents to humans, implying conservation of the 
neuroendocrine and anatomical control of rhythms by the SCN across species 
(Reviewed in Panda and Hogenesch, 2004).
The SCN is a paired nucleus, located adjacent to the third ventricle and on top of the 
optic chiasm in the anterior hypothalamus. Each nucleus contains about 10 000 
tightly packed neurons (Reviewed in Van Esseveldt et al., 2000). Based on 
morphological differences, the SCN can be divided into shell and core areas, 
suggesting that the two parts may play different roles in the generation and 
regulation of circadian rhythmicity. The shell is characterized by small-elongated 
neurons containing large nuclei and few cell organelles (Leak et al., 1999). The core 
has spherical neurons, which have organelle rich cytoplasm (Leak et al., 1999). 
Individual neurons show different circadian periods when isolated in vitro (Bos et al., 
1990). The mechanism for communication between neurons within one SCN 
nucleus and between the paired nuclei, enabling synchronization, is still unclear.
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Therefore, the circadian clock is composed of many oscillators, which upon 
removal of all time cues free-run at the mean time period of all of the clock cells in 
the SCN (Liu et al., 1997a). Morphological studies failed to show neuronal gap 
junctions in the SCN (Van den Pol et al., 1980), instead complex synaptic 
arrangements have been found suggesting so called ephaptic interaction 
(generation of electrical field) between the neuronal cells of the SCN.
The difference between the shell and the core of the SCN is also evident in their 
neuropeptide contents. In the rat, most of the neurons in the shell synthesize 
vasopressin (VP), whereas neurons in the core of the SCN synthesize vasoactive 
intestinal polypeptide (VIP), peptide histidine isoleucine (PHI) and gastrin releasing 
peptide (GRP) (Card et al., 1981). GABA is present in most, if not all, SCN neurons 
(Moore and Speh, 1993) (Fig. 1.5).
Hypothalamus, Thalamus,
Pons, BF (ACh) 
s ’  Medulla (NE)
L  S ' Post. Hyp. (HA)
BF
GABA 
■ VP^
GABA
VP
GABA
VIP
GRP
GABA
VIP
GRP
IGL (GABA)
Raphe (5-HT)
Retina (Glu, SP,PACAP)
Fig. 1.5 Input and output pathways to and from the SCN core (light gray) and SCN shell 
(dark gray) with major neurotransmitters (GABA, VP, VIP, GRP) located in these regions. 
Adapted from Moore, 1993
BF-basal forebrain; Ach-acetylcholine; NE-noradrenaline; Post. Hyp.-posterior hypothalamus; 
HA-histamine; GABA-y-aminobutyric acid; VP-vasopressin; VIP-vasoactive intestinal 
polypeptide; GRP-gastrin releasing peptide; 5-HT-serotonin; Glu-glutamate; SP-substance 
P; PACAP-pituitary adenyl cyclase-activating peptide; IGL-intergeniculated leaflet
Chapter 1
-------------- 15
The circadian oscillation that is generated in the SCN is imposed on many 
physiological functions, including body temperature, activity, performance, alertness, 
sleep, oxygen utilization, water and food intake, adrenal corticosterone production 
and pineal melatonin synthesis. These functions are controlled by efferent 
projections of the SCN.
1.1.3 Output Efferent Pathways from the SCN
Most of the efferent projections of the SCN travel very short distances, usually 
terminating within the SCN itself or along the middle of the hypothalamus (Moore, 
1983). The SCN sends dorsal projections to the thalamic paraventricular nucleus 
(PVT) and paraneial thalamic nucleus (Watts and Swanson, 1987). Many neurons in 
this region contain factors that regulate secretion of several hormones, including 
prolactin, growth hormone (GH), adrenocorticotropic hormone (ACTH) and thyroid- 
stimulating hormone (TSH). Dorsal projections from the SCN also go to other 
hypothalamic regions such as the subparaventricular zone (vSPZ), paraventricular 
hypothalamic nucleus (PVH), dorsomedial hypothalamic nucleus (DMH), supraoptic 
nucleus and retrochiasmatic area (RCA). The SCN may influence the brain’s arousal 
system in the locus coeruleus via indirect projections through the DMH (Panda and 
Hogenesch, 2004). The SCN projects to limbic structures such as the lateral septum 
and the bed nucleus of the stria terminalis (BSTL), medial preoptic area (MPOA) 
and ventro lateral preoptic nucleus. Projections to the VLPO are important for sleep- 
wake regulation. The SCN also send a minor lateral projection to the IGL, olivary 
pretectal nucleus (OPT) and the central gray matter (Leak and Moore, 2001). The 
projections of the SCN core and shell partially overlap, but it is known that both 
subdivisions project strongly to the SPZ and thalamic nuclei.
Efferents from the shell project more strongly to the MPOA, DMH and BSTL, while 
the SCN core projects more to other hypothalamic areas (Leak and Moore, 2001) 
(Fig. 1.6). These SCN targets influence the endocrine and autonomic systems 
directly or through multisynaptic connections.
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DMH
PVH
vSPZ
OPT
PVT
IGL
Septum
BSLT ^  RCA
SCN
MPOA
VLPO
Fig. 1.6 Output pathways from the SCN to different regions of the brain.
Adapted from Moore, 1993
VLPO- ventro lateral preoptic nucleus; MPOA-medial preoptic area; BSTL-stria terminalis; 
PVT-thalamic paraventricular nucleus; vSPZ-subparaventricular zone; PVH-paraventricular 
hypothalamic nucleus; DMH-dorsomedial hypothalamic nucleus; OPT-olivary pretectal 
nucleus; IGL-intergeniculated leaflet; RCA-retrochiasmatic area
1.1.4 The Pineal Gland
The pineal gland is a small neuroendocrine gland that produces the hormone 
melatonin. The gland is derived from the neural tube and is located at the border 
between the mesencephalon and diencephalon of the brain. Neuroanatomically, the 
pineal gland is described as a part of the epithalamus and therefore as a part of the 
diencephalon. The pineal gland is composed of five cell types: the interstitial cell, 
paravascular phagocytes, neurons, peptidergic neuron like cells and pinealocytes, 
which produce the hormone melatonin.
SCN regulation of pineal melatonin release is mediated via a complex polysynaptic 
circuit in which SCN efferent neurons connect to the PVN of the hypothalamus with 
GABA as a main neurotransmitter (Kalsbeek et al., 1999). From the PVN 
glutaminergic neurons project to the sympathetic preganglionic neurons of the 
intermediolateral cell column (IML) in the upper thoracic spinal cord (UTC). The IML 
sends a cholinergic projection to the superior cervical ganglion (SCG), which by via 
noradrenergic projections innervate the pineal gland (Fig. 1.7a). The SCG 
projections release noradrenaline into the paravascular space near the pinealocytes 
(Reviewed in Kalsbeek et al., 2006)(Fig. 1.7b).
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The SCN is most active during the day inhibiting activation of PVN neurons, likely 
via GABAergic inhibition of the firing rate in the rest of the pathway thus inhibiting 
melatonin synthesis (Kalsbeek et al., 2000). Consequently, melatonin is produced 
during the night when SCN activity is low. Nocturnal melatonin production is a 
common feature for both nocturnal and diurnal animals. Exposure to light during the 
night activates SCN neurons resulting in inhibition of melatonin synthesis and 
melatonin levels start to decline until the light stimuli is removed.
1.2 Circadian Rhythms
Circadian rhythms in melatonin, cortisol, core body temperature (CBT) and circadian 
behaviors such as alertness and performance, in normal conditions have a 
characteristic time of peak and nadir and there is a set time interval (phase 
relationship) between different rhythms (Reviewed in Arendt, 2003) (Fig. 1.8).
The peak in the melatonin rhythm and the low point of the temperature rhythm are 
within 1-2 h of each other. The low point of the alertness and performance rhythms 
is shortly after the melatonin peak and the peak in triacylglycerol is close to the 
melatonin peak (Reviewed in Skene and Arendt, 2006).
Light is the most potent entraining zeitgeber (time cue) of the human circadian 
system, responsible for synchronization of the SCN clock to the 24h day. Exposure 
to changes in the light-dark cycle can reset the timing of the circadian pacemaker 
and therefore the rhythms of melatonin production and core body temperature and 
the timing of the sleep-wake cycle.
In the late 1950s, it was first demonstrated that a single light pulse could reset 
circadian phase (Bruce and Pittendrigh, 1956) and that the magnitude and direction 
of these phase shifts were dependent on the intensity and the duration of the light 
exposure (dose response curve - DRC) as well as on the circadian phase of the light 
exposure (Hastings and Sweeney, 1960). Since then, circadian phase response 
curves (PRC) to light have been described in nearly every eucaryotic organism 
studied (Reviewed in Johnson, 1999).
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The resetting response to light described by the PRC has been found to share 
three main properties across many species (Reviewed in Johnson, 1999): (a) light 
stimuli early in the subjective night induce phase delay shifts, (b) light stimuli late in 
the subjective night induce phase advance shifts, (c) light stimuli during the 
subjective day induce minimal phase shifts. Thus, it is possible to use appropriately 
timed light to phase shift (reset) the human circadian system.
Phase shifting experiments have become a primary tool for the analysis of the 
kinetics of circadian oscillators with over 300 measured PRCs to light in a number of 
organisms collected in a “PRC atlas” (Reviewed in Johnson, 1999). Constructing 
PRCs to light is very important for circadian biology because it reveals the 
mechanisms by which pacemaker driven circadian rhythms are synchronized to the 
24-h day.
The first PRC to a single pulse of light in humans was constructed using CBT as the 
circadian marker (Minors et al., 1991). Light given before the CBT minimum 
produced a phase delay, while light administered after the CBT minimum gave a 
phase advance showing that the human PRC to light does not differ from that of 
other species. The most reliable PRC using a single light pulse was constructed 
under strict conditions where all exogenous factors that may cause masking effects 
were controlled (Khalsa et al., 2003).
Recent research has demonstrated that the ability of light to cause a phase shift is 
wavelength dependent. Short wavelength light (470 nm) has been shown to be 
strongest in phase advancing (Warman et al., 2003; Revell et al., 2005) and phase 
delaying (Lockley et al., 2003) the circadian rhythms of melatonin.
1.2.1 Melatoriin
Melatonin (N-acetyl-5-methoxytryptamine) is produced rhythmically by the 
pinealocytes with very high levels during the night and very low levels during the day 
in both nocturnal and diurnal species (Reviewed in Menaker et al., 1997). Levels of
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melatonin during the night increase between 7-150-fold compared to daytime 
levels. Plasma melatonin levels in normally entrained humans peak between 02:00- 
04:00 h and become barely detectable again by about 11:00 h. Due to these 
characteristics melatonin rhythm can be used to measure the phase of the circadian 
system. Melatonin is a highly lipophilic molecule, as well as having some hydrophilic 
properties. Therefore upon synthesis it is released directly into capillaries where up 
to 70% is bound to albumin (Cardinali et al., 1972) ensuring rapid distribution. The 
half-life of melatonin in the blood after intravenous infusion is approximately 30 mins 
(Mallo et al., 1990), but a biphasic elimination pattern with a half-life of about 3.75 h 
has also been observed following oral administration (Reviewed in Arendt et al., 
1995).
Acting through its receptors, melatonin is involved in a number of physiological 
processes including not only circadian entrainment (Dubocovich et al., 1998) but 
also oncogenesis (Bordt et al., 2001) retinal physiology (Dubocovich et al., 1997), 
seasonal reproduction (Morgan and Mercer, 1994), ovarian physiology (Clemens et 
al., 2001) and induction of osteoblast differentiation (Roth et al., 1999). Wide 
distribution and different types of melatonin receptors (MTi, MT2 and MT3) can 
explain the diversity of melatonin’s role within the body and the inability to explain its 
function. However, the most commonly accepted function of melatonin is to 
transduce solar day-night information to the rest of the body (Reviewed in Arendt, 
1988). The duration of high levels of melatonin at night indicate the length of the 
dark phase, which is longer during the winter months as compared to the summer 
months (Arendt et al., 1985a).
The circadian rhythm of melatonin production is one of the most reliable markers of 
the circadian clock due to its ability to exhibit day-to-day and week-to-week 
reproducibility (Reviewed in Arendt, 1988). Usually, the dim light melatonin onset 
(DLMO) and peak (acrophase time) of melatonin are used as marker of the 
melatonin rhythm. Using these markers the integrity of the circadian system from the 
eye to the pineal gland can be assessed.
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Parameters of plasma melatonin, salivary melatonin and 6-sulphatoxymelatonin 
(aMT6s) profile (acrophase, duration, mid-range crossing, 25% rise and fall, onset 
and offset of secretion) are used to characterize the timing of the circadian clock 
(Fig. 1.9).
80 Duration
70
60
£^
 50
Acrophase (c aicufateci peak time)
s
1 40 $
|  30 
<a
I  20
iS
10
£5% rise/fall 
Onset/offset
0
150017001900 2100 2300 100 300 500 700 900 11001X015001700
Clock time (h)
i J
Fig. 1.9 Normal profile of plasma melatonin including the parameters of the rhythm.
Taken from Arendt and Skene, 2005
Usually aMT6s acrophase is approximately 1-2 h after the plasma melatonin 
acrophase. Sleep occurs 1-2 h after plasma melatonin onset and ends 1-2 h before 
melatonin offset (Reviewed in Skene and Arendt, 2006). There is very large inter 
individual variability in the amplitude of the melatonin rhythm with a small number of 
healthy individuals who have no detectable plasma melatonin rhythm at any time of 
day (Arendt et al., 1985a). These subjects have not displayed any major 
abnormalities adding to the difficulty of providing a function. Within an individual 
melatonin production is reasonably constant (Reviewed in Skene and Arendt, 2006).
Apart from being a marker of circadian phase, melatonin measurements are also 
used to assess the function of pineal gland in conditions such as pineal tumors
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(Reviewed in Skene and Arendt, 2006). Measurement of melatonin can also 
assess the integrity of eye-SCN-pineal gland polysynaptic pathway (Section 1.1.4).
1.2.1.1 Melatonin Synthesis and Degradation
The primary site for melatonin degradation is the liver where 6-hydroxylation of 
melatonin occurs followed by sulphate and glucuronide conjugation producing 
aMT6s, the major urinary melatonin metabolite in humans (Kopin et al., 1961). 
Melatonin is metabolized via a cytochrome P450 by CYP1A2 (Facciola et al., 2001; 
Skene et al., 2001). Therefore, drugs such as caffeine and nicotine, known to affect 
the activity of CYP1A2 and fluvoxamine, drug metabolized by CYP1A2 affect levels 
of melatonin by affecting the melatonin metabolism (Reviewed in Skene and Arendt, 
2006).
Measurement of aMT6s has been used as an indicator of circulating levels of 
plasma melatonin (Deacon and Arendt, 1994; Kennaway et al., 1999) because its 
urinary concentration accounts for up to 90% of administered melatonin (Reviewed 
in Arendt, 2003). A very close correlation is found between plasma melatonin levels 
and urinary aMT6s with the peak levels of aMT6s being delayed by one to two hours 
and the morning decline by three to four hours compared to plasma melatonin 
(Reviewed in Arendt, 1988). Liver and kidney pathologies (e.g. cirrhosis and chronic 
renal failure) are known to alter clearance rate and in these cases aMT6s levels may 
not correlate with melatonin plasma levels (Lane and Moss, 1985). Melatonin can 
also be measured in saliva and cerebrospinal fluid (CSF) (Rollag et al., 1977). In the 
CSF concentration of melatonin is much higher than in blood plasma (Rousseau et 
al., 1999). In the anterior chamber of the eye the concentration of melatonin is 
equivalent to those in blood, possibly due to production by the ciliary body (Martin et 
al., 1992).
Melatonin is also found in many fluids related to reproduction, such as semen, 
amniotic fluid, preovulatory follicles and breast milk (Reviewed in Cagnacci, 1996). 
Melatonin levels that are detected in plasma, CSF, saliva and urine by techniques
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that are in use today are eliminated by pinealectomy and therefore reflect 
production by the pineal gland (Nelson and Drazen, 1999). However, several studies 
have established the existence of additional sites of melatonin synthesis, such as 
the retina, gut and bone marrow (Reviewed in Cagnacci, 1996).
Melatonin synthesis is triggered once NA is released near the pinealocytes where it 
activates a adrenergic and/or p adrenergic receptors on the pinealocyte membrane 
leading to an increase in cAMP activation of CREB. CREB activates the enzyme 
arylalkylamine N-acetyltransferase (AANAT) that acetylates serotonin to N- 
acetylserotonin, the precursor of melatonin (Weissbach et al., 1960) (Fig. 1.10). This 
is the rate limiting step in melatonin synthesis. The rhythm of AANAT production 
shows daily variations with 30-100 times higher levels during the night compared to 
the daytime and it is this enzymatic activity that is responsible for the rhythmic 
production of pineal melatonin (Klein et al., 1970).
Tryptophan
I  Tryptophan Hydroxylase
5-Hydroxytryptophan
■ Decarboxylase
i
Serotonin 
(5-Hyd roxy try ptam i ne)
i
Arylalkylamine N-acetyltransferase 
(AA-NAT)
N-Acetyiserotonin
i
Hydroxyindol-O-methyltransferase
(HIOMT)
MELATONIN
Fig. 1.10 Pathway of melatonin synthesis in the pineal gland. 
Simplified from Klein, 1985
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1.2.1.2 The Effect of Light on the Melatonin Rhythm
The most important regulatory factor in the production of pineal melatonin is the 
daily light-dark cycle. In the absence of environmental light the melatonin rhythm is 
endogenously driven by the SCN with a periodicity slightly different from 24 h (free- 
running period).
Some 20 years after the first phase shifting experiments it was discovered that 
bright light was a potent suppressor of nocturnal melatonin production. Lewy and 
colleagues (1980) demonstrated for the first time that melatonin is suppressed by 
high intensity light. They investigated 2500 and 500 lux light levels and found that 
2500 lux significantly suppressed plasma melatonin levels in comparison to 500 lux.
Therefore, light has two effects on melatonin. It can acutely suppress the nocturnal 
melatonin production and it can phase shift the endogenous melatonin rhythm in 
sighted humans. In sighted individuals, under real life conditions, exogenous 
melatonin may not be able to sufficiently override the effects of light (Burgess et al., 
2001). In comparison, in totally blind subjects with free-running circadian rhythms, 
exogenous melatonin administration is able to entrain the circadian system 
(melatonin or cortisol rhythm) (Lockley et al., 2000; Sack et al., 2000; Hack et al., 
2003) and stabilize sleep-wake timing (Reviewed in Arendt et al., 1997).
1.2.1.3 Suppression of Melatonin by Light
Nocturnal light administration acutely suppresses melatonin production, which is 
restored once the light stimulus is removed. The degree of melatonin suppression is 
affected by many photic factors. These are properties of light such as light intensity, 
duration, timing, wavelength, light source, previous light history. Other factors such 
as gender, female menstrual status, age, medication, exercise, alcohol or caffeine 
consumption, shift work and body posture may affect circadian phase and amplitude 
and should be taken into the consideration when conducting light-induced melatonin 
suppression experiments (Table 1.1).
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1.2.1.3.1 Light Intensity and Duration of Light Exposure
There is a dose-response relationship between light intensity and melatonin 
suppression, with higher light intensities producing more melatonin suppression 
McIntyre et al. (1989) demonstrated that by increasing the level of light intensity, the 
percentage of melatonin suppression was increased over 60 minute periods timed 
between 24:00 h and 01:00 h. Lights of 200 lux produced 16%, 350 lux -  38%, 500 
lux -  44%, 1000 lux -  67% and 3000 lux -  71% melatonin suppression.
Aoki et al. (1998) looked at the minimum level of light intensity required to suppress 
saliva melatonin. This group studied 6 volunteers each exposed to 5 different white 
light conditions: <10 lux background and 4 experimental light conditions: 500, 1000, 
2500 and 5000 lux. Maximum suppression was observed at 04:00 h with melatonin 
suppression of 40% at 500 lux, 53% at 1000 lux, 78% at 2500 lux and 83% at 5000 
lux. Minimum white light intensities for suppression were calculated, combining the 
duration of light exposure in combination with light intensity: 393 lux for 30 mins, 366 
lux for 60 mins, 339 lux for 90 mins and 285 lux for 120 mins.
The duration of light exposure is also an important factor in the suppression of 
melatonin. As little as 5 minutes exposure to 2500 lux light at 02:00 h caused a 
significant suppression of melatonin in 8 volunteers (Byerley et al, 1989). Further 
studies (Petterborg et al., 1991) unsurprisingly demonstrated significant suppression of 
plasma melatonin by 15 mins exposure to 1500 lux light at 22:00 h. Longer exposure 
(18:00 -  07:00 h) to high light intensity (3000 lux) again almost totally suppressed 
plasma melatonin (Strassman et al., 1987).
Taking all these findings into consideration, it can be concluded that a shorter duration 
of light exposure requires a higher light intensity to suppress melatonin, and vice 
versa.
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1.2.1.3.2 Timing of Light Exposure
Beck-Fris et al. (1985) investigated evening versus morning effects of light exposure 
on plasma melatonin levels. They showed that exposure to -  2500 lux light intensity in 
the evening for 30 -  60 mins suppressed melatonin. This light exposure during the 
evening also exhibited a “rebound phenomenon”, increased melatonin concentrations 
occurring after removal of the light exposure. Despite significant suppression of 
melatonin during the morning hours (05:00 -  06:00 h), this rebound phenomenon was 
not observed, which can probably be explained by the declining levels of melatonin 
usually observed in the morning.
McIntyre et al. (1989) studied 3 different timing periods: 21:00 -  22:00 h; 00:00 -  01:00 
h and 04:00 -  05:00 h, by exposing 2 subjects to 3000 lux and 2 subjects to 1000 lux 
for 60 minutes. The greatest melatonin suppression was observed between 04:00 -  
05:00 h. No significant melatonin suppression was seen in the 21:00 -  22:00 h period. 
Others have reported similar findings (Owen and Arendt, 1992). This conclusion can 
be explained by the fact that light suppression of melatonin occurred on the falling 
phase of the melatonin rhythm when melatonin levels are declining.
1.2.1.3.3 Wavelength of Light
Brainard et al. (1985, unpublished data) initiated investigation into the effectiveness of 
different wavelengths of light in suppressing nocturnal melatonin in three healthy male 
volunteers (24-34 years). At 02:00 h volunteers were exposed to monochromatic light 
of different wavelengths, A max 448, 476, 509, 542, 574 and 604 nm, for 90 minutes. 
The mean percent suppression of plasma melatonin produced was 12%, 26%, 64%, 
20%, 16%, and 8%, respectively indicating that monochromatic light of Amax 509 nm 
wavelength was the most effective wavelength to suppress melatonin synthesis. 
However, the study protocol did not account for inter-individual differences in the 
timing of melatonin rhythm as they studied a fixed time of light exposure (02:00 -  
03:00 h) with absence of a baseline night. Furthermore, only one single light irradiance 
was tested for each wavelength, resulting in different amounts of light reaching the
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retina as it was not controlled for photon density. It was therefore impossible to 
compare the findings between wavelengths in this study.
The only way to identify the spectral sensitivity of a light response is to perform an 
action spectrum study where a number of different wavelengths of light of various 
intensities are investigated. Thapan et al. (2001) conducted an action spectrum study 
and identified a novel opsin with a peak sensitivity of around 459 nm (457-462 nm) 
responsible for melatonin suppression (Fig. 1.11). Brainard et al. (2001) also 
conducted an action spectrum study where it was identified that 446-477 nm light was 
the most potent wavelength for suppression of melatonin synthesis. Both these studies 
indicated that neither rod (peak absorbance 500 nm) nor cone (peak absorbance: 419 
nm-blue; 531 nm-green and 558 nm-red) photopigments for vision are the major 
photoreceptor systems responsible for light-induced melatonin suppression in humans. 
These pioneering studies presented the first direct evidence for short wavelength 
sensitivity of non-image forming photoreception distinct from image forming 
photoreception in humans.
400 450 500 550 600 650 700
Wavelength (nm)
Fig. 1.11 Action spectrum for melatonin suppression physiologically derived ( I )  compared to 
scotopic (Amax 505 nm, continuous line) and photopic (Amax 555 nm, dashed line) vision curves. 
Taken from Thapan et al, 2001
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However, before short wavelength light can be used in real life situations repeatedly, 
and over a prolonged period of time, light-induced photochemical damage to the retina 
(photoretinitis), also known as blue light hazard, needs to be assessed (Section 7.2.2).
1.2.1.3.4 Previous Light History
There are wide inter-individual differences in the degree of melatonin suppression to a 
given light intensity of specific duration and spectral composition, which may reflect 
individual differences in light sensitivity. In winter there is less bright light, which could 
lead to an increase in light sensitivity. Previous light history may affect light sensitivity. 
Greater melatonin suppression was noted in laboratory-raised squirrels than in wild 
captured ones (Reiter et al., 1983). Owen and Arendt (1992) showed greater 
melatonin suppression during the winter when light intensity was approximately 500 
lux compared to the summer period when light intensities increased up to 100 000 lux.
Hebert et al. (2002) artificially created a week of bright light and a week of dim light 
after which they investigated whether these short term changes in light history affected 
the degree of melatonin suppression. The results from this study indicated statistically 
greater suppression of salivary melatonin after the dim week compared with the bright 
week (53 and 41%, respectively).
Smith et al. (2004) investigated difference in melatonin suppression following 3-day 
(6.5 h) exposure to either 200 lux or 0.5 lux of white light. A significant increase in 
melatonin suppression was found following a history of exposure to 0.5 lux light 
compared to 200 lux.
These data suggest adaptation of circadian photoreception indicating that translation 
of a photic stimuli into drive on the human circadian pacemaker involves more 
complex temporal dynamics then previously recognized (Smith et al., 2004).
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1.2.1.3.5 Gender
Gender-related differences in pineal sensitivity to light in 6 healthy male (25-31 years) 
and 6 female (22-34 years) volunteers have been reported (Monteleone et al., 1995). 
Females were tested in the follicular phase of their menstrual cycle and none of them 
were taking oral contraceptives. Each subject underwent two experimental sessions. 
In one of these sessions, volunteers were exposed to 2000 lux white light for 2 h 
between 02:00 h and 04:00 h. In females, the suppression of plasma melatonin levels 
was more marked than in males (53% vs 14% at 03:00h; 64% vs 26% at 03:30 h and 
71% vs 26% at 04:00 h) suggesting a greater sensitivity of melatonin suppression to 
light in females.
In contrast, Boyce and Kennaway (1987) showed no significant gender differences in 
the suppression of plasma melatonin by different intensities of bright white light. This 
discrepancy between the two studies may be due to the small sample size used in 
both studies.
Nathan et al: (1997) conducted two separate studies, the first investigating the effects 
of dim light on the suppression of nocturnal melatonin in healthy males (n=22; aged 
19-34 years) and females (n=21; aged 20-56 years). The second study examined the 
sensitivity of nocturnal melatonin to 500 lux in healthy men (n=4; aged 27-58 years) 
and women (n=7; aged 25-51 years). Subjects in both groups were exposed to light 
between 24:00 -  01:00 h. These studies found no significant gender differences in the 
sensitivity of melatonin to either 200 or 500 lux light. However, both studies had no 
baseline night, no age control nor knowledge of the circadian phase at which the light 
treatment was given.
Nathan et al. (2000) also investigated the effect of gender on light-induced 
suppression of melatonin at five different light intensities (0, 200, 500, 1000 and 3000 
lux) in 5 males and 5 females (aged 19-28 years). Each subject attended all 5 
sessions where they were exposed to 5 different intensities of light between 24:00 and
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01:00 h. No gender differences were found in light-induced melatonin suppression at 
any of the 5 light intensities.
1.2.1.3.6 Menstrual Cycle
During their reproductive years, non-pregnant females normally experience a cyclical 
sequence of changes in the ovaries (ovarian cycle) and uterus (menstrual cycle). Each 
cycle takes about a month and is a series of events associated with the maturation of 
an oocyte and changes in the endometrium of the uterus. Each monthly cycle is 
composed of three phases governed by hormonal changes: menstrual phase, follicular 
(preovulatory) phase and luteal (postovulatory) phase.
The studies into the effect of the female reproductive cycle on the melatonin rhythm 
have shown controversial findings. Many of the earlier studies suggested variations in 
plasma melatonin concentrations depending on the stage of the female reproductive 
cycle (Wetterberg et al., 1976; Brun et al., 1987; Berga and Yen, 1990). Some studies 
reported that melatonin levels were lowest immediately prior to ovulation and highest 
during the luteal phase (Wetterberg et al., 1976; Webley and Leidenberger, 1986; Brun 
et al., 1987) while others reported melatonin levels to be unaffected by menstrual 
status (Brzezinski et al., 1988; Parry et al., 1990; Ito et al., 1993; Delfs et al., 1994).
One of the studies (Parry et al., 1997) examined the effects of follicular phase versus 
luteal phase on melatonin sensitivity to light (500 lux). No difference in melatonin 
suppression was seen between the two menstrual cycle phases. These findings were 
further supported by Nathan et al. (1999b), who found no significant difference in 
suppression of melatonin by dim white light (200 lux) in the luteal, follicular and 
menstrual phases of the menstrual cycle. The inconsistency in the findings of these 
studies may be due to the lack of a controlled light-dark environment before and during 
the study, which allowed for masking factors, such as sleep-wake cycle, ambient 
illumination, posture, exercise, caffeine, alcohol and drug consumption (Table 1.1).
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1.2.1.3.7 Ageing
Nathan et al. (1999a) investigated the effect of age on melatonin sensitivity to dim (200 
lux) white light in three different age groups: 18-25 years (n=40), 26-35 years (n=13) 
and >36 years (n=10), the oldest age group being 41.7 ± 2 years (mean ± SD). The 
study, however, did not control for gender nor menstrual cycle phase. No relationship 
was seen between the age of the individuals and the degree of suppression of 
nocturnal melatonin by light, suggesting that age does not affect light-induced 
melatonin suppression. However, since older individuals (> 45 years) were not studied, 
further studies are needed before any conclusions can be made. Furthermore, 
studying the effects of different wavelengths of monochromatic light are required in 
order to compare the spectral sensitivity of the circadian system between young and 
elderly and the possible effects of age-related changes in lens transmission (Section 
1 .3.2.1).
1.2.2 Sleep-Wake Cycle
More has been learned about sleep in the past 60 years than in the preceding 6000, 
but it is remarkable that the function of sleep is still unknown. It has been established 
that sleep is a special activity of the brain, controlled by elaborate and precise 
mechanisms. In sleep, the brain remains active, but it does not effectively process 
information received from the senses as it does during wakefulness (Reviewed in Dijk 
and Lockley, 2002). Sleep is accompanied by a typical body posture, usually the eyes 
are closed and the responsiveness to external stimuli is diminished.
A state of wakefulness is maintained by neurons within the brainstem reticular 
formation, which in turn excite neurons in the non-specific thalamocortical projection 
system, posterior hypothalamus and basal forebrain. Stimulation of portions of the 
reticular formation called the reticular activating system (RAS) results in increased 
cortical activity (Tortora and Grabovski, 1996). With activation of this area, increased 
nerve impulses pass upwards into the thalamus and disperse to widespread areas of 
the cerebral cortex. Arousal, or awakening from sleep, is associated with increased
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activity of RAS by input signals, such as painful stimuli detected by nociceptors, 
touch, bright light and the sound of an alarm clock. The VLPO contains a cluster of 
sleep-active neurons, which contain galanin and GABA and project to many 
components of the arousal system (Shiromani et al., 2000).
Sleep is most accurately defined by electroencephalogram (EEG), which allow, 
together with the electromyogram (EMG) and electrooculogram (EOG) sleep 
classification into different stages according to a set of criteria. Normal sleep is 
composed of two states: rapid eye movement (REM) sleep and non-rapid eye 
movement (NREM) sleep. During sleep the cortical activity of the brain undergoes 
regular cyclic changes between the two main sleep states. During NREM sleep 
physiological variables such as heart rate, respiration and cortical activity slow down 
and energy consumption is lowered (Roschke and Aldenhoff, 1991). Activity of the 
motor neurons at the level of the brain and spinal cord is inhibited impairing muscle 
movement. During human REM sleep, the EEG displays the low amplitude, high 
frequency pattern of stage 1 non-REM sleep. The autonomic nervous system and the 
eye muscles are physically active, giving REM sleep some resemblance to the awake 
state, for which reason it is sometimes referred to as paradoxical sleep (Reviewed in 
Roth and Roehrs, 2000).
In any typical adult human, sleep is entered through NREM sleep and REM sleep 
occurs only about 80 mins later and for the rest of the night NREM and REM sleep 
alternate with an approximately 90 mins cycle. This process is under ultradian control. 
In humans, NREM sleep is usually composed of stages 1-4, which correspond roughly 
to increasing depths of sleep. Stage 1 is a transition stage between wakefulness and 
sleep normally lasting from 1 to 7 minutes (Reviewed in Roth and Roehrs, 2000) and 
occurs as a transitional stage through the night. Sleep is easily disrupted at this stage 
and therefore it is associated with a low arousal threshold.
Sleep spindles or K-complexes indicate stage 2 NREM sleep in the EEG recordings, 
and last around 10 to 25 mins. A more intense stimulus is needed to produce arousal 
from stage 2 NREM sleep. Stage 3 NREM sleep lasts for only a few minutes in the first
Chapter 1
-------------- 35
cycle and acts as a transition to stage 4 sleep with high frequencies of 12 -  15 Hz 
recorded on the EEG. Stage 4 NREM sleep usually lasts approximately 20 to 40 mins 
in the first cycle. A very large stimulus is needed for arousal from this sleep stage. 
Stages 3 and 4 are representative of deep sleep and the EEG recordings characterize 
this sleep as slow wave sleep (SWS) with a frequency below 5 Hz. SWS is very 
concentrated at the beginning of the night and starts to decrease throughout the sleep 
episode and it may even disappear completely. The distribution of SWS towards the 
beginning of the sleep episode is linked to the initiation of sleep and the length of prior 
wakefulness (Reviewed in Roth and Roehrs, 2000). The greater the homeostatic drive 
for sleep (i.e. the longer the wake episode) the greater the amount of SWS. SWS and 
spindles are known to originate in a neural circuit in the thalamus and cortex and the 
transmission from spindles to SWS has been demonstrated at the neural level 
(Steriade et al., 1993).
REM episodes are very short (1 to 5 mins) at the beginning of the sleep episode and 
are longer during the second part of the night. Short awakenings may occur at the 
NREM/REM transition during the second part of the night, but in normal adult sleep 
they are usually short and not remembered in the morning (Reviewed in Roth and 
Roehrs, 2000).
1.2.2.1 Sleep-Wake Cycle Regulation
It has been recognized that two separate but interacting oscillatory processes control 
sleep-wake timing. The circadian oscillator and sleep wake oscillatory process or sleep 
homeostat (Borbely, 1982) contribute about equally to sleep consolidation and waking 
performance (Dijk and Czeisler, 1994). The homeostatic process is determined by the 
amount of prior sleep and wakefulness. During a normal day, the homeostatic 
propensity to fall asleep increases, but this increase is opposed by the circadian 
oscillator (Reviewed in Dijk and Kronauer, 1999). A good physiologic indicator of sleep 
homeostasis was found to be SWS because it appears to reflect the “sleep need” that 
builds up during the day and is reflected in the beginning of sleep, which then declines 
across the sleep episode. This decline in SWS was suggested to represent the decline
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in homeostatic sleep pressure during the sleep episode (Reviewed in Borbely and 
Achermann, 1999). SWS distribution across the sleep episode is not changed in SCN- 
lesioned animals (Tobler et al., 1983) suggesting localization of the sleep homeostat is 
distinct from the SCN, although its actual site is unknown. There is now substantial 
evidence for the role of the neurotransmitter adenosine in mediating the sleep 
homeostatic signal with levels of adenosine in basal forebrain areas increasing during 
prolonged wakefulness and administration of adenosine to these brain areas leading 
to sleep (Basheer et al., 2000).
A circadian process is also responsible for the organization of sleep and waking over 
the 24 h day and it is independent of prior sleep and waking history. In humans, the 
SCN is thought to generate a wake or arousal signal that increases in strength 
throughout the habitual wake period peaking in the evening hours around 22:00  h 
(Wurts and Edgar, 2000). At a certain point on the melatonin rising curve this circadian 
drive for wakefulness begins to dispel rapidly, leading to the increase in sleep 
propensity and the opening of the sleep gate. In the absence of this circadian arousal 
signal, sleep-wake consolidation is lost and the one long sleep episode that should 
occur during the night is replaced by a polyphonic sleep-wake cycle, suggested to be 
under homeostatic control alone (Edgar et al., 1993). The strength of this arousal 
signal declines across the biological night reaching a minimum around 06:00 h, the 
time of temperature minimum (Dijk and Czeisler, 1994). SCN-lesion studies in humans 
and animals as well as forced desynchrony studies in humans support the view of the 
SCN clock actively promoting sleep, especially in the second half of the normal sleep 
episode (Wurts and Edgar, 2000). By scheduling sleep to occur at many circadian 
phases, Dijk and Czeisler (1994) showed that a consolidated 8 h sleep episode can 
only be obtained when sleep is initiated approximately 6 h before the temperature 
minimum.
A putative pathway for the circadian regulation of sleep and wakefulness has been 
characterized. Neuronal tracing techniques have identified the SPZ as the densest 
output target of the SCN. The SPZ innervates similar regions of the brain as the SCN 
but in much greater density, leading some to postulate that the SPZ functions as the
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amplifier of the SCN output (Leak and Moore, 2001). Lesions in the area of the SPZ 
abolished the circadian rhythms of the sleep-wake cycle, locomotor activity and 
temperature (Chou et al., 2003). The second order projection for circadian regulation 
of sleep and wakefulness was found to extend from the SPZ to the DHM. Lesions of 
the DHM area abolished the circadian rhythms of sleep-wake cycle, locomotor activity 
and feeding but not body temperature (Chou et al., 2003). The DMH projections to the 
brain are involved in the regulation of sleep and wakefulness primarily via GABAergic 
projections to the VLPO, a sleep active area in the anterior hypothalamus (Chou et al., 
2003). The VLPO is thought to promote sleep via its projections to the ascending 
monoaminergic arousal system (Sherin et al., 1996). Wakefulness is promoted by the 
glutaminergic projections from the DMH to the lateral hypothalamus that contains the 
wake promoting population of orexin expressing neurons (Chou et al., 2003).
Assessment of sleep as a zeitgeber have been investigated with earlier studies 
reporting small phase shifts in melatonin and CBT rhythms after a 2 h (Hoban et al., 
1991) or 3 h sleep advance or delay in sleep timing (Gordijn et al., 1999; Jelinkova- 
Vondrasova et al., 1999) or a 12 h sleep displacement (Zeitzer et al., 1997). Another 
study has reported that sleep is only a very weak zeitgeber (Wright et al., 2001), 
findings that were recently confirmed by a very well controlled study done by 
Danilenko et al. (2003). These recent studies suggest that sleep has very little 
zeitgeber strength to adjust the circadian clock and that previous findings may have 
arisen from lack of control of lighting conditions and from other nonphotic zeitgebers, 
in particular, shifts in meal times, posture, motor activity and arousal.
1,2.2.2 Sleep Across Development
The emergence of different behavioral states of sleep (NREM and REM) and 
wakefulness is one of the most significant aspects of early brain maturation in infancy 
(Mirmiran, 1995). Early in gestational development a large amount of time is spent in 
undetermined sleep, a sleep that is not characterized by the two states (NREM and 
REM) (Nijhuis et al., 1982). NREM and REM sleep could be differentiated as early as 
32 weeks gestation although the stages within NREM sleep could not be distinguished
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(Reviewed in Mirmiran et al., 2003). A significant increase in NREM sleep was found 
between gestational week 36 to 3 months of age (Reviewed in Mirmiran et al., 2003). 
Sleep spindles rapidly develop during the first 3 months of life, most probably reflecting 
developmental changes in thalamo-cortical activity (Peirano et al., 1993). By 6 months 
of age stages 2, 3 and 4 of NREM sleep were classified (Guilleminault et al., 1979).
Comparing infants (up to one year of age) to children and adults showed a decrease in 
nocturnal SWS across the night in children and adults, but not infants (Bes et al., 
1991) suggesting that the homeostatic drive for sleep does not decrease with the 
onset of sleep in infants as it does in older children and adults. At birth, human 
newborns spend 16 to 18 h a day asleep with more than half of this occupied by REM 
sleep (Anders et al., 1994) and the longest continuous sleep episode lasting between 
2.5 and 4 h. The decline in REM sleep is very slow in humans and does not reach low 
levels until preschool years (Anders et al., 1994). As the infant matures, consolidation 
of sleep duration and timing is seen during the nighttime hours. Around 3 months of 
age REM sleep begins to concentrate in the second half of the sleep episode with 
NREM sleep dominating the first part of sleep (Reviewed in Davis et al., 2004). The 
ultradian organization of NREM/REM alterations can be seen with the cycle of 50 to 60 
mins (Reviewed in Davis et al., 2004). As the infant grows sleep drive decreases, 
probably due to the increase in the wakefulness drive by the circadian system, 
improving the organization of the sleep-wake cycle. By 6 months of age the longest 
continuous sleep episode is approximately 6 h in length. By the first year of life, the 16 
to 18 h sleep length that is seen in the newborn and very young infants decreases to 
14 to 15 h. Total daily sleep need decreases to about 13 h in a two year old, 12 h in 
three and four year olds and 11 hours in 5 year olds. The sleep episode is 
consolidated during the night and naps are still common in two and three year olds 
(Reviewed in Davis et al., 2004).
Overall, the NREM/REM cycle length at age 3 is approximately 60 mins gradually 
extending to the adult level of 90 mins by age 5 years. Children in this age range have 
six to eight sleep cycles per night with the first REM sleep episode usually beginning 
60 mins after sleep onset (Reviewed in Davis et al., 2004).
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Between childhood and adulthood, there is a period of puberty and adolescence and 
one of the conspicuous properties of adolescence is the capacity to stay up late and 
wake up very late in the morning or afternoon. Roenneberg et al. (2004) noted that 
young children are early chronotype “larks”, meaning that they go to sleep early and 
wake up early. As they get older they become progressively delayed “owls” reaching a 
peak in their lateness at around the age of 2 0 , which they proposed to be the first 
biological marker of the end of adolescence. After 20 years, it was found that 
advancing of the timing of sleep occurs, and this increases with increasing age 
(Roenneberg et al., 2004).
There are also gender differences in chronotype changes, with young women reaching 
their maximum delayed peak earlier (19.5 years) when compared to young men who 
continue to delay their sleep until around the age of 21 (20.9 years) (Roenneberg et 
al., 2004). On average it was found that males continue to be later chronotypes for 
most of their adult life, when compared to females (Robilliard et al., 2002; Roenneberg 
et al., 2004). These gender differences were found to disappear around the age of 50, 
which coincides with the average age for the menopause (Roenneberg et al., 2004).
1.2.2.3 Melatonin and Sleep
In humans the onset of endogenous melatonin release is associated with an increase 
in sleepiness, which is often referred to as “the opening of the sleep gate” (Lavie, 
1986). In parallel, the entire thermoregulatory cascade begins with a decrease in heat 
production, increase in heat loss and subsequent decrease in core body temperature.
Melatonin onset seems to be the hormonal signal timing the rise in blood flow in the 
skin causing heat loss (Strassman et al., 1991; Cajochen et al., 2003). In experiments 
where the increase in heat loss, subjective sleepiness and melatonin secretion in the 
evening hours was abolished by light exposure, exogenous melatonin administration 
(5 mg) acutely reinstated the evening increase in heat loss and sleepiness (Krauchi et 
al., 1997b) also affecting theta activity in the waking EEG (Cajochen et al., 1998). 
These findings led to the suggestion of a casual relationship between melatonin and
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sleepiness mediated by thermoregulatory mechanisms (Krauchi et al., 2000). It is still 
unclear whether melatonin (endogenous or exogenous) acts via the SCN and the 
thermoregulatory centers in the preoptic area of the hypothalamus, or whether it acts 
on the peripheral receptors, or both.
The direct effects of melatonin on the SCN have been examined using an isolated 
brain slice preparation in which the SCN clock continues to cycle for several days 
(McArthur et al., 1991). In this preparation, administration of melatonin at dusk and 
dawn caused phase shifts in the circadian rhythm of electrical activity recorded from 
the SCN neurons. Melatonin administration at other times had little or no effect. MT2 
receptors appear to be responsible for the phase shifting effects of exogenous 
melatonin on the SCN (Hunt et al., 2001; von Gall et al., 2002) whereas MT1 receptors 
ere responsible for the acute inhibition of electrical activity recorded from the SCN 
neurons (Liu et al., 1997b). The number of melatonin receptors in the SCN were found 
to be rhythmically expressed in the circadian manner. Their expression levels were 
found to be influenced by light and melatonin (Masson-Pevet et al., 2000; Poirel et al., 
2002). Levels of MT1 receptors were shown to be low during the subjective day and 
high during the subjective night.
The diurnal soporific effects of exogenous melatonin could be due to the activation of 
melatonin receptors in other brain areas, such as the hippocampus (Savaskan et al., 
2005). However, it has been suggested that MT1 receptors are involved in nocturnal 
sleep promotion by inhibiting the firing rate of the SCN neurons (Birkeland, 1982; 
Reviewed in Sack et al., 1997) probably through the activation of GABAergic neurons 
at the SCN level (Golombek et al., 1996). As a result it has been proposed that 
endogenous melatonin promotes sleep by inhibiting the circadian wakefulness 
generating mechanisms (Reviewed in Lavie et al., 1997).
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1.2.3 Alertness
Human cognitive performance and alertness varies across the 24 h day. This variation 
is considered to be generated by a three process model (Reviewed in Folkard et al., 
1999) based upon the original two process model for sleep-wake regulation (Borbely, 
1982). Under normal entrainment the phase relationship between homeostatic and 
circadian regulation ensures that performance and alertness are maintained at a 
stable level during the 16 h of wakefulness (Cajochen et al., 1999). The third 
component is the wake up process or process W representing sleep inertia or 
impairment in alertness and performance upon waking from sleep (Reviewed in 
Folkard et al., 1999). Sleep inertia is described as short lived in some studies with 
inertia length lasting from 1 min (Webb and Agnew, 1964) to more that 3 h (Naitoh,
1993). If the period of wakefulness is extended into the night there is deterioration in 
alertness and performance (Cajochen et al., 1999) The circadian drive for wakefulness 
ceases to oppose the homeostatic drive for sleep consequently disturbing the balance 
for stable maintenance of alertness and performance. Therefore, once “the opening of 
the sleep gate occurs” deterioration in alertness and performance occurs.
Light during the subjective night is known to acutely improve performance and 
alertness (Campbell and Dawson, 1990). Cajochen et al. (2000) have shown that 
nocturnal exposure to typical room lighting of 90 -  180 lux white light increases the 
alerting effects in a dose-dependent manner as assessed by subjective rating, slow 
eye movement and EEG. The half maximum alerting effect of light was between 90 
and 180 lux (Cajochen et al., 2000). The half maximum effect for melatonin 
suppression was between 50 -130 lux and for circadian phase resetting was 8 0 - 1 6 0  
lux (Cajochen et al., 2000). The dose response function found in all of these 
parameters may imply that these effects are mediated by the same photoreceptors 
that mediate the circadian response to light.
Recently, it was demonstrated that the alerting response to light is wavelength 
dependent such that short wavelength light (460 nm) was more effective than longer 
wavelength of light (550 nm) (Cajochen et al., 2004; Lockley et al., 2006). These
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findings are in.agreement with the short wavelength sensitivity of the circadian 
pacemaker, as indicated by the action spectra for human melatonin suppression 
(Brainard et al., 2001; Thapan et al., 2001) and assessment of phase shifting (Lockley 
et al., 2003; Warman et al., 2003; Revell et al., 2005).
An anatomical pathway for the light-inducing alerting effects from the eye to the brain 
has yet to be identified, although candidates include the SCN, the pretectal area, the 
IGL and VLPO. Projections from the retina directly and indirectly (via the SCN) 
innervate the VLPO and that in turn innervates the major nuclei of the ascending 
system thought to play a key role in wakefulness (Lin et al., 1998).
1.2.3.1 Alertness, Mood, Performance and Melatonin
The acute effects of exogenous melatonin on human mood and performance have 
been studied only sporadically using different doses of melatonin. Lieberman et al. 
(1984) found that a dose of 240 mg given over a 2 h period during the day raised 
serum melatonin levels several thousand fold and also impaired mood and 
performance. Dollins et al. 1993 showed similar findings with a lower dose of 
melatonin (10 mg) administered during the day. Even lower doses 0.1, 0.3 and 1 mg 
melatonin given at 13:30 h decreased alertness, mood and performance (Dollins et al.,
1994). To the authors knowledge, no studies have so far assessed mood and 
performance in the morning following nighttime melatonin administration.
1.3 Ageing
According to the United Nations (2004) there has been a rapid increase in the number 
of elderly (over the age of 60 years) in the last 50 years as a direct result of the 
prolongation of the mean life expectancy worldwide. In 2000 the elderly increased to 
10% of the world’s population (609 million) compared to 8.2% (205 million) in 1950. In 
the next 50 years it is projected that this number will reach 21.7% of the world 
population with 2 billion over 60 year olds including 379 million over 80 year olds and
3.2 million over 100 year olds.
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As a result of the dramatic demographic changes that are occurring around the 
world, research is focusing more on understanding the mechanisms of ageing (both 
normal ageing and pathological ageing) in the hope of improving the quality of life of 
the increasing elderly population.
Some changes in sleep timing and consolidation are a normal part of ageing and 
deterioration in both sleep quality and quantity has been reported in the ageing 
population (Feinberg, 1974; Reviewed in Bliwise, 1993). Reduction in total sleep 
duration probably due to the increase in number and duration of nighttime awakenings, 
especially in the second part of the night is often a major complaint (Dijk et al., 2001). 
Ageing is often accompanied by advanced sleep onset and offset times (Duffy et al., 
1998) and an increase in daytime naps (Hock et al., 1992). Changes within the 
circadian and homeostatic sleep regulatory systems may be able to explain some of 
the age-related changes in sleep pattern. Also changes in both the amplitude and 
timing of circadian rhythms of melatonin and CBT have been reported in elderly 
humans and these may reflect overall changes of the circadian system with ageing.
Untreated sleep problems have been found to be associated with a 4.5-fold increase in 
the general risk of serious accidents and injuries (Balter and Uhlenhuth, 1992) 
including car accidents due to drowsiness (Rosekind, 1992) and hip fractures due to 
falls (Suzuki et al., 1997) whilst chronic sleep disturbances have been associated with 
reduced quality of life and an increased mortality rate (Mallon and Hetta, 1997).
1.3.1 Sleep-Wake Cycle in the Elderly
Various systematic changes occur in rhythmic processes as organisms age. Survey 
data (Abe and Suzuki, 1985; Reyner et al., 1995) indicate gradual, rather then rapid, 
alterations in sleep timing and structure in healthy people that are not necessarily 
associated with sleep complaints. While these alterations may be considered a 
general reflection of normal ageing, it is also apparent that a high prevalence of 
individual differences exists and the way these contribute to the ageing progress is not 
known.
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1.3.1.1 Epidemiological Studies
Epidemiological studies indicate that 40 -  70% of the elderly population suffers from 
chronic sleep disturbances (Buysse et al., 1991; Maggi et al., 1998) with only 20% not 
reporting any disturbances at all (Foley et al., 1995; Maggi et al., 1998). Aged 
individuals often exhibit an increase in sleep onset latency, increased periods of 
wakefulness during nighttime sleep, impaired sleep consolidation and less sleep 
stability (Reviewed in Pandi-Perumal et al., 2002). Reduction in sleep continuity, a 
decline in both sleep efficiency and total sleep time, marked fragmentation of the 
sleep-wake cycle and longer lasting awakenings have all been documented (Feinberg 
et al., 1967; Webb and Swinburne, 1971; Miles and Dement, 1980; Bixleret al., 1984).
Gender-related differences in sleep patterns in older subjects have also been noted. 
Women appear to complain more of sleep disturbances than men (Ohayon, 1996; 
Leger et al., 2000). Insomnia has been reported in 15% of women between 50 and 65 
years of age whilst the prevalence in the age group of 65 years and above has been 
reported to be around 25%. A significant increase in sleep disturbances was noted 
during the menopause in women (Reviewed in Dzaja et al., 2005) with frequent 
awakenings especially in the early morning hours associated with vasomotor 
symptoms (Polo-Kantola et al., 1999).
1.3.1.2 Circadian Changes
From a circadian perspective, age-related changes in sleep timing and structure could 
be related to: (a) changes in the timing of the endogenous circadian system, (b) a 
change in the phase relationship between the sleep-wake cycle and endogenous 
circadian rhythms, (c) a change in the intrinsic period (x) of the SCN, (d) a change in 
sleep need, sleep structure and EEG recordings or (e) a change in the amplitude of 
the circadian rhythms driven by the SCN (Reviewed in Dijk and Duffy, 1999). As a 
result of alterations in the timing of the sleep-wake cycle, together with long sleep 
latencies and frequent nighttime awakenings it is not surprising that many studies have
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reported a decline in sleep quality with age (Kahn & Fisher, 1969; Monk, 1991; 
Reynolds et al., 1990; Reynolds et al., 1991).
The timing and internal organization of sleep are known to be partly controlled by the 
circadian system with the onset of sleep paralleling the falling phase of the 
temperature rhythm and the rising phase of the melatonin rhythm. The timing of 
awakening under conditions of a self-selected but regular sleep-wake schedule was 
compared in 101 young healthy men aged 1 8 - 3 0  years and in 44 healthy older 
people over the age of 65 years (Duffy et al., 1998). The study showed that older 
people woke on average at 06:59 h and the young group woke on average at 08:17 h. 
The earlier waking time of the older subjects was accompanied by an earlier phase of 
the endogenous CBT minimum (05:15 h) compared to the young where the CBT 
minimum occurred at 06:00 h (Duffy et al., 1998). These data were in agreement with 
previous findings of earlier timing of the rhythms of endogenous CBT (Czeisler et al., 
1992; Weitzman et al., 1982), activity (Lieberman et al., 1989), plasma cortisol (Van 
Coevorden et al., 1991; Sharma et al., 1989) and melatonin (Dijk et al., 1999) in older 
people. This shift towards earlier awakening and earlier timing of endogenous 
circadian rhythms in the elderly has been linked to a shift towards morningness as 
assessed with the Horne-Ostberg questionnaire (Duffy et al., 1999; Robilliard et al., 
2002). These findings of an overall advance in the circadian rhythmicity suggest that 
the changes observed may be part of a general effect of ageing on the SCN and/or its 
regulation (Reviewed in Skene and Swaab, 2003).
Interestingly, the phase relationship between the timing of habitual sleep offset and 
CBT changed with age so that the interval between sleep offset and CBT minimum 
became shorter and more variable in the elderly (Duffy et al., 1998). This was 
confirmed by assessment of the phase relationship between the timing of the plasma 
melatonin rhythm and the sleep-wake cycle (Duffy et al., 2002). These studies 
revealed a shorter phase angle between two markers of circadian phase (CBT and 
melatonin) and the sleep-wake cycle in the elderly. Both studies found that wake up in 
the elderly occurred just after the CBT minimum whilst endogenous melatonin levels 
were still elevated indicating a change in the internal phase relationship between the
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sleep-wake cycle and outputs of the SCN. Waking up at this circadian phase and 
being exposed to light in the early morning could explain the advances observed in the 
circadian rhythms in the elderly on the basis of the light PRC (Section 1.2.2). 
Assessments of the phase relationship between the sleep-wake cycle and the 
endogenous CBT minimum in young morning types did not reveal the same change in 
phase relationship as in the older people (Duffy et al., 1999). Therefore, while it 
appears that age-related changes in the timing and structure of sleep are mediated by 
changes in the morningness preference of older people, analysis of the phase 
relationship between young morning types and older people suggests that different 
mechanisms are involved. Morningnes in young subjects has been suggested to be 
related to a short intrinsic circadian period ( t ) (Duffy et al., 1998).
The advance in the timing of sleep onset and offset seen in the elderly has been linked 
to changes in the circadian timing system, such as shortening of the circadian period 
(t). However, under strictly controlled conditions no change in circadian period with 
ageing has been detected (Czeisler et al., 1992). In constant darkness, circadian 
rhythms “free-run” with an intrinsic period which is slightly shorter or longer than 24 
hours. The average human period in sighted people is believed to be in the range of
24.2 -  24.4 hours (Czeisler et al., 1995; Middleton et al., 1996; Hiddinga et al., 1997; 
Wright et al., 2001). Several studies have looked at the change in endogenous period 
of the SCN with age and there are discrepancies in the findings. Some studies have 
observed a decrease in period length (Pittendrigh and Daan, 1974; Weitzman et al., 
1982) whereas some studies have observed an increase in period length (Welsh et al., 
1986; Valentinuzzi et al., 1997; Aujard et al., 2001). Other studies have shown no 
change in period length (Sharma et al., 1989; Czeisler et al., 1995). Czeisler et al. 
(1995) used a forced desynchrony protocol to assess the intrinsic period in humans. 
They found that ageing was not associated with systematic changes in circadian 
period. Early assessments of the intrinsic period in humans used free-running time 
isolation protocols, in which subjects self selected their sleep-wake and light-dark 
times. Young subjects chose to go to sleep later and in general were exposed to light 
at night during the phase delay portion of the light PRC, while remaining in the dark 
and asleep during the advance portion of the light PRC. This resulted in artificially
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lengthening of the measured circadian period (Klerman et al., 1996). With the elderly 
the reverse occurred resulting in the apparent shortening of circadian period. The 
results of these studies are light confounded and need to be considered with caution.
The circadian process is strongly linked to sleep maintenance playing a crucial role in 
sleep consolidation. The circadian drive for sleep is strongest in the early morning 
hours enabling sleep continuity after the disappearance of the homeostatic drive for 
sleep (Dijk and Czeisler, 1994). In older individuals alterations in circadian timing 
would reduce the circadian drive for sleep in turn accounting for the lack of sleep 
maintenance during the second part of the night. The attenuated circadian drive in the 
elderly has been demonstrated by reduced incidence, amplitude and frequency of 
spindle waves (characteristic for stage 2 sleep) compared to young subjects (Wei et 
al., 1999). Assessing the circadian regulation of sleep using a forced desynchrony 
protocol demonstrated the tendency of early awakenings in older people even in the 
absence of knowledge of clock time (Duffy et al., 1998). The duration of self-reported 
early awakenings was found to be longer in older people compared to young people in 
particular when the end of the sleep episode occurred after the CBT minimum (Duffy 
et al., 1999), a time when the circadian drive for sleep is at its highest in young people 
(Dijk and Czeisler, 1994). These observations were confirmed by objectively measured 
sleep using polysomnography (Dijk and Cajochen, 1997). Older people have greater 
difficulty in sustaining sleep after the CBT minimum. These findings are in agreement 
with simulated jet lag studies (Reviewed in Haimov and Arendt, 1999) and shift work 
studies (Campbell, 1995) in middle aged adults where it has been shown that sleep in 
this group of subjects is more susceptible to arousal in the early morning (after the 
CBT minimum).
Age-related reductions in SWS, particularly in older men, were first noted by Webb 
and Swinburne in 1971 and later by others (Feinberg, 1974; Miles and Dement, 1980). 
Reduction in SWS affects the deep sleep component allowing for easy environmental 
disturbances and lack of sleep maintenance. However, SWS is largely confined to the 
first half of the sleep period and thus an age-related reduction of this sleep stage 
cannot fully explain the inability to maintain sleep in the second part of the night.
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1.3.1.3 Homeostatic Changes
A gender variation in sleep has been reported in REM sleep. Although, generally 
better preserved of the two sleep states, longer REM latencies and increased REM 
sleep have been reported in elderly women compared to age-matched men (Kahn and 
Fisher, 1969; Reynolds et al., 1991). These findings have been linked to better 
preservation of SWS in the elderly women (Campbell et al., 1989). The mechanisms 
behind the age-related reduction in SWS nor the gender differences are yet not 
known.
1.3.2 The Circadian System and Ageing
Alterations in one or more components of the circadian system (input, clock and 
output) could influence circadian timing ( t , phase).
1.3.2.1 Ageing Eye
There are a number of age-related changes in the human eye contributing to a 
reduction in the amount of light reaching the retina. Major ones are the reduction in 
pupil size (Verriest, 1971) and changes within the crystalline lens (Weale, 1985) 
(Fig.1.12). In general, elderly people have much smaller pupils than the young and 
more of the colored iris can be seen (Verriest, 1971). The pupil admits light to the 
retina and a reduction in pupil size reduces the amount of light that reaches the retina 
(Weale, 1961, Weale, 1985).
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The ciliary muscle 
loses its power to 
control lens thickness
The vitreous produces 
harmless floaters
The pupil size d im in is h e s ^ ' 
reducing the amount ot light 
that can enter the eye
Y O U N G
O L D
The lens grows larger 
and loses its ability 
to focus for near objects: 
it also yellows and darkens
The retina and optic pathways 
lose some of their cells, 
making it harder to see 
detail and contrast
The sclera may yellow
Fig. 1.12 Principal differences between a young and old eye.
Taken from Weale, 1988
The lens is the optical clear structure located behind the iris and in front of the vitreous 
body and retina (Section 1.1.1.1). The shape, clarity and reflective index of the lens, 
which helps focus the light onto the retina, changes with ageing. The lens is formed 
from the ectodermic tissue and epithelial cells, which produce, lens fibers throughout 
life. Therefore, with increasing age the lens becomes thicker and more compact 
(Asbell et al., 2005) (Fig 1.13a). Furthermore, the ageing lens darkens and develops a 
yellow pigmentation that further reduces light transmission to the retina, especially in 
the short wavelength region (Lerman et al., 1976; Lerman et al., 1987; Brainard et al., 
1997) (Fig. 1.13b).
Brainard et al. (1997) studied post-mortem lenses collected from 288 donors ranging 
from prenatal to 92 years of age. Figure 1.13b shows that the lenses from humans 
aged 50-59 years transmitted less short (400-500 nm) wavelength light than did lenses 
from humans aged between 20-29 years of age. Thus, the age of the human lens 
significantly modulates both the amount and spectral distribution of light reaching the 
photoreceptors in the retina.
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SPECTRAL DENSITY OF LENS WITH AGE
SO YR 
30 YR 
40 YR 
SO YR 
60 YR 
70 YR 
80 YR
3 8 0  4t 2 O 460  500  540  5 8 0  620 660
WAVELENGTH
(b)
H U M A N  L E N S E S  A V E R A G E  T R A N S M IT T A N C E
N EW BO RN <N=S) 
AG E 20-29 (N*36>  
AGE 60-69 (N = 4Q)
200 230 300 350 400 450 500 550 600 650 700 
W A V E L E N G T H  ( n m )
Fig. 1.13 Mean, (a) spectral density of lenses for ages 20-80 years and (b) transmittance of 
visible and UV wavelengths of post-mortem human lenses from newborn donors, from donors 
aged 20-29 years and from donors aged 60-69 years.
(a) Taken from Xu et al., 1997; (b) Brainard et al., 1997
As short wavelength light has been found to be most effective in suppressing nocturnal 
plasma melatonin (Section 1.2.2.1.3) and transmission of these short wavelengths is 
reduced with ageing it might be expected that with ageing the sensitivity of people to
0.5
-0.5 ~r
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short wavelength light would be reduced. However, whether transmission of short 
wavelength light by the ageing eye is reduced sufficiently to affect photic entrainment 
is not yet known.
The sensitivity of the peripheral field of vision declines more rapidly with ageing than 
that of the central field with scotopic vision being more affected than photopic vision 
(Bonnel et al., 2003). Approximately half of all rods are lost between the second and 
fourth decade in humans, with an annual disappearance of 970 cells/mm2 from the 
peripheral retina (Gao and Hollyfield, 1992). Curcio et al. (1993) showed that the 
density of rods in the central retina decreases by 30 % between the ages of 34 and 90 
years, whereas the number of cones in the macular area remains stable.
The number of ganglion cells in the fovea and peripheral retina are also decreased 
during ageing in humans (Curcio and Drucker, 1993). This may have implications for 
melanopsin-mediated mechanisms, as melanopsin is located in these cells (Section 
1.1.1.1.2.1).
1.3.2.1.1 Diabetes Mellitus and Eye Changes
Changes within the eye of patients with type 1 or insulin-dependent diabetes mellitus 
occur at the level of the crystalline lens and retina. An increase in lens density has 
been shown in diabetic patients (Van Best et al., 1985; Bursell et al., 1989). Lutze and 
Bresnick (1991) demonstrated that lenses in young type 1 diabetic subjects increase in 
density and yellow color at an accelerated rate that is similar to that of older people 
(over the age of 60 years). Furthermore it was demonstrated that transmission of light 
through the lens of diabetic subjects decreases at a greater rate than in healthy 
controls of the same age (Zeimer and Noth, 1984; Weiss et al., 1984; Bleeker et al., 
1986). Van Best et al. (1985) found a dramatic decrease in lens transmission of short 
wavelength light in individuals suffering from diabetes mellitus who have had the 
disease for 10 years or longer.
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The lens is transparent when lens proteins (crystalins) are properly ordered, and lens 
transmission is reduced when there is disorder in the proteins (Benedek et al., 1999). 
Spector et al. (1974) showed that protein disorder occurs with age. Similar crystalin 
disorders were found in the lenses of diabetic patients (Monnier and Cerami, 1982). 
This disorder of crystalins within the lens of diabetic patients has been linked with 
excessive plasma glucose levels, resulting in the accumulation of nonenzymatic 
glycosylation of the lens proteins (Monnier and Cerami, 1982). Measurement of this 
accumulation has been proposed as a tool that would give insight into the long-term 
control of diabetes and likelihood of developing secondary complications (Oimomi et 
al., 1989). Currently this is done by estimation of the level of hemoglobin Aic that only 
reflects hyperglycaemia over the previous two months (Gabbay et al., 1977). Diabetic 
retinopathy is a common complication of both types of diabetes and it is a leading 
cause of blindness between the ages of 20 and 74 years (Klein et al., 1995).
1.3.2.1.2 Insufficient Zeitgeber Exposure
The importance of ocular light as a time cue has been very clearly demonstrated in 
study of blind subjects (Lockley et al., 1997). The incidence of abnormal melatonin 
rhythms is dependent on the degree of visual loss (Lockley et al., 1997). Blind subjects 
who have no light perception show desynchronization or “free-running” circadian 
rhythms, including the sleep-wake cycle, melatonin and cortisol (Section 1.4.3).
Some of the sleep disturbances experienced by aged individuals (Section 1.3.1) may 
also relate to insufficient zeitgeber strength, particularly when individuals are house 
bound or institutionalized (Campbell et al., 1988; Van Someren et al., 1997; Monk and 
Kupfer, 2000, Mishima et al., 2001). Some studies have shown an inverse relationship 
between light intensity and sleep disturbances in the elderly (Shochat et al., 2000; 
Mischama et al., 2001). Exposure to higher levels of light during the day was predictive 
of fewer nighttime awakenings (Shochat et al., 2001).
Reduced levels of illumination may result in desynchronization of the circadian clock, 
leading to disruption of the rhythmic outputs controlled by the clock. It has been
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demonstrated that increased daytime environmental illumination improves the 
stability of rest-activity rhythms in Alzheimer's patients (Van Someren et al., 1997). 
Low light levels could thus be a partial cause of circadian rhythm related sleep 
problems experienced by the elderly. This along with the ocular age-related changes 
(Section 1.3.2.1) could lead to reduced zeitgeber strength and dysentrainment.
1.3.2.2 The SCN and Ageing
Recent experiments with rodents suggest that the age-related deterioration in 
circadian clock function occurs at the level of individual cells in the SCN, possibly 
accounting for changes in circadian rhythmicity (Aujard et al., 2001). During the ageing 
process, several SCN changes occur. An age-related reduction in circadian amplitude 
can be demonstrated in the SCN itself by decreased neuronal activity (Swaab et al., 
1985). The number of arginine vasopressin (AVP)-expressing neurons in the SCN 
decreases with a marked decline in subjects 80-100 years old (Swaab, 1999). 
Furthermore, the oscillation in the number of AVP-expressing neurons in the SCN of 
young subjects (low AVP neuron numbers during the night and peak values during the 
early morning) disappears in subjects over the age of 50 (Hofman and Swaab, 1994). 
Older subjects showed a reversed pattern with a high number of AVP neurons during 
the night and a low number of AVP neuron during the day (Hofman and Swaab, 1994). 
The significance of this is unclear. A disrupted annual cycle with reduced amplitude is 
also seen in the elderly group when compared to the young group who showed a low 
number of AVP neurons during the summer and peak values in autumn (Hofman and 
Swaab, 1995). Apart from a decline of AVP neurons, the volume and total cell count in 
the SCN were found to be decreased in the elderly indicating an age-related decline of 
function of the biological clock (Swaab et al., 1985). Marked changes in the SCN and a 
decrease in AVP cell number has also been observed in Alzheimer patients (Swaab et 
al., 1992; Liu etal., 2000).
The number of vasoactive intestinal protein expressing neurons in the SCN of women 
did not show any age-related changes whereas in men, a complex pattern of changes 
was observed with advancing age (Hofman and Swaab, 1995). The male SCN (aged
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10-40 years) usually contains twice as many VIP neurons in comparison to females. 
The subsequent age-related decrease (between 40-65 years) results in fewer VIP 
neurons in men than in women. This phenomenon is also characteristic of Alzheimer 
sufferers (Reviewed in Wurtman, 2000).
These findings might have some involvement in the disturbances of the sleep-wake 
rhythm of elderly and Alzheimer’s sufferers (Larner et al., 1997), however, the precise 
mechanisms and its relationship to circadian rhythmicity is not yet known (Reviewed in 
Skene and Swaab, 2003). In Alzheimer patients, nighttime sleep is less efficient with a 
high frequency , of arousals and awakenings. Daytime activity is also disrupted by 
multiple short daytime nap episodes and in many, is associated with evening delirium 
represented by agitation, wandering, irritability and confusion (Larner et al., 1997).
1.3.2.2.1 Development of Circadian Rhythms
A foetal biological clock responsive to the maternal entraining signal is already 
oscillating by the last trimester of gestation in primates (Reppert and Schwartz, 1984). 
Therefore, the mother entrains the developing circadian rhythm of the unborn baby to 
the light-dark cycle. Most of the studies looking at circadian rhythms in human infancy 
have resulted in controversial discrepant findings because it is very hard to control the 
environment and therefore show the unmasked endogenous circadian system. Thus 
rhythms described in infants cannot really be considered “circadian”. While some 
studies have shown no evidence of an endogenous melatonin rhythm before 9-12 
weeks of age (Kennaway et al., 1992) others have shown active production of 
melatonin during the first week of life (Reviewed in Mirmiran et al., 2003). Antonini et 
al. (2000 ) showed a rhythm in salivary cortisol levels in over half of the infants at 2 to 8 
weeks of life, while the group as a whole developed a cortisol rhythm between 8 and 
12 postnatal weeks. McGraw et al. (1999) found evidence of rhythms in body 
temperature within one week of life, which is in contrast to other findings where no 
clear circadian rhythmicity in temperature was noted before 6 to 12 weeks of age 
(Reviewed in Mirmiran et al., 2003). There are also high interindividual differences in
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the developmental rate of circadian rhythms in infants with pre-term and term births 
adding to the variation.
1.3.2.2.2 Entrainment Abnormalities in the Elderly
Neuronal processes involved in entrainment of the clock may be dysfunctional or sub 
sensitive in the elderly (Reviewed in Skene and Swaab, 2003). These authors suggest 
that there may be a weakened link to the SCN with any part of the photic input 
pathway (eye-RHT-SCN) being dysfunctional. One technique to assess the integrity of 
the circadian system is to test the degree of light-induced melatonin suppression or 
phase shifting in the elderly compared to a young group of subjects using different 
wavelengths of light. In particular the effects of short wavelength of light should be 
investigated, since transmission of this wavelength of light through the lens is reduced 
with ageing (Section 1.3.2.1).
Klerman et al. (2001 ) tested the phase shifting capacity of the circadian system in 24 
healthy older subjects (65-81 years) and 23 young men (19-27 years). All subjects 
were exposed to scheduled ocular bright light stimuli (10 000 lux) for 5 h administered 
for 3 consecutive days. Light administration was centered 1.5 and 3.5 h after the CBT 
minimum to produce phase advances and 1.5 h before the CBT minimum to induce 
phase delays. Results showed that phase advances were significantly attenuated in 
older subjects when compared to the young group. No difference in the degree of 
phase delay was noted between the two groups. Authors discussed a possibility of two 
different mechanisms, including separate neuroanatomical and/or neurotransmitter 
systems, being involved in phase advances and phase delays. These systems may be 
affected differently by ageing thus the difference in advances were seen and not the 
phase delays between young and elderly. Alternatively, they suggested that the light 
stimulus used in this study was so strong inducing a saturating response in the phase 
delay region of both young and elderly subjects and that the age-related reduction in 
the sensitivity of the system was therefore not detected. Whether the same results 
would be seen by exposing subjects to different wavelengths of monochromatic light 
remains to be investigated.
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1.3.2.3 The Pineal Gland and Ageing
Arieti (1954) was the first scientist to examine 50 human pineal glands in relation to 
ageing. These findings indicated that the pineal remained functional during advanced 
age although calcareous deposits were prominent in the pineal gland from 
adolescence onwards. These pineal concretions consist mainly of calcium and 
variable amounts of magnesium, trace elements and organic substrates. It was found 
that concretions increase in number and size with ageing (Vollrath, 1981; Kloeden et 
al, 1990) becoming very common in elderly people. A later study by Hasegawa et al. 
(1987) investigated 168 human pineal glands. They found a lack of correlation 
between the weight of the pineal gland and ageing (independent of gender). The 
degree of calcification was found to vary between individuals and in some it can start 
very early in life with 3% of 1 year olds and 7 % of 10 year olds examined by 
computed tomography showing pineal calcification (Winkler and Helmke, 1989).
However, it was found that although pineal calcification increases with age (Kloeden et 
al., 1990) it had no effect on melatonin secretion (Bojkowski and Arendt, 1990). 
Furthermore, it was found that calcification of the pineal body did not affect histology 
(Tapp and Huxley, 1972) nor the pineal activity of the pinealocytes (Wurtman et al., 
1964). In contrast, estimation of the uncalcified portion of the pineal gland correlated 
positively with the 24-h output of urinary aMT6s (Kunz et al., 1999).
Age-related decline in melatonin levels (Section 1.3.2.3.1) also have been attributed to 
degenerative changes in the neural structures controlling the pineal gland, rather than 
changes in the pineal tissue (Ruzsas and Mess, 2000).
In animals, age-related changes within the pineal gland include decline in number of (3 
- adrenergic receptors in the pinealocyte membranes and unresponsiveness of 
pinaelocytes to noradrenaline of ageing rodents (Greenberg and Weiss, 1978). It has 
also been shown that the activity of AANAT, the key enzyme responsible for synthesis 
of melatonin, decreases dramatically in the pineal gland of old rats paralleling the
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decline of rat serum melatonin (Selmaoui and Touitou, 1999). These changes may 
contribute to the age-related alterations in the melatonin rhythm.
The age-related changes in a number of pineal processes could, in part, explain the 
decline in melatonin amplitude.
1.3.2.3.1 Melatonin Rhythms in the Elderly
Many scientific papers have reported that plasma melatonin concentrations decline 
with age in humans. Touitou et al. (1981) investigated plasma melatonin levels across 
the 24 h period in young (24 year olds; n=7) and elderly (72 year olds; n=18) finding a 
45 % reduction in melatonin levels in the elderly subjects. Melatonin levels were not 
statistically different between elderly women and men (Touitou et al., 1981). Numerous 
other studies have shown similar results when looking at plasma melatonin levels in 
young and old subjects respectively (Iguichi et al., 1982; Bartsch et al., 1985; Thomas 
and Miles, 1989; Van Coevorden et al., 1991; Ferrari et al., 1995; Cagnacci et al., 
1995; Hajak et al., 1995; Uchida et al., 1996; Magri et al., 1997; Mazzoccoli et al., 
1997; Ohashi et al., 1997).
Some studies have looked at age-related differences in melatonin production in more 
than two groups using either plasma (Nair et al., 1986; Sharma et al., 1989), urinary 
aMT6s (Sack et al., 1986; Bojkowski and Arendt, 1990; Skene et al., 1990; Kennaway 
et al., 1999) or CSF (Liu et al., 1999). All of these studies found a decline in melatonin 
levels with ageing (Table 1.2). A reduction in melatonin production with age is also 
supported by numerous animal studies (Reiter et al., 1980; Reviewed in Touitou,
1995).
Some studies, however, have failed to find any age-related decline in melatonin 
production (Claustrat et al., 1984; Cowen et al., 1985). Zeitzer et al. (1999) analysed 
the amplitude of individual plasma melatonin profiles during a constant routine in 34 
healthy old subjects (20 women: 68.9 ± 4.2 years and 24 men: 67.7 ± 3.3 years; mean 
± SD) compared to 98 young healthy men (23.2 ± 3.8 yrs). During the 30 h constant
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routine protocol subjects remained awake, in bed in a semi-recumbent position under 
constant dim (15 lux) light receiving equicaloric snacks and fluids hourly. The study 
found that the amplitude amongst most of the elderly was similar to that of the young 
adults. The mean 24 h melatonin concentrations, duration and the mean and 
integrated area of the nocturnal plasma melatonin peak were also similar. Therefore, 
they concluded that their results did not support the hypothesis that decreased 
melatonin concentrations are characteristic of healthy ageing. Nonetheless, they had a 
small group of elderly subjects (n=6 ) whose plasma melatonin rhythms had 
significantly lower amplitude. Zeitzer et al. (1999) suggested that the differences in 
their findings and those of previous studies might be due to the recruitment criteria 
(other studies using subjects that are taking medication that affects melatonin) and 
differences in lighting exposure between the young and older subjects in the previous 
studies.
Kennaway et aL (1999) investigated the amount of aMT6s excreted by subjects aged 
between 21 and 82 years finding that the oldest subjects excreted approximately 36 % 
less aMT6s than the youngest. When they analyzed their data according to 5 year age 
groups, performing ANOVA, they again found a significant correlation with age, but a 
post-hoc analysis indicated that no consistent changes could be found after the age of 
25 years.
The above studies were cross-sectional studies comparing melatonin or aMT6 levels 
between young and elderly groups of subjects. In order to find out the individual 
decline of this hormone or its major metabolite with ageing, longitudinal studies need 
to be conducted. To date, no such studies have been completed probably due to the 
limitations of the length of the study, subject recruitment and changes in the sensitivity 
or nature of the analytical techniques used.
The role of endogenous melatonin in the human circadian system is still not clear, 
therefore it is hard to pinpoint a physiological consequence of reduced melatonin 
levels with ageing although numerous authors have linked this to increased cancer risk 
and oxidative damage (Reviewed in Wurtman, 2000; Zisapel, 2001; Reiter, 2002).
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Furthermore, whether supplementation of this hormone for the individuals with low 
endogenous levels can bring potential benefits is still debatable.
The mechanism by which melatonin levels appear to decline with ageing is not yet fully 
understood. A number of factors may explain this decrease. Age related changes in 
the eye-SCN-pineal pathway may also explain the changes in the melatonin rhythm 
(Section 1.3.2).
1.3.2.3.2 Melatonin Rhythm and Diabetes Mellitus
Only few studies have looked at the melatonin production in diabetic patients. Cutando 
et al. (2003) have found a significantly lower salivary and plasma melatonin levels in 
20 subjects suffering from type 1 diabetes and 23 subjects suffering from type 2 
diabetes compared to age- and gender- and body mass index (BMI)-matched controls. 
Lower salivary and plasma melatonin levels were noted in patients suffering from type 
1 diabetes compared to type 2 diabetes. However, this difference was not statistically 
significant. In this study sampling was performed only once (the time was not stated) 
so it is hard to say whether a 24h production would be different between diabetic 
patients and controls. Radziuk and Pye (2006) have found a significantly attenuated 
melatonin production in patients suffering from type 2 diabetes mellitus compared to 
age -  and BMI-matched controls. In this study the sampling was done every 4h for 24h 
but type 1 diabetics were not investigated.
Conti and Maestroni (1998) have demonstrated that neonatal pinealectomy in female 
nonobese diabetic mice model (type 1 diabetic model) accelerates the development of 
type 1 diabetes while exogenous administration of melatonin protects animals from 
this acceleration. Therefore, melatonin influences the development process of this 
disease but the mechanism behind this is not known.
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1.4 Effects of Melatonin Administration
1.4.1 Acute Effects
Daytime melatonin administration in doses above 0.5 mg produce blood levels in the 
pharmacological range of about 200 pg/ml or more (Dawson et al., 1996) causing 
acute hypothermic effects and sleepiness (Tzischinsky and Lavie, 1994, Deacon and 
Arendt, 1995, Cajochen et al., 1996). Even smaller doses of 0.1 -  0.3 mg, that 
produce physiological circulating melatonin levels (under 200 pg/ml) administered 
during the daytime induced sleep (Dollins et al., 1994, Zhdanova et al., 1995) 
suggesting that melatonin’s efficiency in the daytime does not differ between 
physiologic and. pharmacological doses of melatonin. Therefore, there appear to be 
no dose response relationship between melatonin and sleep induction during the day. 
However, there is a time-dependent course between melatonin administration and 
sleep initiation. Tzischinsky and Lavie (1994) administered 5 mg of melatonin at 
different times of day 12:00, 17:00, 19:00 and 21:00 h with sleep latency decreasing in 
a linear manner from 3 h 40 mins at 12:00 h to 1 h sleep latency at 21:00 h suggesting 
the importance of the timing of melatonin administration. Melatonin administration 
during the day thus appears to have time dependent, but not dose dependent effect on 
sleep initiation. All of the above is true only if the environment conditions are 
appropriate for sleep initiation. Stimuli that interfere with normal sleep, such as lights 
on, posture changes, need for high levels of attention or motivation, interfere with the 
effects of melatonin on sleep. Under these circumstances a person would typically feel 
alert despite high circulating melatonin levels (Reviewed in Zhdanova, 2005). Once 
this interference is removed, the ability to fall asleep is restored (Reviewed in 
Zhdanova, 2005). These are well documented differences between melatonin and 
common hypnotics such temazepam (Rogers et al., 2003).
Exogenous administration of melatonin (5 mg) during the subjective day causes the 
same electroencephalogram changes (i.e. suppression of low frequency EEG 
components and increase in activity in the sleep spindle frequency range) that are 
seen during the subjective night when endogenous melatonin levels are high (Dijk et 
al., 1995). However, administration of exogenous melatonin after the onset of
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endogenous melatonin secretion (subjective night) did not affect EEG recordings any 
differently to placebo (Cajochen et al., 1998). These findings suggest that once 
endogenous melatonin is secreted exogenous melatonin has no further effect on the 
spectral composition of the sleep EEG (Reviewed in Cajochen et al., 2003). This was 
confirmed by Stone et al. (2000) where melatonin (0.5, 1, 5 and 10 mg) was 
administered at 18:00 h and 23:30 h in a double blind placebo controlled study. No 
significant effect on nighttime sleep was noted with the administration of melatonin at 
23:30 h while administration at 18:00 h showed the hypnotic activity of melatonin to be 
similar to temazepam (20mg).
In relation to nocturnal sleep, the most consistent finding is that exogenous melatonin 
administered at night reduces sleep latency, even at low doses (Zhdanova et al.,
1996). Sleep consolidation or sleep efficiency were not affected by nighttime melatonin 
administration in some studies, but not all (Reviewed in Mendelson, 1997). The lack of 
effect of melatonin administration on sleep efficiency or total sleep time may not be 
surprising given the short half-life of melatonin in the circulation (less than 1 h) 
(Waldhauser et al., 1984). However, during the daytime melatonin improved sleep 
efficiency (Wyatt et al., 1999). Data from a forced desynchrony protocol, where 
exogenous melatonin was given across a range of circadian phases, confirmed that 
exogenous melatonin can only increase sleep efficiency outside the time window of its 
normal production (Wyatt et al., 1999). These findings support the hypothesis that 
exogenous melatonin attenuates the wake promoting signal of the circadian 
pacemaker located in the SCN, allowing for increased sleep efficiency at circadian 
phases corresponding to the habitual wake episode (Reviewed in Arendt and Deacon, 
1997; Cajochen et al., 2003).
1.4.2 Phase Shifting Effects
The PRC to orally administered melatonin show that circadian phase delays are 
produced with melatonin administration in the morning hours and phase advances with 
melatonin administration in the afternoon and early evening hours (Lewy et al., 1998). 
The melatonin PRC is approximately 12 h out of phase with the light PRC (Lewy et al.,
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1998). However, in this study, light was not controlled to provide unmasked 
melatonin onset times and melatonin was given in repeated doses. In another study, 
which was double blind, placebo controlled, conducted under dim light and constant 
posture conditions, it was shown that a single melatonin (5 mg) dose at 18:00 h 
induced an advance in the core body temperature, heart rate and DLMO 24 h after 
melatonin administration and an advance in sleep offset 29 h after melatonin 
administration (Krauchi et al., 1997a). An advance was also noted in circadian timing 
of EEG sleep with exogenous melatonin (1.5 mg) (Rajaratnam et al., 2004).
In a similar study where melatonin was given at 07:00 h no evidence of phase delay in 
any of the circadian markers were found (Wirz-Justice et al., 2002). In contrast, 
another weir controlled study showed a delay in the onset of melatonin secretion with 
administration of exogenous (5 mg) melatonin at 07:00 h (Deacon et al., 1994). These 
data suggest that it is more difficult to phase delay than phase advance circadian 
rhythms by exogenous melatonin administration and that timing of administration is 
crucial, proving the chronobiotic properties of melatonin. There is need for a complete 
PRC using a single dose of melatonin under controlled conditions in subjects with free- 
running rhythms.
1.4.3 Entrainment of Free-Running Rhythms
Abnormally timed circadian rhythms have been demonstrated in shift work (Reviewed 
in Waldhauser et al., 1986) and jet lag (Reviewed in Arendt et al., 1987). Blind subject 
with no light perception and in particular those who have been bilaterally enucleated 
show desynchronized (free-running non 24 h) circadian rhythms (Lockley et al., 1997; 
Reviewed in Skene et al., 1999). Earlier studies showed phase advances of free- 
running circadian rhythms (melatonin and cortisol), but entrainment was not observed 
(Sack et al., 1991). Only recently it has been shown that melatonin can entrain free- 
running circadian rhythms in blind subjects (Lockley et al., 2000; Sack et al., 2000). 
First study to demonstrate the ability of 5 mg melatonin administration to entrain the 
free-running circadian rhythm concluded that all their subjects that entrained began 
their treatment in the phase advance portion (CT 6-18) of the published PRC (Section
Chapter 1
-------------- 64
1.4.2). Those that failed to entrain began their treatment in the delay portion of the 
PRC (Lockley et al., 2000). Even smaller doses (0.5 mg) have been shown to be 
effective in entrainment of free-running circadian rhythms in blind subjects (Hack et al., 
2004).
1.4.4 Effects in the Elderly
The decline in melatonin secretion with age has been suggested as one of the major 
reasons for increased sleep disturbances in older people (Nair et al., 1986; Sharama 
et al., 1989; Haimov et al., 1994; Hajak et al., 1995; Rodenbeck et al., 1999). Although 
this reduced melatonin amplitude may reflect a reduction in circadian oscillatory 
amplitude, rather then a cause per se, some groups have justified the use of 
melatonin, with its low toxicity, and no apparent side effects as an ideal "replacement” 
treatment for aged people with sleep related problems. Administration of different 
doses of melatonin (0.6 - 6 mg, orally) in some studies improved overnight sleep in 
elderly subjects (Garfinkel et al., 1995; Haimov et al., 1995; Jean-Louis et al., 1998; 
Zhdanova et al., 2001). Zhdanova et al. (2001) used polysomnography to assess 
sleep after administration of 0.1, 0.3 and 3 mg of melatonin and placebo reporting 
improvements in sleep efficiency, especially in the middle portions of the night. In a 
recent study involving a large population of 517 subjects aged 55 years and over with 
sleep problems, lower nocturnal aMT6s production was noted in these subjects with 
sleep problems (9.0 ± 8.3 pg/per night) compared to healthy controls of the same age 
groups (18.1 ± 12.7 pg/per night) (Leger et al., 2004). Subjects that were characterized 
as low melatonin secretors responded to the melatonin treatment better than subjects 
without sleep problems and normal melatonin levels. As the melatonin replacement 
therapy was found to be beneficial in subjects with low melatonin levels and sleep 
problems, the authors suggested that the decline of melatonin production with age was 
a major factor in the impairment of sleep seen in the elderly (Leger et al., 2004). 
Earlier investigations by Zhdanova et al. (1995) agreed with these findings but used 
lower doses of melatonin 0.1 and 0.3 mg which produce physiological levels (under 
200 pg/ml) of circulating melatonin.
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In contrast other studies failed to document significant changes in the sleep of elderly 
patients after administration of 0.5 mg (Hughes et al., 1998) or 5 mg (Baskett et al., 
2003). Baskett et al. (2003) used polysomnography to assess sleep and failed to find 
any improvements in sleep quality upon melatonin administration compared to 
placebo. Hughes et al. (1998) tested 0.5 mg of melatonin in different preparations, an 
immediate release dose taken 30 mins before bedtime and 4 h after bedtime and a 
controlled release dose taken 30 mins before bedtime. Regardless of the preparation 
used, melatonin showed no significant effect on sleep maintenance. They also showed 
that subjects with low levels of melatonin were not preferentially responsive to 
melatonin administration. Dawson et al. (1998) investigated the effects of 0.5 mg 
sustained nocturnal transbuccal melatonin administration on sleep quality in 12 
subjects (> 55 yrs) with sleep maintenance insomnia using polysomnographic 
measures. Their findings show no positive significant effects on any polysomnographic 
measures of sleep quality that is in agreement with other studies (James et al., 1990; 
Ellis et al., 1996).
Furthermore, some studies have reported no difference in the melatonin and aMT6s 
levels between older people with and without sleep problems (Lushington et al., 1998; 
Baskett et al., 2001). Lushington et al. (1998) failed to find any significant relationship 
between melatonin excretion and any self reported sleep parameters. In a later study, 
Lushington et al. (1999) looked at the relationship between other characteristics of the 
melatonin rhythm (time of onset/offset and time/magnitude of peak production) and 
polysomnographically measured sleep. They found no correlation between any 
melatonin and polysomnographic sleep parameters in the group of subjects studied. In 
contrast, Kripke et al. (1998) reported a high prevalence of abnormally timed aMT6s 
acrophases in a group of subjects suffering from sleep problems and depression. 
However, these authors observed that 37 out of 72 aged subjects had aMT6s 
acrophase times in the expected range of 02.00 -  06.00 h. Furthermore, 8 of the older 
subjects had aMT6s acrophases which were 180 degrees out of phase with the 
day/night cycle. Therefore, their original conclusion that abnormal aMT6s acrophases 
in the elderly with combined sleep problems and depression could be explained by
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depression alone because abnormal phase angles have been reported in depressive 
subjects (Reviewed in Wirz-Justice, 2006).
Systematic search of the literature resulted in 78 articles where melatonin 
administration and its effects on sleep parameters were investigated. As it is not 
possible to discuss all of these articles in detail, the ones that are presented above 
illustrate the controversies in the findings, which could be due to many factors. Criteria 
for subject recruitment are very different amongst the studies. Some of the studies 
reviewed above (Garfinkel et al., 1995) recruited subjects who apart from sleep 
problems, suffered from a variety of chronic diseases, such as ischaemic heart 
disease, spondylarthrosis, Parkinson’s disease, diabetes, hypertension. These 
subjects were likely to be taking medication that may affect melatonin production. 
Furthermore, preparations, doses and time of administration of melatonin were 
different in each study, making it difficult for comparison. Also exposure to light was 
not taken into the consideration when comparing endogenous melatonin levels 
between subjects with sleep problems and those without sleep problems. Subjects that 
suffer from sleep problems are likely to stay up with lights on during the night, which 
may affect endogenous melatonin production. Also, light exposure in the early morning 
hours in subjects suffering from sleep problems may influence melatonin production by 
decreasing endogenous melatonin levels.
More consistent findings have been demonstrated in totally blind individuals where 
melatonin administration has been shown to successfully improve nighttime sleep and 
reduce napping during the day in addition to entrainment of their free running cortisol 
rhythms (Lockley et al., 2000; Hack et al., 2003). Thus, showing both the soporific and 
chronobiotic potential of melatonin treatment in non 24 h sleep-wake disorders 
(Section 1.4.2).
1.4.5 Side Effects
In the UK melatonin is classified as a medicine and it is currently unlicensed for use 
and is only available on a "named patient" basis. Melatonin is generally well tolerated
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due to its low toxicity with few immediate side-effects such as drowsiness and slower 
reaction time. However, the effects of chronic administration of melatonin are not 
known.
Meta analysis of 17 randomized controlled studies with 651 participants involved 
showed no evidence of side effects with short-term melatonin use (three months or 
less) (Buscemi et al., 2006). Only four complaints regarding melatonin have been 
report to the United States of America Food and Drug Administration (FDA, Adverse 
Effects Reporting Department), where melatonin is licensed as over the counter drug. 
The only consistent side effect reported has been drowsiness.
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1.5 Aims and Hypotheses of the Studies
1.5.1 Light Responses in Ageing
Two action spectra investigating the spectral sensitivity of the ability of the light to 
suppress nocturnal melatonin in humans have shown distinct short wavelength 
sensitivity. Wavelengths with the peak around 460 nm were identified as the most 
potent wavelength in suppressing nocturnal melatonin production (Section 1.2.1.3.3) 
Age-related changes within the eye may cause not only a decrease in the light input 
signal but also a change in the spectral distribution of the light reaching the retina 
(Section 1.3.2.1).
As short wavelength of light has been found to be the most effective in suppressing 
nocturnal melatonin in young subjects and as transmission of these wavelengths is 
reduced with ageing, it might be expected that the melatonin response to short 
wavelength light is reduced with ageing. Whether light-induced melatonin suppression 
differs in subjects with and without sleep problem was investigated.
The aims and hypothesis of the study were to:
• Investigate the effectiveness of short (456 nm) and medium (548 nm) 
wavelength light in suppressing nocturnal plasma melatonin in young and 
elderly postmenopausal women (Chapter 3).
Null Hypothesis: There will be no difference between young and elderly 
postmenopausal subjects in their response to short and medium wavelength 
light.
Alternative hypothesis: There will be a significant difference between young and 
elderly postmenopausal subjects in their response to short and medium 
wavelength light.
• Establish any differences in the amount of nocturnal melatonin suppression 
following exposure to short (456 nm) and medium (548 nm) wavelength light 
between elderly postmenopausal women with self-reported sleep problems and
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elderly postmenopausal women without self-reported sleep problems (Chapter 
5).
Null hypothesis: There will be no difference between elderly postmenopausal 
women with self-reported sleep problems and elderly postmenopausal women 
without sleep problems in their response to short and medium wavelength light. 
Alternative hypothesis: There will be a significant difference between elderly 
postmenopausal women with self-reported sleep problems and elderly 
postmenopausal women without sleep problems in their response to short and 
medium wavelength light.
1.5.2 Melatonin Responses in Ageing
There are controversial findings in the published literature on the effectiveness of 
exogenous melatonin administration to improve sleep quality in the elderly (Section
1.4.3).
The aims and hypothesis of the study were to:
• Investigate the relationship between melatonin rhythm markers (aMT6s 
production levels and acrophase timing, salivary DLMO) and subjective and 
objective.sleep parameters in postmenopausal women (Chapter 5).
Null hypothesis: There will be no relationship between melatonin markers and 
subjective and objective sleep parameters in postmenopausal women. 
Alternative hypothesis: There will be a significant relationship between 
melatonin markers and subjective and objective sleep parameters in 
postmenopausal women.
• Investigate the difference in melatonin rhythm markers (aMT6s production 
levels, aMT6s acrophase timing, salivary DLMO) between postmenopausal 
women with and without self-reported sleep problem (Chapter 5).
Null hypothesis: There will be no difference in melatonin rhythm markers 
between postmenopausal women with and postmenopausal women without 
self-reported sleep problem.
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Alternative hypothesis: There will be a significant difference in melatonin 
rhythm markers between postmenopausal with and those without self reported 
sleep problem.
• Test the effectiveness of melatonin (5 mg daily for 4 weeks), compared to 
placebo, on subjective and objective sleep in postmenopausal women with self- 
reported sleep problems (Chapter 4).
Null hypothesis: There will be no effect of melatonin, compared to placebo, on 
subjective and objective sleep in postmenopausal women with self-reported 
sleep problems.
Alternative hypothesis: There will be a significant effect of melatonin, compared 
to placebo, on subjective and objective sleep in postmenopausal women with 
self-reported sleep problems.
• Assess the effectiveness of melatonin administration (5 mg), compared to 
placebo, on subjective alertness, mood and performance in postmenopausal 
women with self-reported sleep problems (Chapter 4).
Null hypothesis: There will be no effect of melatonin, compared to placebo, on 
subjective alertness, mood and performance in postmenopausal women with 
self-reported sleep problems.
Alternative hypothesis: There will be a significant effect of melatonin, compared 
to placebo, on subjective alertness, mood and performance in postmenopausal 
women with self-reported sleep problems.
1.5.3 Light Responses in Diabetes Mellitus
There is little data on melatonin rhythms in patients suffering from diabetes mellitus 
(Section 1.3.2.3.2). Only two studies have, indirectly, looked at melatonin production in 
these patients and found a significant reduction compared to age- and BMI-matched 
controls. Type 1 or insulin dependent diabetes mellitus is often accompanied by 
changes in the eye, especially in the crystalline lens (Section 1.3.2.1.1). These 
changes are more prominent in the patients who have suffered from this disease for
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10 years or longer. These patients may still be in their early thirties but the rate their 
lens ages resembles someone who is 60 years or older. With such a rapidly ageing 
lens the spectral transmission of light to the retina may be affected. What effect this 
may have downstream on circadian entrainment and the response to light is not 
known.
The aims and hypothesis of the study were to:
• Investigate urinary aMT6s and plasma melatonin rhythms in young type 1 
diabetics and age- and gender- matched controls (Chapter 6).
Null hypothesis: There will be no difference between young type 1 diabetics and 
age- and gender-matched controls in their urinary aMT6s and plasma melatonin 
rhythms.
Alternative hypothesis: There will be a significant difference between young 
type 1 diabetics and age- and gender-matched controls in their urinary aMT6s 
and plasma melatonin rhythms.
• Adapt existing (Chapter 3) protocol to investigate the effectiveness of short (456 
nm) wavelength light to suppress nocturnal plasma melatonin in type 1 diabetes 
mellitus sufferers compared with age and gender-matched controls (Chapter 6). 
Null hypothesis: There will be no difference between young type 1 diabetics and 
age- and gender-matched controls in their response to short wavelength light. 
Alternative hypothesis: There will be a significant difference between type 1 
diabetics and age- and gender-matched controls in their response to short 
wavelength light.
Chapter 2
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2.1 METHODS
2.1.1 Pre-study Questionnaires
As a part of the pre-screening procedure all subjects were required to fill in a medical 
health questionnaire to identify any heath problems and medication in use (Appendix 
A). In order to assess subjects’ sleep quality they were asked to complete the 
Pittsburgh Sleep Quality Index questionnaire (PSQI) (Buysse et al., 1989). The PSQI 
assesses sleep quality over the previous month, with certain components such as 
sleep latency, awakenings during the night and total sleep time contributing to the final 
score (PSQI range: 0-21). A PSQI score of > 5 was taken as indicator of a subjective 
sleep problem. Morning or evening preference was assessed by the Horne-Ostberg 
questionnaire (Horne and Ostberg, 1976). An inhouse sleep quality questionnaire was 
later added to some studies (Chapters 4, 5 and 6) and it was used to get more 
information about subjects’ sleep (Appendix B).
2.2 Data Collection
2.2.1 Sleep and Nap Diaries
Sleep and nap diaries were completed according to the protocols described in each 
chapter. Subjects were asked to fill in the sleep diaries upon wakening in the morning 
and completed the nap diary in the evening. In total the subjects answered 9 sleep 
related and 4 nap related questions.
Sleep related questionnaires were as follows:
1. What time did you go to bed? (hh:mm)
2. At what time did you try to sleep? (if different to above answer)
3. How long did it take you to fall asleep? (minutes)
4. How many times did you wake up?
5. How long were you awake for? (minutes)(Please try to estimate time and 
duration of each night awakening).
6. What time did you wake up? (hh:mm)
7. What time did you get up? (hh:mm)
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8. Would you describe this as a typical night? (yes/no)
9. How would you rate your quality of sleep on a 1 to 9 scale? (1 is the best sleep 
ever and 9 is the worst sleep ever)
Nap related questionnaires were as follows:
1. What time did the nap start? (hh:mm)
2. What time did the nap end? (hh:mm)
3. How long was the nap? (minutes)
4. Please record any time you would have liked to nap but were unable to for 
whatever reason e.g. wanted to nap at 16:00 h.
2.2.2 Urine Sampling
Urine was sequentially collected 4 hourly during the day and an overnight sample 
(approximately 8 h) for 48 h. Urine passed during each collection period was collected 
into a plastic urine collection bottle. At the end of each collection period subjects were 
asked to mix the contents of the urine bottle and measure the volume of urine 
collected using a plastic measuring cylinder. Once measured subjects were instructed 
to aliquot a small sample (about one tablespoon) of urine into a small plastic vial using 
a plastic Pasteur pipette. The collected sample was frozen at -20°C. Subjects were 
asked to record the date, time and volume of each sample on the urine collection
sheet. When all the urine samples were collected for the 48 h period they were
wrapped in bubble wrap and posted to the University. On reaching the University urine 
samples were stored at -20°C prior to analysis for aMT6s by radioimmunoassay 
(RIA)(Section 2.3).
2.2.3 Blood Sampling
A trained nurse inserted an indwelling cannula into the arm. 5 ml of blood was 
collected in accordance with the specific protocol into sterile 5 ml syringes. 
Immediately after collection the blood was transferred to lithium heparin coated tubes 
to prevent coagulation. Once in the lithium heparin tubes the tube was inverted 3 times
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to ensure equal spread of heparin through the blood. The blood sample was 
centrifuged for 10 mins at 3000 rpm to ensure the separation of blood plasma from the 
red blood cells. The plasma was removed using a Pasteur pipette and placed into the 
LP4 tubes. The plasma samples were frozen at -20°C until analysed for melatonin by 
RIA.
2.2.4 Saliva Sampling
In field conditions, where saliva samples were collected in the subjects’ own home, 
individuals were asked to remain seated for as long as possible in dim light. They were 
advised to have a lamp on but to place the lamp on the other side of the room from 
their sitting position. If they needed to get up (e.g. toilet, phone) they were advised to 
do so immediately after the saliva sample collection and to return to their sitting 
position as soon as possible. They were asked to abstain from caffeinated drinks from 
13:00 h on the day of saliva collection.
Subjects were asked to start collecting samples from 17:00 h and to continue sampling 
every 30 mins until bedtime. They were provided with Salivettes (Sarstedt Ltd, 
Leicester, UK), a plastic tube containing a cotton plug. They were asked to chew the 
cotton plug for 1-2 mins and place it back into the plastic tube. Subjects were 
instructed to freeze the sample at -20°C. Saliva samples were personally collected by 
the researcher and transported to the University on dry ice. The samples remained 
frozen until analysed for melatonin by RIA.
During the laboratory studies performed in the Clinical Investigation Unit (CIU) the 
timing of the saliva sample collections was done according to each protocol. The 
collection procedure was the same as in the field conditions.
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2.2.5 Actigraphy
Ambulatory activity was measured continuously using a watch-like device called the 
Actiwatch L or AWL (Cambridge Neurotechnology Ltd, UK). The AWL (Fig 2.1) is 
about the size of a wristwatch and it is light so it can easily be worn on the wrist. The 
comparison of actigraphy against sleep diaries have shown some variations in the 
results, with actigraphy overestimating sleep duration and night-time awakenings 
compared to subjective sleep diaries (Lockley et al., 1997b). Therefore, in our 
laboratory actigraphy is used in combinations with sleep diaries in field studies 
(Middleton et al., 1996; Lockley et al., 2000; Hack et al., 2003).
Fig. 2.1 The Actiwatch L a) size and b) appearance on the wrist.
Subjects were instructed to wear the AWL on their non-dominant wrist and over their 
clothing to avoid covering the light detector used to monitor the light intensity subjects 
were exposed to. Since the AWL is not waterproof subjects were instructed to remove 
it while in the bath or shower. The memory capacity of an AWL is approximately 21 
days so in the protocols where recordings were performed for longer (Chapters 4 and 
5) a replacement watch was supplied. The AWL was posted back to the University (in 
field studies) and the data were downloaded using computer software (Actiwatch 
Activity and Sleep Analysis, version 5.10, Cambridge Neurotechnology Ltd, UK). The 
data were imported into an Excel spreadsheet for further analysis.
2.2.6 Mood Tests
Mood tests entailed drawing a vertical line across a 10-cm visual analogue scale 
(VAS)(Appendix C). Three parameters from a 12 parameter mood test were analysed, 
namely happiness, alertness and sleepiness.
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The distance between the beginning of a visual analogue scale and the marked line 
was measured (cm.mm). This value was entered into an Excel spreadsheet and 
analysed further.
2.2.7 Performance
Subjects’ performance was assessed using a digital symbol substitution test (DSST) 
(Appendix D). In this test numbers 1-10 were assigned to symbols on top of the page. 
The numbers are than mixed and subjects need to assign the given number to a 
symbol going from left to right. The test was timed and subjects needed to complete as 
many symbols as possible in a 2 min period. Parameters assessed were the number 
of correctly completed symbols after a 2 min period. The data were entered into an 
Excel spreadsheet and further analysed.
2.3 Radioimmunoassay (RIA)
2.3.1 Basic Principles
A sample containing an unknown amount of antigen (e.g. aMT6s) is incubated with a 
fixed amount of antiserum specific to the antigen and a fixed amount of radiolabelled 
antigen (e.g. 125l-aMT6s). The labelled and unlabelled antigen compete for the fixed 
number of antibody binding sites. Once equilibrium is reached the free and antibody 
bound fractions of the antigen are separated using charcoal (aMT6s and plasma 
melatonin) that binds small molecules The radioactivity is measured in the free 
(aMT6s) or bound (plasma melatonin) fractions and it is compared to a standard curve, 
which is constructed using a set of aMT6s/melatonin standards of known 
concentration. This provides the concentration of unknown antigen in the samples.
All assays were performed in a similar manner with the tubes being set up in duplicate 
to ensure reliability. The zero point of the standard curve was always set up in 
quadruplicate to allow calculations of the limit of detection of the assay.
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At the start of each assay there were duplicate tubes containing only the 
radiolabelled antigen giving a measure of total radioactivity present in each tube. 
Preceding the standard curve were non-specific binding tubes that do not contain the 
antibody. Therefore, any binding of the antigen in these tubes will be due to physical or 
matrix effects. Non-specific binding should be less than 5%. The standard curve, 
against which the samples were measured, was constructed fresh for each assay. 
Following the standard curve, tubes for quality controls (QC) were included in order to 
assess intra-assay and inter-assay variability. The QC samples contain known 
concentrations of antigen. A range of QCs were used in the RIA (low, medium and 
high QC) to cover the range of concentrations of antigen being measured. The QC 
tubes were also placed after the samples, at the end of the assay, to measure any 
intra-assay drift.
2.3.2 RIA of aMT6s in Human Urine
The RIA of aMT6s in human urine is based on methods described first by Arendt et al. 
(1985b) and later modified for the use of an iodinated aMT6s radiolabel (Aldhous and 
Arendt, 1988).
Pre-prepared reagents
• Buffer: Tricine buffer -  product number T0377 (Sigma Ltd., UK)
Tricine was made up at 0.1 M with 0.9% NaCI and 0.1% gelatine in 
double glass-distilled water (DGDW). Gelatine was dissolved in the 
buffer by stirring on a hot plate for 30 mins.
• Separation system: dextran-coated charcoal
2% activated charcoal (product number C5260-Sigma Ltd., UK) was 
suspended in tricine buffer with 0.02% dextran (product number D1390- 
Sigma Ltd., UK) and stirred for at least an hour at 4°C.
Sample preparation
• Antigen measured: aMT6s
• Sample: human urine
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The samples were defrosted before assay. Once defrosted samples 
were mixed and diluted 1:250 with tricine buffer using an automatic 
dilUtor (Hamilton G.B. Ltd. Lancashire, UK) to give a total volume of 500 
pi.
Standard Curve Preparation
• Matrix for standard curve: charcoal striped urine (Stockgrand Ltd., UK)
Supplied in freeze-dried 100 pi aliquots and reconstituted with 25 
(1:250) ml of tricine buffer.
• Standard curve
Standard curve was made up fresh for each assay in charcoal stripped 
urine. The total volume in each tube was 500 pi and had standards with 
the following concentrations 0, 0.5, 1, 2, 4, 7,10, 20, 50 ng/ml.
• Antiserum: Sheep antiserum -  product number G/S/118-23884 (Stockgrand 
Ltd., UK)
Supplied freeze-dried and reconstituted with 1 ml of DGDW and 9 ml of 
tricine buffer providing an intermediate dilution of 1:100. 100 pi aliquots 
were stored at -20°C and were further diluted up to 20 ml (1:20000) with 
tricine buffer providing enough antiserum for 100 tubes. Antiserum was 
made up fresh for each assay from the intermediate dilutions and 200 pi 
added to the standard, QC and sample tubes. The tubes were vortexed 
and incubated at room temperature for 30 mins.
• Radiolabelled antigen: 125l-aMT6s (Stockgrand Ltd., UK)
125l-aMT6s was made up fresh for each assay by diluting 125l-aMT6s with 
tricine buffer to give approximately 8000-10 000 cpm per 100 pi. 100 pi was 
added to each tube of the assay after pre-incubation with the antibody was 
complete. The tubes were vortexed and incubated overnight at -4°C.
• Separation system: dextran-coated charcoal
Following overnight incubation charcoal was stirred continuously for at 
least 30 mins and then 100 pi added to each tube, apart from the total
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tubes. The tubes were incubated with dextran-coated charcoal for 15 
mins at 4°C. Following incubation the tubes were centrifuged at 3500 
rpm at 4°C for 15 mins. After centrifugation the supernatant was 
decanted leaving a pellet of dextran-coated charcoal containing small- 
unbound molecules of aMT6s. The radioactivity of the free fraction was 
measured using a gamma counter (Wallac, Milton Keynes, UK) and the 
aMT6s concentration in the samples was determined by extrapolation 
from the aMT6s standard curve that was automatically fitted by the 
counter program.
2.3.3 RIA of Melatonin in Human Plasma
Levels of melatonin in plasma were determined by a direct RIA using the method 
described by Fraser et al. (1983). All plasma samples for each subject for each study 
session were analysed in one assay. They were assayed in order of the time they 
were taken across all three nights of collection (e.g. 20:00 N1, N2, N3; 20:30 N1, N2, 
N3 etc). This assay sequence was performed in order to minimise the effects of any 
assay drift.
Pre-prepared reagents:
• Tricine buffer and dextran coated charcoal were prepared in the same way as in 
section 2:3.1.
• Scintillation fluid
The scintillation fluid was made up of 2.5 I toluene (Fisher Chemicals, 
UK) to which 12.5 g 2,5-diphenyloxazole (Fisons, UK) and 0.75 g 1,4-bis- 
[2-(5-phenyloxazolyl)j benzene (Fison, UK) were added.
Sample preparation
• Antigen measured: melatonin
• Sample: human plasma
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The samples were defrosted before assay. Once defrosted and mixed 
500 pi of sample was aliquoted to each tube. As each sample 
measurement is performed in duplicate a total of 1 ml of plasma was 
required.
Standard Curve Preparation
• Matrix for standard curve: affinity stripped melatonin free plasma (Stockgrand 
Ltd., UK)
Supplied in freeze-dried form and reconstituted with 12.5 ml of DGDW.
• Standard curve
Standard curve was made up fresh for each assay in affinity stripped 
melatonin free plasma. The total volume in each tube was 500 pi with the 
following standard concentrations 0, 5,10, 25, 50,100, 200, 500 pg/ml.
• Antiserum: Sheep antiserum -  product number G/S/704-6483 (Stockgrand Ltd., 
UK)
Supplied freeze-dried and reconstituted with 2 ml (1:10) of DGDW. This 
was stored in 50 pi aliquots at -20°C. On the day of the assay a working 
solution was made up by diluting 50 pi aliquots with 20 ml (1:4000) of 
tricine buffer. 200 pi of this antiserum solution was added to each tube, 
apart from the total and non-specific binding tubes. The tubes were 
vortexed and incubated for 30 mins at room temperature.
• Radiolabelled antigen: 3H-melatonin -  product number TRK-798 (Amersham 
Ltd., UK)
An intermediate dilution was made from stock 3H-melatonin by diluting 50 
pi up to 2 ml in absolute ethanol and storing at -20°C. A working dilution 
was made up fresh for each assay in tricine buffer to give approximately 
4000 cpm in 100 pi. 100 pi of labelled antigen was added to each tube, 
vortexed and left to incubate overnight at 4°C.
• Separation system: dextran-coated charcoal
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Following overnight incubation charcoal was stirred continuously for at 
least 30 mins and then 500 pi was added to each tube, apart from the 
total tubes. The tubes were incubated with dextran-coated charcoal for 
15 mins at 4°C. Following incubation the tubes were centrifuged at 3500 
rpm at 4°C for 15 mins. After centrifugation the supernatant, containing 
(bound) antigen-antibody complexes, was decanted into plastic 
scintillation vials. 4 ml of scintillation fluid was added to each vial, which 
were then shaken at room temperature for 1 h in order to extract the 3H- 
melatonin into the organic phase. The radioactivity was measured using 
a p counter (Wallac, Milton Keynes, UK) and the melatonin concentration 
in the samples was determined from the standard curve that was 
automatically constructed by the program.
2.3.4 RIA of Melatonin in Human Saliva
Levels of melatonin in saliva were determined by a method described by English et al.
(1993).
Pre-prepared reagents:
• Tricine buffer was prepared in the same way as in section 2.3.1.
• Brij/saline wash solution
Wash solution was prepared by dissolving 9 g NaCI in 998 ml DGDW 
and adding 2 ml Brij 35.
Sample preparation
• Antigen measured: melatonin
• Sample: human saliva
The samples were defrosted before assay. Once defrosted samples 
were centrifuged at 350 rpm for 15 mins to separate saliva from the 
cotton plug. 500 pi of samples were aliquoted to each tube. As each 
sample measurement is performed in duplicate a total of 1 ml of saliva 
was required.
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Standard Curve Preparation
• Matrix for standard curve: DGDW
• Standard curve
Standard curve was made up fresh for each assay in DGDW. The total 
volume in each tube was 500 |J and had standards for the following 
concentrations 0, 0.8, 2, 4, 10, 20, 50, 100, 200 pg/ml.
• Antiserum: rabbit anti-melatonin antiserum -  product number AB/R/031 
(Stockgrand Ltd., UK)
Supplied freeze-dried and reconstituted with 15 ml of tricine buffer. 100 
\x\ was added to each tube apart from the total and non-specific binding 
tubes. The samples were vortexed and incubated at room temperature 
for 30 mins.
• Radiolabelled antigen: 125l-melatonin (Amersham Ltd., UK)
125l-melatonin came pre-prepared by the manufacturer and 5 \i\ of 125l- 
melatonin was diluted in 10 ml of tricine buffer to give approximately 
6500 cpm. The samples were incubated overnight at 4°C.
• Separation system: solid phase double antibody separation system -  product 
number AA-SAC 1 (IDS, UK)
After overnight incubation 100 \x\ of solid phase double antibody was 
added to all tubes apart from the total and non-specific binding tubes. 
The samples were vortexed and incubated for 1 h with intermittent 
mixing every 15 mins. 1 ml of brij/saline wash solution was added to 
each tube apart from the total tubes. The samples were then centrifuged 
at 3500 rpm at 4°C. After centrifugation the supernatant was discarded 
and the pellet containing double antibody and small unbound melatonin 
molecules were then placed into the gamma counter (Wallac, Milton 
Keynes, UK) and melatonin concentration were determined from the 
standard curve that was automatically fitted by the program.
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2.4 General Methods for Data Analysis
2.4.1 aMT6s
After assaying the urine samples the concentrations of aMT6s were corrected for 
length of collection period (h) and the urine volume collected during that collection 
period (ml). This correction provided the aMT6s excretion rate in ng/h. These values 
were used to determine the acrophase time for the aMT6s rhythm by using cosinor 
analysis (Nelson et al., 1979) using software programmed by Dr. D. S. Minors 
(University of Manchester, UK). Excretion rate in ng/h was also used to determine 
aMT6s ng/24 h production levels.
2.4.2 Plasma Melatonin
2.4.2.1 Dim Light Melatonin Onset (DLMO)
The assay provided the concentration of melatonin in pg/ml. Samples from N1 
(Chapter 3) were used to calculate the dim light melatonin onset using a twice baseline 
method. The DLMO, in this method, is defined as twice the average baseline value.
For example, if baseline values for 3 time point were: 20:00 h -  6 pg/ml; 20:30 h -  6 
pg/ml and 21:00 h -  7 pg/ml. The mean of these 3 time points (6.3 pg/ml) is the mean 
baseline value. Twice baseline value is thus 12.6 pg/ml. This value is between time 
point 21:00 h (7 pg/ml) and time point 21:30 h (13.2 pg/ml). The change in melatonin 
concentrations during this period is then calculated (13.2 -  7) as it is the change of 
concentration per min ((13.2 -  7)/30). The number of minutes after the start of this time 
period (21:00 h) that the twice baseline value occurs was calculated as follows:
No. of mins= twice baseline value -  lowest melatonin concentration in time period
Change in melatonin concentration/min
In this example . 12.6 -  7 = 28 mins
(13.2 -  7)/30
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The number of mins is then added to the start of the time period 21:00 h + 28 mins = 
21:28 h (21.48 decimal h). Therefore, DLMO calculated using twice baseline method 
occurs at 21:28 h (21.48 decimal h).
2.4.2.2 Melatonin Suppression
Melatonin suppression was calculated as the difference in melatonin concentrations 
before (0 mins) and after lights on (mean value of 30 and 45 mins) using the following 
formula:
% suppression = (N2 or N3 0 mins -  N2 or N3 (mean 30, 45 mins)) ^   ^qq
N2 or N3 0 mins
2.4.3 Saliva Melatonin
Salivary melatonin data were analysed in the same way as the plasma melatonin data 
(Section 2.4.2.1). In the field conditions only DLMO calculations were performed, while 
in some laboratory studies performed at the CIU both DLMO and melatonin 
suppression analysis were performed on the salivary data.
2.4.4 Sleep Diary
In studies where the sleep diaries were only used to establish that the pre-study 
instructions of a regular sleep/wake pattern were followed before participating in the 
laboratory study, sleep diary data were just visually checked and visually compared to 
the AWL data. They were not analysed further.
In the field studies (Chapter 4 and 5), the following parameters were taken from the 
sleep and nap diaries and analysed:
• sleep onset (h)
• sleep latency (mins)
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• number of night awakenings/night
• duration of night awakenings/night (mins)
• actual sleep duration (h)
actual sleep duration (h) = (sleep offset -  sleep onset) -  (sleep latency + 
night sleep awakenings)
• sleep offset (h)
• sleep quality (1-9; 1 - best sleep, 9 - worst sleep)
• actual sleep efficiency (%; formula includes sleep latency and night 
awakenings)
actual sleep efficiency (%) = (actual sleep duration/(sleep offset -  sleep 
onset)) * 100
• number of naps/day
• duration of naps/day (mins)
2.4.5 Actigraphy
From the actigraphic sleep analysis program (Actiwatch Activity and Sleep Analysis 
version 5.10) the following sleep parameters were analysed:
• sleep onset (h)
• sleep offset (h)
• sleep latency (mins)
• fragmentation index corresponding to the number of night awakenings/night
• actual wake time corresponding to the duration of night awakenings (mins)
• actual sleep duration (h) (includes sleep latency and night awakenings)
• sleep efficiency (%) (includes sleep latency and night awakenings)
2.4.6 Mood and Performance
The raw data for both the VAS mood scales (length from the start of the line to the 
marked vertical point by the subject in cm.mm) and DSST performance (number of
Chapter 2
correctly completed symbols in 2 mins) tests were normalised for each subject using 
the z-score method. The following formula was used:
z -  score = raw value -  mean value (x)
;  SD (x)
Raw value -  score for each time point
Mean value (x) -  mean value of all time points across the day
SD (x) -  standard deviation from the mean value
2.4.7 Statistical Analysis
Methods for statistical analysis will be detailed in each chapter separately.
Chapter 3
Chapter 3:
LIGHT-INDUCED MELATONIN SUPPRESSION: EFFECT OF AGE IN THE 
RESPONSE TO SHORT WAVELENGTH LIGHT
Chapter 3
-------------- 89
3.1 INTRODUCTION
Distinct short wavelength sensitivity was identified as the most potent wavelength in 
the suppression of nocturnal melatonin synthesis (Section 1.2.1.3.3). Recent research 
also demonstrates that the ability of light to phase advance and phase delay circadian 
rhythms shows short wavelength sensitivity (Section 1.2).
Many studies have reported age-related alterations in different components of the 
circadian system (Section 1.3). Of particular relevance are changes in the ageing eye 
(Section 1.3.2.1), especially the reported reduction in the transmission of short 
wavelength light. This age-related change may affect photic entrainment of the 
circadian clock and may in part explain some of the age-related changes in circadian 
rhythmicity (Section 1.3.2).
As short wavelength light has been found to be the most effective in suppressing 
nocturnal plasma melatonin (Section 1.2.1.3.3) and as transmission of these short 
wavelengths is reduced with ageing it might be expected that with ageing the 
sensitivity of older people to short wavelength light is reduced. This hypothesis, 
however, has not been tested to date.
3.2 AIMS and HYPOTHESES
The aim of the present study was to investigate any age-related changes in the ability 
of short wavelength light to suppress nocturnal melatonin. Using the action spectrum 
data (Thapan et al., 2001) the present study was designed to test the effectiveness of 
short (456 nm) wavelength light compared with medium (548 nm) wavelength light to 
suppress nocturnal melatonin, in young and postmenopausal women (Section 1.5.1).
Null hypothesis stated that there would be no difference between young and elderly 
postmenopausal subjects in their response to short and medium wavelength light. 
Alternative hypothesis stated that there would be a significant difference between 
young and elderly postmenopausal subjects in their response to short and medium 
wavelength light (Section 1.5.1).
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3.3 METHODS
The spectral sensitivity of light-induced melatonin suppression was investigated in 
the elderly and young. Ethical permission was obtained from the University of Surrey 
Ethics Committee (ACE/97/53/SBS). All subjects gave informed consent (Appendix 
E) after reading participants information sheet (Appendix F) and approval from 
subjects general practitioner was obtained.
3.3.1 Subject Inclusion Criteria
The subject inclusion criteria for the young group was as follows:
• Females 18-30 yrs old
• Taking oral contraceptives
• Not on a “break week” from the contraceptives during the study nights
• Not taking medication that affects melatonin production (p-blockers, calcium 
channel blockers, a-blockers, non steroidal anti inflammatory drugs - NSAID, 
benzodiazepines, antidepressants, hypnotic drugs, antipsychotic, 
barbiturates, antiepileptic drugs)
• Have a detectable (> 5 pg aMT6s/24 h) aMT6s rhythm
• Attend an ophthalmological examination (Section 3.3.4.3)
• Free of optical disorders (glaucoma and cataract)
• Not colour blind
The subject inclusion criteria for the elderly group was as follows:
• Postmenopausal females (50 yrs and over). Postmenopausal status was 
defined as a period of 12 months without menstruation. Hormonal status was 
confirmed by blood serum analysis for follicle stimulating hormone (FSH), 
lutenising hormone (LH) and oestradiol
• Not taking hormone replacement therapy (HRT)
• Have a detectable (> 5 pg aMT6s/24 h) aMT6s rhythm
• Attend an ophthalmological examination (Section 3.3.4.3)
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• Not taking medication that affects melatonin production (p-blockers, calcium 
channel blockers, a-blockers, NSAID, benzodiazepines, antidepressants, 
hypnotic drugs, antipsychotic, barbiturates, antiepileptic drugs)
• Free of optical disorders (glaucoma and cataract)
• Not colour blind
3.3.2 Subject Exclusion Criteria
• Subjects were excluded if the inclusion criteria were not met
• They had donated blood in the previous 4 months
• They had been doing any shift work within a month of the experiment
• They had travelled over more than 2 time zones within a month of the 
experiment
• They suffered from glaucoma, cataract or tropicamide allergy
• Were colour blind
• Failed to obtain GP’s consent
• Failed to sign a participant’s consent form
3.3.3 Subjects Studied
Detailed demographic details of all the subjects studied are shown in Table 3.1. In 
total, 41 subjects were recruited onto the study, 4 withdrew during the study and 3 
were excluded from the calculations due to low undetectable melatonin levels. Two 
groups of subjects, young (n = 13, aged 24.2 ± 3 .1  yrs, mean ± SD) and 
postmenopausal (n = 21, aged 57.5 ± 4.8 yrs) women were included in the analysis.
3.3.4 Pre-Study Measurements
3.3.4.1 General Health and Sleep Screening
General health and sleep screening of all subjects was performed as described in 
Section 2.1.1.
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Table 3.1 Demographic details of young and postmenopausal women.
Subject Age Hormonal Status PSQI
O1X Acr. 
Time (h)
aMT6s 
(pg/24 h)
Light Treatment 
Start (hh:mm)
Young
EULSS-02 20 Microgynon 30 5 neither 4.6 26.8 23:30
EULSS-03 21 Depa-provera (inj) 2 neither 4.9 47.9 00:15
EULSS-04 25 Microgynon 30 2 neither 4.3 20.9 00:15
EULSS-05 30 Microgynon 30 3 neither 6.1 13.9 01:00
EULSS-06 23 Mercilon 4 mod evening 5.5 20.2 01:00
EULSS-10 25 Dianette 4 mod morning 3.0 13.8 00:15
EULSS-11 25 Microgynon 30 3 neither 5.2 25.9 01:00
EULSS-12 26 Micronor 5 neither 4.6 23.8 01:00
EULSS-14 21 Microgynon 30 1 neither 5.7 22.2 01:00
EULSS-16 25 Microgynon 30 0 morning 5.0 20.8 01:00
EULSS-17 21 Ovranitt 2 neither 4.6 28.8 00:15
EULSS-18 24 Meliane 1 mod evening 5.6 14.2 00:15
EULSS-25 29 Implanon 4 evening 5.9 13.6 02:30
mean 24.2 2.8 5.0 22.5
SD 3.1 1.6 0.8 9.2
Postmenopausal
EULSS-01 54 No HRT 4 morning 3.6 19.3 23:30
EULSS-08 62 No HRT 1 neither 3.0 9.9 23:30
EULSS-15 63 No HRT 10 mod morning 4.2 5.0 23:30
EULSS-20 64 No HRT 3 neither 4.8 2.4 00:15
EULSS-21 55 No HRT 15 neither 4.4 6.6 00:15
EULSS-22 60 No HRT 4 mod morning 2.9 2.8 23:30
EULSS-23 63 No HRT 6 mod morning 4.6 18.5 23:30
EULSS-24 54 No HRT 13 mod morning 5.6 4.0 01:00
EULSS-26 51 No HRT 6 mod morning 3.9 12.4 00:15
EULSS-28 70 No HRT 13 mod morning 1.2 12.3 22:00
EULSS-29 54 No HRT 4 neither 4.6 14.9 00:15
EULSS-31 53 No HRT 6 mod morning 0.5 12.3 22:00
EULSS-32 56 No HRT 3 neither 2.9 16.1 23:30
EULSS-34 60 No HRT 1 neither 4.3 14.8 00:15
EULSS-35 54 No HRT 6 mod morning 3.5 4.2 23:30
EULSS-36 52 No HRT 4 mod morning 8.7 19.6 02:30
EULSS-37 55 No HRT 1 neither 5.4 16.3 01:00
EULSS-38 59 No HRT 8 mod morning 3.2 6.5 23:30
EULSS-39 56 No HRT 3 mod morning 4.0 29.3 00:15
EULSS-40 54 No HRT 2 mod morning 3.8 12.6 23:30
EULSS-41 58 No HRT 3 mod morning 4.3 20.8 00:15
mean
SD
57.5
4.8
5.5
4.1
4.0
1.6
12.4
7.0
PSQI - Pittsburgh sleep quality index score; H-0 Horne-Ostberg score; Acr. Time - 
Acrophase Time
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3.3.4.2 aMT6s Screening
All subjects collected urine as described in Section 2.2.2. aMT6s concentrations 
were determined by RIA in human urine (Section 2.3.2). Analysis of aMT6s 
production levels and acrophase times were performed as described in Section 
2.4.1.
These results were used to schedule the timing of light administration to occur on 
the rising phase (circadian time (CT) 16.5 - 18.5 h) of the endogenous melatonin 
rhythm (CT 21 was taken as the peak time of the aMT6s rhythm). Subjects that had 
less than 5 pg aMT6s/24h production were not recruited onto the study because it 
was assumed that it would be very hard to determine a degree of melatonin 
suppression in those subjects.
3.3.4.3 Ophthalmology
All subjects underwent an extensive ophthalmologic examination (uncorrected 
vision, near vision, ophthalmoscopy of retina and macula, pupil reactions, Henson 
field test, refraction, intraocular pressure, oculomotor status, stereo acuity, 
accommodation, colour vision). All examinations were performed by the Nicklins 
Opticians, Guildford.
3.3.4.4 Menopausal Status
Blood (10 ml) was collected from each subject. After clotting at room temperature 
the blood was centrifuged and the serum separated. Serum samples were stored at 
-20°C prior to analysis. Analysis was performed by Southhampton General Hospital. 
Menopausal status was confirmed by hormone analysis of FSH, LH and oestradiol 
(FSH 22-153 |U/L, LH 11-40 IU/L and oestradiol < 200 IU/L).
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3.3.4.5 Stability of Circadian Phase
To ensure the stability of estimated circadian phase all subjects were asked to keep 
to a regular sleep wake schedule (23:00 -  07:00 h) for 3 days before the study 
commenced. Regularity of the subject’s sleep/wake cycle was assessed subjectively 
by a sleep diary (Section 2.2.1) completed each day upon wakening. Subject 
compliance was objectively monitored by Actiwatch L (Section 2.2.5), which was 
analysed when subjects entered the Clinical Investigation Unit (CIU). Actigraphic 
and sleep diary recording continued throughout the study sessions.
Subjects were asked to refrain from heavy exercise, alcohol, caffeine and bright light 
for 24 h before the study sessions. This was subjectively confirmed when subjects 
entered the CIU by questions asked by a researcher (Have you done any exercise 
in the last 24 h? How many cups of coffee/tea have you consumed in the last 24 h? 
Have you had any chocolates or alcohol in the last 24 h?).
3.3.5 Experimental Protocol
3.3.5.1 Study Design
The study was conducted in the CIU, School of Biomedical and Molecular Sciences 
at the University of Surrey. Each study session was composed of 2 study legs 
separated by 5 days. Each study leg lasted 3 consecutive nights (Fig. 3.1). Upon 
arrival at the CIU subjects had an indwelling cannula placed in one arm under local 
anaesthetic by a qualified nurse. Night 1 (N1) of each week was a baseline night 
(20:00-07:00 h) with no light exposure. Blood samples for dim light melatonin onset 
(DLMO) were collected at 30 minute intervals on N1 (20:00-23:00 h). Following N1 
were two light exposure nights, N2 and N3.
Posture and environmental light were controlled throughout the study (N1- 19:00- 
23:00 h: < 5 lux at eye level in direction of gaze and 23:00-07:00 h: 0 lux, complete 
darkness with subjects wearing eye masks; N2 and N3 -  21:00-23:00 h: < 5 lux and
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23:00-07:00 h: 0 lux, complete darkness with all subjects wearing eye masks, 
except during light treatment). Pupils were dilated with one drop of a short acting 
pupil dilator, Tropicamade 0.5% (Ghauvin Pharmaceuticals, UK) administered to 
each eye 90 mins before light exposure. On each night of the study session (N1, N2 
and N3) blood samples were taken at -90, -15, 0, 15, 30, 45, 60, 75, 90 and 120 
mins around the light exposure (0 is the start of light exposure). Blood samples were 
collected into lithium heparin tubes, which were centrifuged for 10 mins at 3000 rpm 
at 4°C. Plasma was separated and stored at -20 °C until analysis.
3.3.5.2 Light Administration
The baseline night (N1) was followed by two "light exposure" nights (N2 and N3) 
with each subject being exposed to 30 mins of monochromatic light at two different 
wavelengths and irradiances (A,max 456: 3.8 and 9.8 |nW/cm2; ^max 548 nm: 28 and 62 
pW/cm2). On N2 subjects were exposed to the lower irradiance of the selected light 
wavelength followed by the higher irradiance on N3. The same 3-night protocol was 
repeated during the second study session using the different wavelength. The order 
of light wavelength exposure was randomised.
During the 30 mins of light administration subjects kept their heads in specially 
constructed 45 cm diameter spheres (Apollo Lighting, Leeds, UK), with an opening 
on one side where an adjustable chin rest and head band allowed subjects to focus 
their gaze on the centre point at the back of the sphere (Fig. 3.2). The inside of the 
spheres were coated with 8 coats of white reflective paint (Kodak White Reflective 
Coating, Integra Bioscience Ltd., Lechworth, Hertfordshire, UK) providing a 96% 
reflective surface. The light sphere was designed to provide uniform illumination of 
the entire retina. The sphere was illuminated by the metal halide arc lamp 
(Enlightened Technologies Associates Inc., Fairfax, VA, USA) and connected to the 
sphere via a fibre optic cable attached at a 20° angle at the top of the dome.
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Fig. 3.2 Light administration system: sphere, light box, optic fibre.
3.3.5.3 Monochromatic Light
Interference filters were used to produce monochromatic light. These filters are 
defined by the maximum transmission (kmax) of their wavelength and half-maximum 
bandwidth (km ). Monochromatic filters at 2 different wavelengths of kmax 460 and 
560 nm and km  10 nm were used (Fig. 3.3). It is important that the light strikes the 
mirrored side of the filter at 90 0 angle as the angle at which light falls on the filter 
can modify their transmission spectra.
(a) (b)
Fig. 3.3 Monochromatic light administration of (a) ?.max 456 nm and (b) Xmax 548 nm.
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The equipment used in this study altered the transmission spectra, which were 
checked with a spectrometer (Spectrascan 650 portable, Photoresearch, 
Chadsworth, CA, USA) at eye level (Table 3.2) (Fig. 3.4).
Table 3.2 Monochromatic filters transmission: original and actual measurements.
Coherent Ealing Original Measurements Actual Measurements
X max (nm) X 1/2 (nm) X max (nm) X 1/2 (nm)
4 6 0 1 0 4 5 6 7 - 1 3
5 6 0 1 0 5 4 8 6 - 1 1
10CH100n
80-80-
60-|  60H
8 
‘Eto c 40-
2
20“20-
1---------1-------- 1—
480 530 580380 430 380 430 480 530 580
Wavelength (nm)
Fig. 3.4 Transmission of (a) Xmax 456 nm light (—) altered by the light set up used and 
compared to the original transmission provided by Coherent Ealing (—) and (b) XmaK 546 nm 
light (—) altered by the set up used compared to the original transmission provided by 
Coherent Ealing (—).
Modified from Thapan, 2001
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3.3.5.4 Light Measurements and Calculations
When studying a light dependent response (e.g. melatonin suppression), radiometric 
irradiance light measures must be used because it measures all radiant energy from 
all directions over 180° field of view (Reviewed in Foster, 2005). The light irradiance 
was measured in pW/cm2 at the subjects' eye level (portable radiometer, Macam 
Photometries Ltd., Livingstone, Scotland, UK) and converted to photons/cm2/sec.
Photons/cm2/sec = irradiance (pW/cm2) / energy of 1 photon at X 456 or 548 nm 
(Table 3.3).
Table 3.3 Photon density for ^max 456 and 548 nm light per second and for 30 mins of light 
exposure.
A,max (nm) Irradiance (pW/cm2) Photons/cm2/sec Photons/cm2
4 5 6 3 . 8 8 . 7 2 E + 1 2 1 . 7 5 E + 1 6
9 . 8 2 . 2 5 E + 1 3 4 . 0 5 E + 1 6
5 4 8 2 8 7 . 7 2 E + 1 3 1 . 3 9 E + 1 7
6 2 1 . 7 1 E + 1 4 3 . 0 8 E + 1 7
This conversion was necessary because photopigments act as photon counters 
where the number of photons is important rather than the photon energy assessed 
by irradiance measures. These light irradiances were chosen to give submaximal 
suppression of nocturnal plasma melatonin, according to the Thapan et al. (2001) 
data.
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3.3.6 Data Analysis
3.3.6.1 RIA of Melatonin
Plasma melatonin levels were measured by RIA for human plasma as described by 
Section 2.3.3. All samples from each subject for each study leg were measured in 
one assay. The mean (± SEM) limit of detection for all assays was 4.6 ± 0.2 pg/ml. 
The interassay coefficients of variation (CV) were 15% at 26 pg/ml (n=46), 18% at 
54 pg/ml (n=38), 14% at 139 pg/ml (n=27) and 9% at 235 pg/ml (n=12).
3.3.6.2 DLMO and Melatonin Suppression
DLMO and light-induced melatonin suppression were calculated as described in 
Sections 2.4.2.1 and Section 2.4.2.2, respectively.
3.3.6.3 Spectral Lens Density
Ideally, individual lens density measurements within each subject would provide 
more precise results when relationship between individual melatonin suppression 
and lens density is analysed. However, due to the difficulties in performing these 
specialised measurements average spectral lens density calculations for each 
subject were done in accordance with the Pokorny et al. (1987) two-factor non-linear 
lens density spectrum model. Currently, this is the best possible alternative method 
that is in use (Van den Berg, 1993; Savage et al., 1993) and that has been validated 
against studies that have individually measured lens density (Xu et al., 1997).
The optical density of the total lens transmission (T l) is separated into two 
components which are light-wavelength dependent, (i) portion of the lens affected by 
ageing after the age of 20 (TLi) and (ii) stable portion after the age of 20 (TL2)-
The optical density of the lens of an average individual between the ages of 20 and 
60 was calculated by the following formula:
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Tl = TLi [1 + 0 .02 (A -32 )] + TL2 
Over the age of 60:
T l = T li [1.56 + 0.0667(A -  60)] + TL2
T l - the optical density of the total lens transmission,
TLi - lens portion affected by ageing after age 20 
TL2 - lens portion not affected by ageing after age 20 
A - age of the subject
Values for Tli and T l2 have been tabulated for each wavelength of light by Pokorny 
et al. (1987). For the optical density of the total lens transmission of a completely 
dilated pupil (> 7 mm) the calculated Rvalue was multiplied by 0.86 (Pokorny et al., 
1987).
Using this model the average spectral lens density was estimated for adults aged 
20-80 years old with completely open (> 7 mm) pupils.
3.3.6.4 Statistical Analysis
Unpaired Student’s t-test was used to compare urinary aMT6s production, aMT6s 
acrophase times and DLMO between the young and postmenopausal subjects.
Melatonin suppression was compared between the two groups (young and 
postmenopausal) across different light treatments using two-way repeated 
measures analysis of variance (ANOVA)(Statistica, StatSoft Ltd. UK). The area 
under the curve (AUC) of the percentage melatonin suppression from 0 mins Gust 
before the lights were switched on) to 45 mins after lights on was also calculated 
and two-way repeated measures ANOVA performed on the data. In view of the 
hypothesis (Section 1.5.1) that states that age-related changes in lens density would 
reduce the response to 456 nm light but not to 548 nm light, the two wavelengths of 
light (456 nm and 548 nm) were analysed separately. Significant results were further 
analysed post hoc using the Tukey Honestly Significant Difference (HSD) test.
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3.4 RESULTS
3.4.1 Urinary aMT6s Production and Acrophase Time
During the pre-screening procedure analysis of urinary aMT6s were performed to 
estimate aMT6s production levels and acrophase times for each subject (Table 3.1).
Statistical analysis of the urinary aMT6s parameters between the two groups of 
subjects showed that young women had significantly higher 24 h aMT6s production 
(22.6 ± 2.6 jig/24 h; mean ± SEM) when compared to the postmenopausal women 
(12.4 ± 1 .5  pg/24 h) (p < 0.05; unpaired Student’s t-test) (Fig. 3.5a). Furthermore, 
the postmenopausal women had significantly earlier aMT6s peak time (4.0 ± 0.3 h) 
compared to the young women (5.0 ± 0.2 h; p < 0.05)(Fig. 3.5b).
( a ) (b)
301
CNJ
*0)
3  s
C  m 20- 
.2 CO
o +lis2 <D
w —  10 -
<1)
E _
■■*= s
8 CO CO
O d) 03 g
CO
CO
CO
6
5
4
3
2
Fig. 3.5 Urinary aMT6s (a) production levels and (b) acrophase times in young \ and 
postmenopausal □  subjects.
* p < 0.05; compared to young group
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3.4.2 Repeatability of the Melatonin Rhythm
Sometimes poor repeatability of the melatonin rhythms was noted between the 
baseline nights and light exposure nights within a subject. When concentrations of 
melatonin (pg/ml) were compared for the 0 min time point on N1, N2 and N3 of both 
light treatments it was seen that 16 subjects out of 32 had 20% or more difference in 
their melatonin levels.
Out of 21 postmenopausal subjects 10 (Table 3.4) had a 20% or more difference in 
their melatonin concentrations between the baseline and light treatment nights and 6 
young subjects out of 13 (Table 3.5) had this difference in at least one of the 
conditions. There was no difference in % repeatability between the two groups with 
46% young subjects showing more than 20% difference in melatonin concentrations 
at the 0 min time point between the baseline night and light treatment nights and 
48% of postmenopausal subjects showing the same poor repeatablity.
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3.4.3 Plasma DLMO
DLMO was calculated for all subjects apart from 3 in the postmenopausal group. In 
these subjects the baseline values were too high for correct calculation and they 
were excluded from the analysis (Table 3.6). Postmenopausal women had a 
sigificantly earlier DLMO (21:08 ± 00:10 hh:mm, 21.13 ± 0.16 decimal h; mean ± 
SEM) compared to the young subjects (21:46 ± 00:16 hh:mm, 21.76 ± 0.26 decimal 
h) (p < 0.05) (Fig. 3.6).
Table 3.6 DLMO values in decimal and clock time for (a) young subjects and (b) 
postmenopausal women.
(a) (b)
Subject
Decimal
Hour
(h)
Clock
Time
(hh:mm) Subject
Decimal
Time
(h)
Clock
Time
(hh:mm)
EULSS-02 20.70 20:42 EULSS-01 20.84 20:50
EULSS-03 21.61 21:37 EULSS-08 21.28 21:17
EULSS-04 21.24 21:14 EULSS-15 22.41 22:25
EULSS-05 21.75 21:45 EULSS-20 22.86 22:52
EULSS-06 23.33 23:20 EULSS-21 21.52 21:31
EULSS-10 22.24 22:14 EULSS-22 20.65 20:39
EULSS-11 21.03 21:02 EULSS-23 21.15 21:09
EULSS-12 22.77 22:46 EULSS-24 21.27 21:16
EULSS-14 21.53 21:32 EULSS-26 20.86 20:50
EULSS-16 20.54 20:32 EULSS-28 20.43 20:26
EULSS-17 21.25 21:15 EULSS-29 * *
EULSS-18 21.47 21:28 EULSS-31 * *
EULSS-25 23.40 23:24 EULSS-32 20.50 20:30
mean 21.76 21:46 EULSS-34 21.21 21:13
SD 0.92 00:55 EULSS-35 21.40 21:24
SEM 0.26 00:16 EULSS-36 * *
EULSS-37 21.09 21:05
EULSS-38 21.35 21:21
EULSS-39 20.55 20:33
EULSS-40 20.63 20:38
EULSS-41 20.31 20:19
mean 21.13 21:08
SD 0.66 00:40
SEM 0.16 00:10
* - baseline values too high for calculation
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Fig. 3.6 DLMO for each individual subject in the young and postmenopausal group. 
—  mean value; * p < 0.05 compared to young group
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3.4.4 Light-Induced Melatonin Suppression
Melatonin suppression (%) was calculated as described in Section 2A.22 . Table 3.7 
shows complete individual melatonin suppression for all light treatments in young 
women. Within the postmenopausal group two subjects (EULSS-23 and EULSS-36) 
had incomplete data sets resulting in inability to calculate melatonin suppression 
(Table 3.9 a). As a result these two subjects were excluded from the statistical 
analysis, altering the mean melatonin suppression (Table 3.8 b).
Table 3.7 Melatonin suppression (%) in young subjects following all light exposures.
n Subject Age
Xmax456 nm 
(p.W/cm2)
3.8 9.8
m^ax 568 nm 
(pW/cm2)
28 62
1 EULSS-02 20 21.7 25.3 31.5 24.7
2 EULSS-03 21 4.3 6.6 -0.5 19.2
3 EULSS-04 25 26.9 39.6 31.0 27.8
4 EUL.SS-05 30 -0.3 4.6 -10.5 -2.1
5 EULSS-06 23 12.2 -6.3 47.4 24.7
6 EULSS-10 25 24.8 19.0 38.0 39.7
7 EULSS-11 25 -14.4 11.4 2.7 3.5
8 EULSS-12 26 9.2 30.5 43.2 39.7
9 EULSS-14 21 40.0 61.8 48.6 55.8
10 EULSS-16 25 52.2 64.3 31.9 25.8
11 EULSS-17 21 24.8 -4.0 25.0 31.3
12 EULSS-18 24 11.0 38.9 54.5 56.8
13 EULSS-25 29 27.0 39.5 48.1 44.0
mean 18.4 25.5 30.1 30.1
SD 17.5 23.0 20.8 17.5
SEM 4.8 6.4 5.8 4.9
n 13 13 13 13
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Table 3.8 Melatonin suppression (%) in all postmenopausal women (a) following all light 
exposures, (b) Due to the missing data, subjects EULSS-23 and EULSS-36 were removed 
from the statistical analysis and the means, SD snd SEM recalculated.
(a)
n Subject Age
^max456 nm 
pW/cm2
3.8 9.8
Xmax568 nm 
pW/cm2
28 62
1 EULSS-01 54 -39.4 0.7 0.7 28.6
2 EULSS-08 62 -7.9 4.2 15.4 43.8
3 EULSS-15 63 10.0 11.4 31.7 11.6
4 EULSS-20 64 -26.5 -5.9 -59.1 33.3
5 EULSS-21 55 15.5 38.9 42.5 44.2
6 EULSS-22 60 2.6 -12.5 -58.3 2.1
7 EULSS-23 63 28.0 51.7 21.1
8 EULSS-24 54 4.6 10.4 19.9 25.5
9 EULSS-26 51 20.5 29.7 43.8 37.7
10 EULSS-28 70 -5.7 -20.7 -14.7 -14.0
11 EULSS-29 54 -48.5 -8.0 -50.0 0.0
12 EULSS-31 53 34.2 47.5 46.2 52.5
13 EULSS-32 56 12.2 21.3 13.8 48.9
14 EULSS-34 60 24.3 37.8 44.8 53.6
15 EULSS-35 54 -30.0 12.5 15.5 -25.0
16 EULSS-36 52 11.0 44.2 35.4
17 EULSS-37 55 26.1 23.5 49.3 31.9
18 EULSS-38 59 10.4 25.0 33.9 48.2
19 EULSS-39 56 -7.0 14.7 20.1 24.0
20 EULSS-40 54 -20.5 9.7 2.9 33.7
21 EULSS-41 58 -0.7 -2.3 1.8 5.4
mean 0.6 15.9 12.2 25.6
SD 22.9 20.6 33.2 23.0
SEM 5.0 4.5 7.3 5.3
n 21 21 21 19
(b)
mean -1.4 12.5 10.5 25.6
SD 23.0 18.5 34.5 23.0
SEM 5.0 4.0 7.5 5.3
n 19 19 19 19
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Figure 3.7 shows an example of light-induced melatonin suppression following 
exposure to different wavelengths and irradiances of light in one young and one 
postmenopausal subject. Maximal suppression of melatonin occurred 30 to 45 mins 
following the start of the light exposure (Fig. 3.8). Melatonin levels returned to 
baseline values 30 to 60 mins after lights were switched off depending on the 
intensity of the light.
Melatonin suppression (%, mean ± SEM) for each light exposure is plotted in Fig. 
3.9. Two-way repeated measures ANOVA revealed a significant effect of both age 
(F(i,30) = 5.80, p = 0.02) and 456 nm light (F(i,30) = 11.83, p = 0.002) on melatonin 
suppression. Tukey HSD post-hoc test revealed a significant reduction in melatonin 
suppression in the postmenopausal subjects following both 3.8 pW/cm2 (-1.4 ± 5%) 
and 9.8 pW/cm2 (12.5 ± 4%) 456 nm light (p < 0.001 and p < 0.05, respectively) 
compared to melatonin suppression following the same light irradiances (18.4 ± 
4.8% and 25.5 ± 6.4%, respectively) in young subjects. No interaction between age 
and the 456 nm light was observed (F(i,3o) = 1.25, p = 0.27). There was also no 
significant effect of age (F(i,30) = 2.17, p = 0.15), light irradiance (F(ii3o) = 2.89, p = 1) 
or interaction (F(i,30) = 2.90, p = 1) with the 548 nm light.
3.4.5 Area Under the Curve
Similar results were obtained from the AUC 0-45 mins analysis (Fig. 3.8). Two-way 
repeated measures ANOVA of AUC 0-45 mins showed an effect of both age (F(i,3o)
= 4.43, p = 0.04) and 456 nm light treatment (F(1i30) = 9.82, p = 0.004) on melatonin 
suppression without interaction (F(i,30) = 0.55, p = 0.46). Tukey HSD post-hoc test 
revealed a significant reduction in melatonin suppression (AUC 0-45 mins) in the 
postmenopausal subjects following 3.8 |iW/cm2 456 nm light (p < 0.01) and a non 
significant trend following 9.8 jiW/cm2 456 nm light (p = 0.07) compared to the 
young subjects. Furthermore, no effect of age (F(1)30) = 0.50, p = 0.48), light 
irradiance (F(i,30) = 0.29, p = 0.59) or interaction (F(i,30) = 0.35, p = 0.55) following 
exposure to 548 nm light was noted.
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(a)
40 'max
35
30
25
20
15
10
5
0
-5
3.8 pW/cm2 9.8 jiW/cm2
»  (b>
Q.Q. 548 nmmax
28 nW/cm2 62 |iW/cm2
Fig. 3.9 Mean % melatonin suppression in young (= , n=13) and postmenopausal 
O . n=19) women across the 4 light treatments: (a) Xmax 456 nm: 3.8 pW/cm2 and 9.8 
|iW/cm2 (b) Xmax 548 nm: 28 pW/cm2 and 62 pW/cm2.
* p < 0.05; *** p < 0.001 compared to the corresponding young group
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3.4.6 Correlation between Lens Density and Melatonin Suppression
Average lens density for each subject was calculated for each wavelength (Amax 456 
and 548 nm) of light as described in section 3.3.6.3 (Table 3.9).
Table 3.9 Average spectral lens density for (a) young and (b) postmenopausal women 
calculated according to Pokorny et al. (1987).
(a)
Average Lens Density
Subject Age Xmax 456 nm A-max 548 nm
EULSS-02 20 0.182 0.063
EULSS-03 21 0.187 0.064
EULSS-04 25 0.206 0.071
EULSS-05 30 0.230 0.079
EULSS-06 23 0.196 0.068
EULSS-10 25 0.206 0.071
EULSS-11 25 0.206 0.071
EULSS-12 26 0.211 0.073
EULSS-14 21 0.187 0.064
EULSS-16 25 0.206 0.071
EULSS-17 21 0.187 0.064
EULSS-18 24 0.201 0.069
EULSS-25 29 0.225 0.077
0.202 0.070mean
SD
SEM
0.015 0.005
0.004 0.001
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Average Lens Density
Subject Age A/max 456 nm A-max 548 nm
EULSS-01 54 0.345 0.119
EULSS-08 62 0.405 0.140
EULSS-15 63 0.421 0.145
EULSS-20 64 0.437 0.151
EULSS-21 55 0.349 0.120
EULSS-22 60 0.373 0.129
EULSS-23 63 0.421 0.145
EULSS-24 54 0.345 0.119
EULSS-26 51 0.330 0.114
EULSS-28 70 0.533 0.183
EULSS-29 54 0.345 0.119
EULSS-31 53 0.340 0.117
EULSS-32 56 0.354 0.122
EULSS-34 60 0.373 0.129
EULSS-35 54 0.345 0.119
EULSS-36 52 0.335 0.115
EULSS-37 55 0.349 0.120
EULSS-38 59 0.368 0.127
EULSS-39 56 0.354 0.122
EULSS-40 54 0.345 0.119
EULSS-41 58 0.364 0.125
mean 0.373 0.129
SD 0.048 0.016
SEM 0.010 0.004
Highlighted subjects were excluded from the statistical analysis
A significant negative correlation was found between an individual’s spectral lens 
density and melatonin suppression following exposure to 456 nm light of 3.8 and 9.8 
juW/cm2 (F(2 ,29 ) = 3.87, multiple r = -0.45; p < 0.05) using multiple regression 
analysis (Fig 3.9). No significant correlation was noted between an individual's 
spectral lens density and melatonin suppression following exposure to 548 nm light.
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Lens Density Index
Fig. 3.9 Correlation between lens density index as calculated by Pokorny et al. (1987) and 
melatonin suppression following exposure to both intensities of 456 nm light ( •  - 3.8 and □  
- 9.8 nW/cm2).
* p < 0.05; multiple regression analysis
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3.5 DISCUSSION
The present study demonstrates, for the first time, that the ability of short 
wavelength light (A,max 456 nm) to suppress nocturnal melatonin is reduced with 
ageing. Melatonin suppression was significantly reduced in elderly women, when 
compared to a young group of subjects, following exposure to both irradiances (3.8 
and 9.8 pW/cm2) of short wavelength light. This statistically significant reduction was 
not observed following exposure to medium wavelength light (^max 548 nm: 28 and 
62 pW/cm2). Percentage of melatonin suppression showed the same age-related 
reduction after exposure to short wavelength light as did analysis of the AUC (0-45 
mins) of the melatonin rhythm. These findings extend the previous demonstration of 
the sensitivity of melatonin to short wavelength light (Section 1.2.1.3.3). Whether 
this reduced sensitivity will be observed when other parameters of the circadian 
system (e.g. phase shifting effects of light) are investigated remains to be 
established.
This phenomenon of an age-related reduction in responsivness of the circadian 
system to short wavelength light was correlated with an increase in lens density. 
Although age-related changes in lens density with a consequent reduction in the 
transmission of short wavelength light has been well characterised (Section 1.3.2.1), 
this is the first time that this phenomenon has been linked to a physiological non­
image forming light response i.e. melatonin suppression. Melatonin suppression was 
only significantly different between the two age groups following exposure to short 
wavelength light not following exposure to medium wavelength light. Both decreased 
pupil diameter (Section 1.3.2.1) and opacification of the ageing lens (Section 1.3.2.1) 
may contribute to the reduced amount of short wavelength light reaching the retina. 
Ideally, knowledge of the lens density of each study subject would be useful so that 
the data could be individually corrected. Using the two-factor non-linear lens density 
spectrum formula (Section 3.3.6.3) the average lens density for each subject was 
calculated. Lens density was shown to be negatively correlated with melatonin 
suppression following short wavelength light exposure. There was no statistically
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significant correlation between lens density and melatonin suppression following 
medium wavelength light exposure.
The current study also confirms the findings of a reduction in urinary aMT6s 
production in elderly subjects (Section 1.3.2.3.1). This reduction is also seen in 
plasma and CSF melatonin levels (Section 1.3.2.3.1). In the present study, the 
plasma data could not be used to estimate the amplitude of the melatonin rhythm 
since the protocol did not include sampling throughout the night. Blood sampling 
ceased 90 mins after the lights were switched off.
In agreement with previous findings (Section 1.3.1.2) the present study shows an 
advance in the peak time of the urinary aMT6s rhythm and in the timing of the 
DLMO in the.elderly subjects compared to the young. In the current protocol, the 
first blood sample was scheduled for 20:00 h on the baseline night where extra 
samples were collected to determine the subjects’ DLMO. In 3 elderly subjects 
20:00 h was too late to obtain baseline melatonin values for calculation of DLMO. An 
advance in the melatonin rhythm of these elderly women may explain this.
The current study also demonstrated poor repeatability of melatonin levels between 
the study nights and between the two study legs. In 16 out of 32 subjects the 
difference in melatonin levels at the 0 min time point (time of lights on) was more 
than 20% between the study nights. Usually the melatonin rhythm has been shown 
to be reliable with a high percentage of day-to-day and week-to-week repeatability 
(Section 1.2.1). There was no difference between the two groups of subjects since 
46% of young and 48% of elderly showed this between-nights variation. A possible 
explanation for this may be the difficulties obtaining blood from women in general, 
since blood sampling in young male subjects using the same protocol did not 
produce as much variation (Thapan et al., 2001). It could also be due to the 
difference in the lighting environment in the CIU between the baseline nights and the 
light exposure nights- light was dimmed at 20:00 h on the baseline night and on the 
light exposure nights it was not dimmed until 21:00 h.
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The present study only assessed light-induced melatonin suppression in women. 
Two studies (Boyce and Kennaway, 1987; Nathan et al., 2000) have shown no 
significant gender difference in melatonin suppression using a range of intensities 
(200 - 3000 lux) of white light. These findings were in contrast to a report, which 
showed females had a greater sensitivity to 2000 lux of white light in comparison to 
males (Monteleone et al., 1995). In a preliminary study comparing the response of 
young men and young women to monochromatic 456 nm and 548 nm light, although 
the young females showed reduced melatonin suppression compared to the men, 
these gender differences were not statistically significant (Skene, Middleton, 
Thapan, unpublished data). Thus, although it is most likely that older men would 
also show reduced sensitivity to short wavelength light similar to that demonstrated 
in older women, this remains to be shown.
Chapter 4
  120
Chapter 4:
EFFECT OF MELATONIN ADMINISTRATION ON SLEEP IN AGEING WOMEN
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4.1 INTRODUCTION
Age-related deterioration in sleep quality is well recognised in the literature (Section 
1.3.1.1). A number of studies have reported various changes in sleep with ageing 
such as earlier timing of sleep onset and offset, increased sleep latency, difficulty in 
maintaining sleep, increased nighttime awakenings and increased daytime napping 
(Section 1.3). In some people these changes cause daytime sleepiness, decreased 
alertness and performance and overall deterioration in the quality of life.
Reduction in melatonin levels with ageing has been shown in a number of studies 
(Section 1;3.2.3.1). Some researches have linked reduced melatonin levels to age- 
related sleep problems, suggesting that melatonin replacement therapy might be a 
solution for sleep problems in the elderly population. This so-called “melatonin 
hypothesis” has led to the experimental investigation of different doses and 
formulations of melatonin in the elderly in order to alleviate sleep disturbances 
(Section 1.4.4). Some studies have concluded that even small doses of melatonin 
(0.1 and 0.3 mg) that produce physiological melatonin levels were enough to 
improve sleep quality in the elderly (Zhdanova et al., 1995). In addition, higher 
doses of melatonin ( 3 - 6  mg) that produce pharmacological levels have also been 
shown to be effective (Section 1.4.4).
However, other studies have failed to find a link between low endogenous melatonin 
levels and sleep problems in the elderly (Section 1.4.4) reporting no differences in 
the aMT6s levels between older people with and without sleep problems 
(Lushington et al., 1998; Basket et al., 2001). Furthermore, Lushington et al. (1998) 
failed to find any significant relationship between aMT6s production levels and any 
self-reported sleep parameters. Using exogenous melatonin (5 mg) failed to improve 
sleep in their elderly subjects.
To the author’s knowledge no studies have investigated whether by improving sleep 
with melatonin administration alertness, daytime sleepiness and performance 
improves as well.
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4.2 AIMS and HYPOTHESES
The aims of. the present study were to investigate the effectiveness of 5 mg 
melatonin compared to placebo on objective and subjective sleep, alertness, mood 
and performance in elderly women (Section 1.5.2).
Null hypotheses stated that there would be no effect of melatonin, compared to 
placebo, on sleep, alertness, mood and performance in postmenopausal women 
with self-reported sleep problems. Alternative hypothesis stated that there will be a 
significant effect of melatonin, compared to placebo, sleep, alertness, mood and 
performance in postmenopausal women with self-reported sleep problems (Section 
1.5.2).
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4.3 METHODS
The effects of exogenous melatonin on objective and subjective sleep, mood and 
performance were assessed in 8 week field study, where placebo or melatonin were 
administered for 4 weeks each. Ethical permission to carry out this experiment was 
obtained from the University of Surrey Ethics Committee (ACE/2003/05/SBLS). All 
subjects gave informed consent (Appendix E) after reading participants information 
sheet (Appendix G) and approval from subjects general practitioner was obtained.
4.3.1 Subject Inclusion Criteria
The following inclusion criteria applied:
• Postmenopausal women (aged 50 yrs or over). Postmenopausal status was 
defined as a period of 12 months without menstruation
• Not taking HRT
• Subjective sleep problem or diagnosed timing and/or maintenance related 
sleep problem
• PSQI score greater than 5
• Not taking medication that affects melatonin production (p-blockers, calcium 
channel blockers, a-blockers, NSAID, benzodiazepines, antidepressants, 
hypnotic drugs, antipsychotic, barbiturates, antiepileptic drugs)
4.3.2 Subjects Exclusion Criteria
The following exclusion criteria applied:
• Regular shift work within a month of the study and during the study
• Travelling more than 2 time zones within a month of the study and during the
study
• Presence of any psychiatric disorders
• Failure to sign a consent form
• Failure to complete health and sleep pre-screening questionnaires
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4.3.3 Subjects Studied
In total, 12 subjects were recruited onto the study with 1 subject withdrawing from 
the study after 2 weeks. Therefore, 11 subjects (59.1 ± 6.2 yrs, mean ± SD) have 
been studied. All subjects were postmenopausal women with self-reported sleep 
problems (PSQI range 6-14) and on average a morning preference (H -0  score 58.9 
± 2.3, mean ± SEM) was observed. All subjects were free from medication known to 
affect the melatonin rhythm (Section 4.3.1) and were not taking HRT (Table 4.1).
4.3.4 Pre-Study Measurements
4.3.4.1 General Health and Sleep Screening
Screening of health and sleep of all subjects was performed as described in Section 
2.1.1. A general sleep quality questionnaire was added to this study in order to 
investigate the nature of the subjective sleep complaint (Appendix B).
4.3.5 Experimental Protocol
4.3.5.1 Study Design
Subjects were studied in their own homes for a period of 8 consecutive weeks. The 
study protocol is shown in Fig. 4.1. Participants were advised to follow their normal 
life style. The study was designed as a single blind, placebo-controlled crossover 
field study with 4 weeks of placebo and 4 weeks of melatonin daily administration. 
During the first 2 and last 2 weeks (weeks 1, 2 and 7,8) of the study placebo was 
administered with weeks 3, 4, 5 and 6 being melatonin administration weeks.
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A fast acting, gelatin capsule containing 5 mg of melatonin mixed with lactose 
(Special Licence Number: ML4351/01; Penn Pharmaceuticals, Tredegar, Gwent, 
UK) or lactose only (placebo) was taken each night 30 minutes before sleep. 
Administration of 5 mg fast acting melatonin produces supra physiological levels of 
melatonin in blood 30 mins after administration lasting for at least 8 h with melatonin 
still detectable in the blood 15 h later (Hack and Skene, unpublished data).
Subjective sleep and daytime napping were assessed by daily sleep and nap diaries 
(Section 2.2.1). Daily mood changes were investigated by VAS (Section 2.2.6) 
completed each morning upon waking. Objective sleep was assessed continuously 
using an AWL (Section 2.2.5).
Sequential urine samples were collected every 4 h (8 h overnight) for 48 h each 
week (Section 2.2.2). Alongside the urine collection, performance (DSST) (Section 
2.2.7) and mood (Section 2.2.6) were assessed every 2 h during wakefulness for the 
same 48 h each week. The mood test was always completed first so as not to be 
influenced by the performance test. On one occasion saliva samples were collected 
every 30 mins (Section 2.2.4) for the assessment of DLMO.
Reports of any adverse effects were encouraged with immediate notification to the 
project's medical supervisor. One subject (EUMT007) complained of a headache, 
tiredness and nausea in the morning while taking placebo and another (EUMT004) 
complained of an inability to sleep and diarrhoea while taking placebo.
4.3.6 Data Analysis
4.3.6.1 RIA of Urinary aMT6s
Urinary aMT6s was measured by RIA (Section 2.3.2). The limit of sensitivity for the 
assay was 0.5 ng/ml. The interassay CV were 13% at 4 ng/ml (n=10), 18% at 13 
ng/ml (n=10), and 11 % at 22 ng/ml (n=10).
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The data were used to estimate 24 h aMT6s production levels and aMT6s 
acrophase times (Section 2.4.1) for each day of the 48 h collection period and each 
week of the study. Only the weeks during the placebo treatment (weeks 1, 2, 7 and 
8) were used for the analysis while the melatonin treatment weeks (weeks 3, 4, 5 
and 6) were used to determine subject’s compliance with the study. The data 
obtained for each week were averaged to give a mean aMT6s production (pg/24 h) 
levels and aMT6s acrophase time (h). Out of 11 subjects, 10 subjects were used in 
the analysis as one subject (EUMT012) was excluded from the analysis due to 
incomplete urine collections.
4.3.6.2 RIA of Salivary Melatonin
Salivary melatonin was measured by RIA (Section 2.3.4). The limit of sensitivity for 
the assay was 0.8 pg/ml. The average quality controls (QC’s) were 6 pg/ml (n=2), 10 
pg/ml (n=2), and 22 pg/ml (n=2). The QC’s did not differ by more than 10%.
In total 10 subjects collected saliva samples and those were used in the analysis to 
determine the time of DLMO (Section 2.4.3), One subject (EUMT005) failed to 
complete the saliva collection diary and was excluded from the analysis.
4.3.6.3 Sleep and Naps Analysis
In total 8 sleep and 2 nap parameters were analysed from the subjective sleep diary 
data (Section 2.4.4) in 11 and 8 subjects, respectively. Three subjects (EUMT001, 
EUMT011 and EUMT014) did not nap during the study. The first 3 days of week 7 
were excluded from the analysis to avoid any hangover effects of residual 
melatonin. Days with missing data (not more than 3 days) were excluded from the 
analysis. The sleep and nap parameters were analysed for each treatment (placebo 
vs melatonin) and each subject to give the overall effects of melatonin. The 
statistical method used was 2-way repeated measured ANOVA to test for the effects 
of treatment and time on sleep parameters. In order to assess the effect of 
melatonin administration (compared to placebo) on subjective sleep parameters in
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each individual subject paired Student’s t-test was performed pairing the 
corresponding days of each treatment with each other (excluding the first 3 days of 
week 7 and 5). Since both treatments commenced on the same day of the week 
pairing was possible. Raw data were used in the analysis.
From actigraphically recorded sleep 7 sleep parameters were analysed (Section 
2.4.5). The first 3 days of week 7 were excluded from the analysis. To determine the 
overall effect of melatonin (compared to placebo) 2-way repeated measures ANOVA 
analysis was performed. In order to assess the effect of exogenous melatonin 
administration on objectively measured sleep parameters in each subject paired 
Student’s t-test was used in a same manner as described in subjectively measured 
sleep section.
4.3.6.4 Mood and Performance Analysis
All mood (both daily and weekly-every 2 h) and performance data were normalised 
as described in Section 2.4.5. The z -  scored data were analysed for the effects of 
melatonin, compared to placebo, the effect of day (for daily collected mood data) or 
the effect of time (for 2 h collected data) and any interaction between the two factors 
(treatment and time) using 2-way repeated measures ANOVA. The same statistical 
test was also performed on the normalised performance data. One subject was 
excluded from the analysis due to an incomplete mood and performance data set. 
Days with, missing data (not more than two days) were excluded from the mood 
analysis (day 6-week 5 and day 7-week 8).
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4.4 RESULTS
4.4.1 Urinary aMT6s Production and Acrophase Ti
Two subjects (EUMT002 and EUMT008) showed an advanced aMT6s acrophase 
time (1.9 and 1.8 h, respectively). One subject (EUMT011) had a delayed aMT6s 
acrophase time (9.5 h). The other 7 subjects had normal aMT6s acrophase times 
ranging from 2.6 to 3.6 h (3.5 ± 0.3 h; mean ± SEM) (Table 4.2).
The aMT6s production levels over 24 h ranged from 6.1 to 21.8 pg/24h with an 
average aMT6s production of 13.5 ± 1.6 pg/24h (Table 4.2).
4.4.2 Salivary DLMO
Average DLMO time for the 10 subjects was 20:15 ± 0:12 hh:mm (20.25 ± 0.20 
decimal h; mean ± SEM) (Table 4.4). The phase relationship between salivary 
DLMO and urinary aMT6s acrophase times ranged between 5.5 and 12.9 h (Table 
4.3). The delayed urinary aMT6s acrophase time observed in subject EUMT011 was 
not seen in the salivary DLMO giving a difference between the two markers of 12.9 
h. Without this value the average difference between the salivary DLMO time and 
the urinary aMT6s acrophase time was 6.9 ± 0.4 h.
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4.4.3 Subjective Sleep
Overall there was no statistical difference between the effects of melatonin or 
placebo on the 10 sleep and nap parameters analysed using the subjective sleep 
diary data (Table 4.4) (p > 0.05, 2-way repeated measures ANOVA). There was also 
no effect of day of the week on the sleep and nap parameters analysed, regardless 
of the treatment administered. No significant interactions between treatment and 
time were seen.
Table 4.4 Effects of melatonin administration, compared to placebo, on subjective sleep and 
nap parameters.
Sleep and Nap Parameters (units) Placebo 
(mean + SEM)
Melatonin 
(mean ± SEM)
Sleep Onset (h) 23.7 + 0.1 23.7 ±0.1
Sleep Latency (mins) 24 ±6 19 ±6
No. of Awakenings/night 1.7 ±0.2 1.6 ±0.2
Duration of Awakenings/night (mins) 42 ±6 43 ±9
Sleep duration (h) 6.5 ± 0.2 6.6 ± 0.2
Sleep Offset (h) 6.9 ±0.3 7.0 ± 0.3
Sleep Quality 4.9 ± 0.4 4.9 ± 0.5
Sleep Efficiency (%) 79.0 ±7.1 87.0 ±1.8
No. of Naps/day 0.3 ±0.1 0.3 ±0.1
Duration of Naps (mins) 9 ± 2 9 ± 3
n = 11 for the sleep parameters; n = 8 for the nap parameters
Comparing the effect of melatonin and placebo within each individual revealed that 
only one subject (EUMT007) showed some improvements in sleep during melatonin 
administration compared to placebo. In this subject a statistically significant 
reduction in the duration of nighttime awakenings was noted during the melatonin 
phase of the trial (29 ± 6 mins; mean ± SEM) compared to placebo (55 ± 9
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mins)(p<0.05). Sleep efficiency was also significantly improved during melatonin 
treatment (86,9 ± 2.3 %) compared to placebo (77.1 ± 15.1 %)(p < 0.05) (Fig 4.2).
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Fig. 4.2 (a) Duration of night awakenings and (b) sleep efficiency during melatonin (•) and 
placebo (o) administration in one subject (EUMT007). 
absent symbol -  missing data; Sat -  Saturday; Sun - Sunday
Statistically worse subjective sleep was noted in 3 sleep parameters of subject 
EUMT004 during melatonin treatment. Duration of nighttime awakenings 
significantly increased during the melatonin phase of the trial (126 ± 9 mins)
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compared to placebo (91 ± 11  mins) (p < 0.01). Sleep duration decreased during 
melatonin administration (6.3 ± 0.2 h) compared to placebo (6.9 ± 0.2 h) (p < 0.05) 
and sleep efficiency dropped during melatonin administration (73.0 ± 1 . 8  %) 
compared to placebo (79.7 ± 1 . 9  %) (p < 0.01) (Fig. 4.3). The sleep maps of 
subjects EUMT007 and EUMT004 are shown in Fig. 4.4.
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Fig. 4.3 (a) Duration of night awakenings, (b) sleep duration and (c) sleep efficiency during 
melatonin ( • )  and placebo (O) administration in one subject (EUMT004). 
absent symbol -  missing data; Sat -  Saturday; Sun - Sunday
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Two subjects showed a significant delay in sleep offset during melatonin treatment 
(EUMT001: 8.5 ± 0.1 h and EUMT010: 8.2 ± 0.2 h) compared to placebo (7.8 ± 0.2 h 
and 7.3 ± 0.2 h, p < 0.01 and p < 0.001, respectively). In contrast, subject EUMT006 
had a significant advance in sleep offset during melatonin administration (5.9 ±0.1 
h) compared to placebo (6.4 ± 0.2 h) (p < 0.05). The sleep maps of subjects 
EUMT001, EUMT010 and EUMT006 are shown in Fig. 4.5.
Out of the 11 subjects studied, 6 subjects showed no statistically significant changes 
in their subjective sleep during melatonin administration compared to placebo.
4.4.4 Objective Sleep
Objectively recorded activity data was analysed using an AWL recording device. No 
statistically significant differences in melatonin and placebo on the 7 actigraphic 
sleep parameters were observed (Table. 4.5) (2-way repeated measures ANOVA). 
In addition there was no significant effect of the day of the week on sleep 
parameters analysed, regardless of the treatment administered. No significant 
interactions between the treatment and time was noted.
Table 4.5 Effects of melatonin administration, compared to placebo, on objective sleep.
Sleep and Nap Parameters (units) Placebo 
(mean ± SEM)
Melatonin 
(mean ± SEM)
Sleep Onset (h) 23.5 ±0.1 23.4 ± 0.1
Sleep Latency (mins) 12 ± 2 12 ± 1
No. of Awakenings/night 28.9 ± 3.5 28.4 ± 3.
Duration of Awakenings/night (mins) 66 ±9 69 ±10
Sleep duration (h) 6.8 ± 0.3 7.0 ± 0.3
Sleep Offset (h) 7.4 ± 0.3 7.6 ± 0.3
Sleep Efficiency (%) 82.6 ±1.8 82.8 ±1.8
A significant reduction in sleep latency during melatonin administration (12 ± 2 mins; 
mean ± SEM) compared to placebo (21 ± 4 mins, p < 0.05) was seen in one subject 
(EUMT003). This finding is not consistent with the subjectively analysed sleep 
where subject EUMT003 showed no significant change in sleep latency while taking 
melatonin (23 ± 3 mins) compared to placebo (24 ± 2 mins).
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Three subjects showed worse objective sleep during melatonin administration. 
Subject EUMT002 showed longer sleep latency while taking melatonin (12 ± 5 mins) 
compared to placebo (4 ± 2 mins) (p < 0.05). Another subject (EUMT005) showed 
reduced sleep efficiency (78.5 ±1.0 %) with increased duration of night awakenings 
(102 ± 6 mins) during the melatonin administration weeks compared to placebo 
(82.3 ±1.3  % and 81 ± 6 mins, p < 0.01 and p < 0.01, respectively). These findings 
are not consistent with the subjectively analysed sleep where only subject EUMT004 
reported worse sleep while taking melatonin. Analysis of objective sleep of subject 
EUMT010 revealed an increase in the duration of nighttime awakenings during 
melatonin administration (63 ± 3 mins) compared to placebo (52 ± 3 mins) (p < 
0.05). This finding was also not consistent with the subjective sleep analysis. In the 
same subject sleep offset determined by actigraphic analysis showed a significant 
delay during melatonin administration (8.5 ± 0.2 h) compared to placebo (7.6 ± 0.2 
h). This was the only consistent finding between the subjectively and objectively 
analysed sleep parameters (Table 4.6).
4.4.5 Mood and Performance
Data collected from the mood tests performed each day upon wakening showed that 
melatonin, taken 30 mins before sleep, had no significant effect on happiness, 
alertness and sleepiness, compared to placebo (p > 0.05, 2-way repeated measures 
ANOVA). There was a significant effect of day across the study period on alertness 
(F(25,450) = 1.9, p < 0.01) and sleepiness (F(25,450) = 1.8, p < 0.01) pointing towards 
changes over the days in these two parameters (Fig. 4.6). There was no interaction 
between treatment and day of the week (p > 0.05).
Data collected from the mood tests performed every 2 h alongside the urine 
collection showed that melatonin had no significant effect on happiness, alertness 
and performance, compared to placebo (p > 0.05). However, there was a significant 
effect of time of the day on alertness (F(i5i270) = 4.4, p < 0.001) and sleepiness 
(F(15,270) = 9.1, p < 0.001) (Fig 4.7). There was no interaction between treatments 
and time of the day (p > 0.05).
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Fig. 4.6 Daily mood, alertness and sleepiness scores normalised (z-scored, mean ± SEM). 
Data were collected each day upon waking, during melatonin ( • )  and placebo (O) 
administration.
n=10 subjects; data missing: day 6 of week 5 and day 7 of week 8; n=26 days for each 
treatment
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(O) administration.
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Performance was assessed every 2 h alongside the 48 h urine collection using a 
DSST test (Section 222.5.6). Melatonin treatment had no significant effect, 
compared to placebo, on 2 hourly performance (F(118) = 1.1, p > 0.05). A significant 
effect of time of day on performance was noted, regardless of the treatment 
administered (F(15i270) = 4.3, p < 0.001). No interaction, however, between time of 
day and treatment was seen (F(i 5i270) = 0.6, p > 0.05) (Fig 4.10).
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Fig. 4.8 Normalised (z-scored) performance data, completed every 2 h alongside the 48 h 
urine collection during melatonin (• )  and placebo (O) administration, 
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4.5 DISCUSSION
Overall, compared to placebo, 5 mg of fast acting melatonin, administered 30 mins 
before sleep for 4 weeks, failed to significantly improve any of the subjective and 
actigraphically derived sleep parameters in postmenopausal women with self- 
reported sleep problems. However, improvements in subjectively assessed sleep 
were observed in one subject (EUMT007) and in the actigraphically assessed sleep 
of another subject (EUMT003). In addition, out of eleven subjects studied, 
subjectively worse sleep was reported by one subject (EUMT004) and 
actigraphically worse sleep was found in three subjects (EUMT002, EUMT005 and 
EUMT010)(Sections 4.4.3 and 4.4.4, respectively).
All the subjects studied, including those that reported improvements or worse sleep 
while taking melatonin, had detectable levels of urinary aMT6s with aMT6s 
production falling within the normal range for this age group (above 5 pg/24h, 
unpublished Stockgrand Ltd. data). In contrast, some studies have found 
significantly reduced aMT6s levels in elderly subjects with sleep problems compared 
to age-matched controls with no sleep problems (Haimov et al., 1995; Leger et al., 
2004). The present study did not investigate subjects without sleep problems 
therefore such a comparison could not be made. This issue of subjects with and 
without sleep problems has been addressed in Chapter 5.
Haimov et al. (1995) also found a delay in the peak time of serum melatonin in 
elderly people suffering from sleep problems, compared with age-matched controls 
without sleep complaints. The present study found interindividual variations in both 
aMT6s production levels and the timing of the aMT6s peak. Two subjects had 
advanced aMT6s acrophase times compared to the normal aMT6s acrophase time 
that falls between 02:00 and 06:00 h (Lockley et al., 1997; Kripke et al., 1998). 
Another subject had a delayed aMT6s acrophase time. Of the three subjects that 
had abnormal aMT6s acrophase times, two subjects showed no change in 
subjectively and objectively assessed sleep while taking melatonin, compared to 
placebo. Worse actigraphically assessed sleep was noted in one of the subjects 
(EUMT002) that also had an early, advanced aMT6s peak (1.9 h). There was no
Chapter 4
________  145
obvious relationship between the abnormal aMT6s acrophase times and the 
effects of melatonin on subjectively and objectively analysed sleep in the present 
study, since the other subject that also had an advanced aMT6s peak time reported 
no change in subjectively and objectively assessed sleep during melatonin 
administration. Further studies are needed to clarify why some subjects report 
improvements and some report worse sleep while taking melatonin. To date, no 
other studies have confirmed a relationship between delayed melatonin peak times 
and sleep problems in the elderly as reported by Haimov et al. (1995).
Studies have shown a tight relationship between the time of DLMO and the peak of 
the melatonin rhythm. Burgess et al. (2002) proposed that, in young healthy people, 
Tmin and aMT6s acrophase occurs 7 h after DLMO. Looking at an elderly sample, 
Duffy et al. (2002) found a reduction in the phase relationship between DLMO and 
extrapolated aMT6s peak time (from melatonin peak time), with a difference of 
approximately 6:20 h (6.33 h). In the present study the aMT6s peak time occurred 
on average 6.9 h after the salivary DLMO. One subject (EUMT011) had an 
extremely delayed aMT6s peak (9.5 h) but the salivary DLMO was normally timed. 
This large phase difference suggests that the subject may suffer from delayed 
aMT6s excretion possibly due to hepatic or renal problems. A simpler explanation 
could be that the urine collections were not done properly with either the timing or 
the volume of the samples incorrectly collected and/or recorded. The fact that this 
delayed aMT6s peak was observed on 4 separate occasions, however, suggests 
that this explanation is unlikely. The present findings showed no reduction in the 
phase relationship between salivary DLMO and urinary aMT6s peak time as 
reported in Duffy et al. (2002) study. The phase relationship reported in the present 
study is similar to that reported in young subject (Burgess et al., 2002).
In the present study exogenous melatonin administration failed to improve sleep in 
postmenopausal women with self-reported sleep problems compared to placebo. 
When all the subjects were analysed together neither objective nor subjective 
measures of sleep significantly improved during melatonin administration, compared 
to placebo. These findings are in agreement with many studies in which melatonin
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failed to affect sleep (Section 1.4.4). However, other studies have shown that 
melatonin improved sleep in the elderly (Garfinkel et al., 1995; Haimov et al., 1995; 
Wurtman and Zhdanova, 1995; Jean-Louis et al., 1998; Zhdanova et al., 2001). 
Reviewing 78 articles reporting the effects of melatonin treatment in elderly people 
complaining of sleep problems, Olde-Rikkert and Rigaud (2001) concluded that 
melatonin was not effective in elderly insomniacs who chronically use 
benzodiazepines and/or people with documented low nocturnal melatonin secretion. 
In contrast, Brzezinski et al. (2005) performing a meta analysis on 17 different 
studies involving 284 subjects concluded that melatonin is effective in increasing 
sleep efficiency and reducing sleep onset latency, especially in aged individuals with 
nocturnal melatonin deficiency. The present study found no significant increase in 
sleep efficiency or a reduction in sleep onset latency with melatonin administration 
compared to placebo. Both Olde-Rikkert and Rigaud (2001) and Brzezinski et al. 
(2005) included studies in which inclusion criteria were lenient, including subjects 
who suffered from ischaemic heart disease, Parkinson’s disease, diabetes and 
hypertension.. Some of these subjects were also taking medication known to affect 
melatonin production. Out of the 78 studies used for the Olde-Rikkert and Rigaud 
(2001) review, only 6 studies were single or double blind and placebo controlled.
In contrast, Basket et al. (2003) conducted a double blind, placebo controlled 
crossover study in the elderly with sleep problems using fast acting melatonin (5 mg) 
for 4 weeks and matching placebo for another 4 weeks. The study had many 
similarities to the present study. Sleep was recorded both subjectively and 
objectively and no significant improvements were seen in any of the parameters 
analysed. These findings confirmed previous findings by Dawson et al. (1998) who 
used polysomnography to record sleep in the elderly with sleep problems after 
ingestion of 0:5 mg of melatonin. No improvement in polysomnographically recorded 
sleep was noted in the Dawson et al. (1998) study. Melatonin administration in 
young people suffering from sleep problems also failed to improve sleep quality 
(Reviewed in Buscemi et al., 2004).
The difference between the studies that claim melatonin can improve sleep and 
those studies that did not see such an improvement (including the present study)
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cannot be explained by one factor alone. All the studies have used different doses, 
preparations and time of administration of melatonin. In addition, the methods for 
measuring sleep were different across studies. Some studies had strict inclusion 
criteria aiming to recruit generally healthy people who only complain of sleep 
problems (Dawson et al., 1998; Hughes et al., 1998; Basket et al., 2003) while other 
studies have included chronically ill patients (Garfinkel et al., 1995; Jean-Louis et 
al., 1998).
The present study may be underpowered by the small sample size. Taking the 
observed subjective sleep latency and objectively measured sleep efficiency 
parameters and performing post hoc power calculations revealed that the present 
study was underpowered with a power of 0.62 and 0.65, respectively for 11 subjects 
included in the present study (Lenth, 2006; Power and Sample Size Computer 
Software). For the statistical power to reach 0.80 (80%), sample size calculations 
revealed that 18 subjects needed to be included in the study. This shows that the 
present study was underpowered and further work should aim to study more 
subjects in order to confirm the results.
Therefore, as discussed above, using melatonin to improve sleep in elderly subjects 
has been investigated quite extensively but with conflicting findings. It is known that 
melatonin is not required for sleep in humans and is not considered a sleep 
hormone (Section 1.2.1). For example, patients who have had their pineal gland 
removed for medical reasons often report no disturbances in their sleep wake cycle 
(Macchi et al., unpublished data).
Possibly the clearest example of an effect of melatonin on sleep has come from 
studies of exogenous melatonin administration to blind individuals, especially those 
with no perception of light (Arendt et al., 1988; Lockley et al., 2000; Sack et al., 
2000; Hack et al., 2003). In these studies melatonin treatment has been shown to 
improve sleep in blind subjects suffering from non-24 h sleep wake disorder. Low 
doses of fast acting melatonin (0.5 mg) improved sleep and reduced the number 
and duration of daytime naps (Hack et al., 2003). In totally blind people exogenous 
melatonin is also able to entrain the free-running sleep-wake cycle depending on the
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time of its administration (Lockley et al., 2000; Sack et al., 2000; Hack et al., 2003). 
Entrainment of the free-running sleep-wake cycle by melatonin may be the reason 
for the observed improvement in the sleep parameters. In contrast, in sighted 
humans, under real life conditions, exogenous melatonin may not be sufficiently 
strong to override the primary zeitgeber, light, to produce a robust and statistically 
significant improvement in sleep. In addition, some researchers believe that the lack 
of effect of melatonin on nocturnal sleep seen in some studies is a result of high 
levels of endogenous melatonin in the subjects (Dawson et al., 1998; Baskett et al., 
2003). Melatonin receptors may thus already been exposed to saturating 
concentrations of endogenous melatonin and any additional melatonin from 
exogenous melatonin administration is unlikely to have an effect (Reviewed in Turek 
et al., 2001).
In conclusion, the present study failed to show any significant improvement in both 
subjectively and objectively analysed sleep following administration of 5 mg fast 
acting melatonin, compared to placebo. In addition, melatonin had no effect on 
alertness, mood and performance. However, improvements in some sleep 
parameters in some subjects were shown. The present study, as mentioned above, 
could be underpowered since only 11 subjects were studied, one of which failed to 
collect urine and saliva. Studying more subjects would confirm the present findings 
and possibly identify a group of individuals that respond well to melatonin treatment.
Furthermore, the present study only included subjects with self-reported sleep 
problems. Many of these subjects had a problem maintaining their sleep or had long 
sleep latency problems, both common complaints in the elderly. It is possible that 
subjects with true circadian rhythm sleep disorders, such as advanced sleep phase 
syndrome (ASPS) or delayed sleep phase syndrome (DSPS), may have more 
benefit from exogenous melatonin. For example, melatonin has been used 
successfully for the treatment of DSPS (Reviewed in Arendt and Skene, 2005). 
Thus, melatonin may be more useful for these circadian rhythm disorders, where its 
phase shifting effects may be of use, rather than for sleep problems that may have 
other “non-circadian” causes.
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Chapter 5:
MELATONIN RHYTHMICITY AND LIGHT -  INDUCED MELATONIN 
SUPPRESSION AS PREDICTORS OF SLEEP PROBLEMS?
Chapter 5
-------------- 150
5.1 INTRODUCTION
Melatonin production is reported to show an age-related decline (Section 1.3.2.3.1), 
which has been proposed as possible explanation for declining sleep quality in the 
aged and the use of melatonin as a “replacement" treatment for aged people with 
sleep related problems (Section 1.4.4). Lushington et al. (1998) tested this 
assumption by assessing total aMT6s excretion in 108 elderly people suffering from 
sleep maintenance insomnia and age matched controls. Analysis showed no 
significant group differences in either total nighttime or total 24 h aMT6s production. 
Furthermore, no significant relationship was observed between total aMT6s 
excretion and any self-reported sleep parameter. These findings were later 
confirmed using polysomnography (Lushington et al., 1999).
Several studies have reported a positive association between the amplitude of the 
endogenous melatonin rhythm and sleep quality. Morris et al. (1990) observed a 
significant positive correlation between melatonin amplitude and 
polysomnographically determined total sleep time in young adults. In the elderly, 
Haimov et al. (1994) observed a significant positive relationship between peak 
melatonin concentrations and actigraphically determined sleep efficiency.
Sensitivity of the circadian system to short wavelength light has been demonstrated 
by action spectrum studies (Section 1.2.1.3.3) and phase shifting experiments 
(Section 1.2). Reduced melatonin suppression following short wavelength light 
administration has been demonstrated in elderly women compared to a young group 
of women (Chapter 3). Whether the same reduced response would be seen in 
elderly women with sleep problems is not known. In addition, whether this response 
is dependent on an individual’s endogenous melatonin rhythm has not been studied.
5.2 AIMS and HYPOTHESES
One of the aims of the present study was to investigate the difference in melatonin 
rhythm markers between postmenopausal women with and without self-reported
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sleep problems. Null hypothesis stated that there would be no difference in 
melatonin rhythm markers between postmenopausal women with and 
postmenopausal women without self-reported sleep problem. Alternative hypothesis 
stated that there would be a significant difference in melatonin rhythm markers 
between postmenopausal with and those without self reported sleep problem 
(Section 1.5.2).
In addition, the relationship between endogenous melatonin and subjective and 
objective sleep in elderly women was investigated. Null hypothesis stated that there 
would be no relationship between melatonin markers and subjective and objective 
sleep parameters in postmenopausal women. Alternative hypothesis stated that 
there will be a significant relationship between melatonin markers and subjective 
and objective sleep parameters in postmenopausal women (Section 1.5.2).
Furthermore, the aims of the present study were to investigate the ability of short 
and medium wavelength light to suppress nighttime melatonin in elderly women with 
and without sleep problems. Null hypothesis stated that there would be no difference 
between elderly postmenopausal women with self-reported sleep problems and 
elderly postmenopausal women without sleep problems in their response to short 
and medium wavelength light. Alternative hypothesis stated that there would be a 
significant difference between elderly postmenopausal women with self-reported 
sleep problems and elderly postmenopausal women without sleep problems in their 
response to short and medium wavelength light (Section 1.5.2).
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5.3 METHODS
Data collected for chapter 4 were analysed further to investigate the relationship 
between the aMT6s rhythm and subjective and objective sleep parameters. An 
additional study was conducted to increase the number of subjects. This study was 
performed in the field over a 4 week period with urine being collected for 48 h each 
week and subjective sleep diaries completed each day upon waking and objective 
sleep measures recorded continuously by Actiwatch L. Ethical permission to carry 
out this experiment was obtained from the University of Surrey Advisory Committee 
on Ethics (AGE/2003/05/SBLS). All subjects gave informed consent (Appendix E) 
after reading participants information sheet (Appendix H).
In addition data from Chapter s were analysed further to establish whether the ability 
of short wavelength light to suppress nocturnal melatonin in elderly women varies 
between individuals with and without self-reported sleep problems.
5.3.1 Subject Inclusion Criteria
See Sections 3.3.1 and 4.3.1 for subject inclusion criteria for the data used in this 
chapter.
i
The inclusion criteria for the additional 4 week field study were similar to the studies 
reported in Chapter 3 and 4 and were as follows:
• Postmenopausal women (aged 50 or over). Postmenopausal status was 
defined as a period of 12 months without menstruation
• Not taking HRT
• Postmenopausal women with self-reported sleep problems and PSQI score > 
5
• Postmenopausal women without sleep problems and PSQI score < 5
• Not taking medication that affects melatonin production (Section 3.3.1 and 
4.3.1)
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5.3.2 Subject Exclusion Criteria
The following exclusion criteria were applied to all the subjects analysed:
• Regular shift work within a month of and during the experiment
• Travelling across more than 2 time zones within a month of and during the 
experiment
• Presence of any psychiatric disorders
• Failure to sign a consent form
• Failure to complete health and sleep pre-screening questionnaires
5.3.3 Subjects Studied
5.3.3.1 Field Study
In order to determine the relationship between aMT6s and subjective and objective 
sleep parameters 16 subjects (aged 61.5 ± 8.6 yrs, mean ± SD) were studied in a 4- 
week field study (Table 5.1a). Out of 16 subjects 7 subjects (59.6 ± 9.5 yrs) reported 
having sleep problems with PSQI scores ranging from 11 to 13, while 9 subjects 
(63.8 ± 7.5 yrs) reported no sleep problems with PSQI scores ranging from 2 to 6. 
Four subjects (EUF006, EUF008, EUF013 and EUF016) had a PSQI score 6, 5, 6 
and 6, respectively, but report not having sleep problems thus were placed into the 
group without self-reported sleep problems.
In order to increase the number of subjects, an additional 11 subjects from the 
melatonin administration study (Table 5.1b) were included in the analysis. In total 27 
subjects were included in the present analysis (n=27, aged 60.5 ± 7.7 yrs) with 9 
subjects (63.8 ± 7.5 yrs) without self-reported sleep problems (PSQI score 4.4 ± 1.4) 
and 18 subjects (58.9 ± 7.4 yrs) with self-reported sleep problems (PSQI score 10.4 
±2.5).
Chapter 5
-------------- 154
5.3.3.2 Light-Induced Melatonin Suppression Study
Investigation into the ability of light to suppress nocturnal melatonin in 
postmenopausal women with and without self reported sleep problems was 
performed using data from Chapter 3 (Section 3.3.3). Postmenopausal women 
(n=12, aged 57.1 ± 3.5 yrs, mean ± SD) without sleep problems (PSQI score 2.8 ± 
1.2) and postmenopausal women (n=9, aged 58.0 ± 6.2 yrs) with self-reported sleep 
problems (PSQI score 9.2 ± 3.6) were included in the analysis. For detailed 
demographic summary see Table 3.1 (Section 3.3.3)
5.3.4 Pre-study Measurements
Subjects were screened prior to inclusion in the study, as described in Section 2.1.1.
5.3.5 Experimental Protocol
The experimental protocol for the additional 11 subjects can be found in Section 
4.3.5. Subjects were studied in their own homes for a period of 4 consecutive 
weeks. Subjective sleep and daytime napping were assessed by daily sleep and 
nap diaries (Section 2.2.1). Objective sleep was assessed by continuous recordings 
obtained by actigraphy (Section 2.2.5). Sequential urine samples were collected 
every 4 h and an overnight sample for 48 h each week (Section 2.2.2). On one 
occasion saliva samples were collected in the evening every 30 mins for DLMO 
analysis (Section 2.4.3).
The experimental protocol for the investigation into the ability of different 
wavelengths of light to suppress nocturnal melatonin in postmenopausal women 
with and without self-reported sleep problem is described in Section 3.3.5.
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Table 5.1 Subject parameters (a) studied in the 4 week field study and (b) from the 
melatonin administration study.
Subject Study Dates Age PSQI H -o Subjective Sleep 
Problem
(a) 4 Week Field Study
EUF001 Feb'02 61 2 54 No
EUF005 Feb'02 62 3 69 No
EUF003 Feb'02 54 4 76 No
EUF007 August'02 68 4 55 No
EUF014 Nov'02 60 4 59 No
EUF008 . August'02 81 5 62 No
EUF006 Feb'02 65 6 52 No
EUF013 August'02 63 6 63 No
EUF016 Nov'02 60 6 65 No
EUF002 Feb'02 62 11 62 Yes
EUF004 Feb'02 53 11 64 Yes
EUF009 August'02 53 11 56 Yes
EUF011 August'02 54 11 50 Yes
EUF010 August'02 55 13 63 Yes
EUF012 August'02 79 13 76 Yes
EUF015 Nov'02 54 13 68 Yes
(b) Melatonin Administration Study
EUMT010 Nov’03/Jan’04 50 6 52 Yes
EUMT011 Nov’03/Jan’04 61 7 54 Yes
EUMT012 Jan/Feb'04 57 7 70 Yes
EUMT005 Jun/Aug’03 56 8 60 Yes
EUMT006 Aug/Oct’03 59 8 62 Yes
EUMT002 Jul/Sep'03 67 9 70 Yes
EUMT003 Jul/Sep'03 59 9 62 Yes
EUMT007 Jul/Sep’03 54 11 50 Yes
EUMT004 Jun/Aug’03 53 12 52 Yes
EUMT008 Aug/Oct’03 71 13 65 Yes
EUMT001 Jun/Aug’03 63 14 51 Yes
PSQI -  Pittsburgh Sleep Quality Index score; H -0  Horne-Ostberg score (16-30: 
definitely evening type; 31-41: neither type; score 42-58: neither type; 59-69: 
moderately morning type; 70-86: definitely morning type)
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5.3.6 Data Analysis
5.3.6.1 RIA of Urinary aMT6s
Urinary aMT6s was measured by RIA (Section 2.3.2). The limit of sensitivity for the 
assays was 0.5 ng/ml. The interassay CVs were 14% at 4 ng/ml (n=14), 10% at 13 
ng/ml (n=14) and 9% at 27 ng/ml (n=14). aMT6s data obtained for each week were 
averaged to give a mean aMT6s production (jig/24h) and aMT6s acrophase time 
(h). Acrophase time was determined as described in Section 2.4.1. Out of 27 
subjects, 26 were included in the analysis of aMT6s production levels and 25 
subjects were included in the analysis of aMT6s acrophase time. One subject from 
the chapter 4 data set (Section 4.3.3) was excluded due to incomplete urine 
collection. One further subject was excluded, as the data did not fit a cosinor 
analysis.
5.3.6.2 RIA of Plasma Melatonin
Plasma melatonin assay characteristics, from which the ability of light to suppress 
nocturnal melatonin in postmenopausal women with and without sleep problems 
were investigated, are described in Section 3.3.6.1.
5.3.6.3 RIA of Salivary Melatonin
Salivary melatonin was measured by RIA (Section 2.3.4). The limit of sensitivity for 
the assay was 0.9 pg/ml. The quality controls were 9 pg/ml (n=2), 15 pg/ml (n=2) 
and 55 pg/ml (n=2).
Out of the 27 subjects studied 16 subjects collected saliva samples and were 
included in the analysis (6 subjects from the 4 week field study and 10 subjects from 
the melatonin administration study, Section 4.3.6.2).
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5.3.6.4 Sleep and Nap Analysis
5.3.6.4.1 Subjective Sleep
In total 8 sleep and 2 nap parameters were analysed from the subjective sleep diary 
data (Section 2.4.4). For each sleep and nap parameter the data from 28 study days 
were averaged. The mean value was used to investigate the relationship between 
each sleep/nap parameter and aMT6s production levels, aMT6s acrophase time and 
salivary DLMO. Five subjects from the 4 week field study (EUF001, EUF003, 
EUF004, EUF008 and EUF014) and 3 subjects from the melatonin administration 
study (Section 4.3.6.3) did not nap and were excluded from the analysis. Therefore, 
19 subjects were included in the nap analysis.
5.3.6.4.2 Objective Sleep
From the actigraphic data 7 objective sleep parameters were analysed (Section 
2.4.5). For each parameter a mean value from 28 study days was taken and used to 
perform multiple correlation analysis.
Additional sleep and nap data analysis for 11 subjects who participated in melatonin 
administration study is described in Section 4.3.6.3.
5.3.6.5 Light-induced Melatonin Suppression
Melatonin suppression was calculated as described in Section 2.4.2.2. Light-induced 
melatonin suppression was then compared between the two groups 
(postmenopausal women with self-reported sleep problems and postmenopausal 
women without self-reported sleep problems) across different light treatments using 
two-way repeated measures ANOVA.
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5.3.6.6 Statistical Analysis
Linear regression analysis (Statistica, StatSoft Ltd., UK) was used to assess the 
relationship between the PSQI score and circadian parameters (aMT6s production, 
aMT6s acrophase time and salivary DLMO).
Unpaired Student’s t-test was used to investigate the difference in aMT6s 
production, aMT6s acrophase time and salivary DLMO between postmenopausal 
women with and without self-reported sleep problem sleep problems.
A multiple correlation method was used to investigate the relationship between 
sleep/nap parameters and aMT6s production, aMT6s acrophase time and salivary 
DLMO (Statistica, StatSoft Ltd., UK).
Chapter 5
-------------- 159
5.4 RESULTS
5.4.1 Urinary aMT6s Production and Acrophase Time
Tables 5.2 shows a summary of aMT6s (a) acrophase time and (b) production levels 
across the 4 week study period and the mean values used in the statistical analysis. 
One subject (EUF008) had an advanced aMT6s acrophase time occurring at 1.8 h. 
One subject (EUF006) showed a delayed aMT6s acrophase time occurring at 6.2 h. 
The other subjects (n=13) had a normal aMT6s acrophase time in the expected 
range 2.0 to 6.0 h (Kripke et al., 1998) (3.9 ± 0.3 h; mean ± SEM) (Table 5.2)
Three subjects (EUF001, EUF008 and EUF012) had production levels below 5 
pg/24h (2.9 ± 1.1 ^g/24h, mean ± SEM). The other subjects had normal aMT6s 
production ranging from 6.9 to 28.4 jag/24h with average production levels of 16.4 ± 
2.0 ^g/24h.
5.4.2 Salivary DLMO
Salivary DLMO was calculated as described in Section 2.4.2.1. The average salivary 
DLMO time for the 4 week field study was 21:36 ± 00:20 hh:mm (21.60 ± 0.34 
decimal h; n=6; mean ± SD) (Table 5.3a). Salivary DLMO for subjects that took part 
in melatonin administration study are shown in Table 5.3b.
5.4.3 Melatonin Rhythm and PSQI
In order to investigate the relationship between the endogenous melatonin markers 
(aMT6s production levels - pg/24 h; aMT6s acrophase time -  h and salivary DLMO 
-  h) and sleep PSQI score was taken as a measure of the severity of the sleep 
problem and linear regression analysis were performed on each data set.
There was no significant correlation between PSQI score and aMT6s production 
levels (F(i,24) = 0.26, r = 0.11, p > 0.05; Fig 5.1a), aMT6s acrophase time (F(i,23) = 
0.17, r = 0.08, p > 0.05; Fig 5.1b) and salivary DLMO (F(1>14) = 1.77, r = 0.33, p > 
0.05; Fig 5.1c).
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Table 5.3 Salivary DLMO timing in subjects (a) from 4 week field study and (b) melatonin 
administration study.
(a)
DLMO DLMO
Subject Date Collected (decimal h) (hh:mm)
EUF007 06/08/2002 22.03 22:02
EUF008 14/08/2002 22.70 22:42
EUF009 03/09/2002 21.09 21:05
EUF010 03/09/2002 21.85 21:51
EUF013 23/08/2002 20.27 20:16
EUF014 23/08/2002 21.67 21:40
mean 21.60 21:36
SD 0.84 00:50
SEM 0.34 00:20
(b)_
Subject Date Collected
DLMO 
(decimal h)
DLMO
(hh:mm)
EUMT001 17/06/2003 21.17 21:10
EUMT002 no date 19.17 19:10
EUMT003 09/01/2003 19.75 19:45
EUMT004 13/08/2003 19.50 19:30
EUMT006 no date 20.87 20:52
EUMT007 18/09/2003 19.95 19:57
EUMT008 no date 20.28 20:17
EUMT010 12/01/2004 20.68 20:41
EUMT011 04/01/2004 20.55 20:33
EUMT012 no date 20.55 20:33
mean 20.25 20:15
SD 0.64 00:39
SEM 0.20 00:20
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Fig. 5.1 Relationship between (a) aMT6s production levels (n=26), (b) aMT6s acrophase 
time (n=25), (c) salivary DLMO (n=16) and PSQI score, 
r -  correlation coefficient; PSQI -  Pittsburgh Sleep Quality Index
Chapter 5
-------------- 163
5.4.4 Melatonin Rhythm and Sleep Problem Status
Following a completion of a medical health questionnaire (Section 2.1.1, Appendix 
A) and additional general sleep questionnaire (Section 2.1.1, Appendix B) subjects 
were classified into those that reported sleep problem (n= 18) and those that did not 
report sleep problem (n=9).
There was no significant difference in 24 h aMT6s production levels between 
postmenopausal women without (n = 9, 13.5 ± 3.2 jig/24h, mean ± SEM) and 
postmenopausal women with self-reported sleep problems (n=17,13.9 ±1.5 pg/24h) 
(p > 0.05, unpaired Student’s t-test) (Fig. 5.2a).
Similarly there was no significant difference in aMT6s acrophase time between 
postmenopausal women without (n = 8, 3.3 ± 0.5 h) and postmenopausal women 
with self-reported sleep problems (n=17, 4.1 ± 0.4 h) (p > 0.05) (Fig. 5.2b).
In contrast, there was a statistically significant difference in salivary DLMO timing 
between postmenopausal women without (n = 4; 21.7 ± 0.5 decimal h) and 
postmenopausal women with self reported sleep problems (n=12; 20.4 ± 0.2 decimal 
h) (p < 0.05) (Fig. 5.2c). Postmenopausal women with self-reported sleep problem 
had an earlier DLMO (1.3 h) than women without sleep problems.
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(a)
5 ^  15
(b)
nsp sp
Fig. 5.2 Mean (a) aMT6s production levels, (b) aMT6s acrophase time and (c) 
salivary DLMO in postmenopausal women without self reported sleep problems 
(nsp, □ )  and postmenopausal women with self reported sleep problems (sp, ■ ).
* p < 0.05, unpaired Student’s t-test
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5.4.5 Melatonin Rhythm and Subjective Sleep and Naps
There was no significant correlation between 8 subjective sleep parameters and 24h 
aMT6s production levels (F(8>17) = 0.89, multiple r = 0.54, p > 0.05; Fig 5.3), aMT6s 
acrophase time -(F(8.16) = 0.90, multiple r = 0.56, p > 0.05; Fig 5.4) and salivary 
DLMO (F(8,7) = 1.90, multiple r = 0.83, p > 0.05; Fig 5.5). However, looking at each 
parameter individually there are statistical trends showing increased duration of 
nighttime awakenings and reduced sleep efficiency with delayed aMT6s acrophase 
time (p=0.07 and p=0.07, respectively) (linear regression analysis) (Fig. 5.4). 
Furthermore, significant reduction in sleep quality was noted with a delay in salivary 
DLMO timing (p < 0.05) (Fig. 5.5).
Similarly, there was no significant correlation between 2 subjective nap parameters 
and 24h aMT6s production levels (F(2,ie) = 1-75, multiple r = 0.42, p > 0.05; Fig 
5.6a), aMT6s acrophase time (F^.is) = 2.43, multiple r = 0.49, p > 0.05; Fig 5.6b) and 
salivary DLMO (F .^s) = 0.24, multiple r = 0.23, p > 0.05; Fig 5.6c).
5.4.6 Melatonin Rhythm and Objective Sleep
There was no significant correlation between 7 objectively recorded sleep 
parameters using actigraphy and 24h aMT6s production levels (F(7,is) = 0.65, 
multiple r = 0.45, p > 0.05; Fig 5.7), aMT6s acrophase time (F(7.17) = 0.39, multiple r 
= 0.36, p > 0.05; Fig 5.8) and salivary DLMO (F(7)9) = 2.01, multiple r = 0.80, p > 
0.05; Fig 5.9).
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5.4.7 Phase Angle Analysis
The phase angle difference between sleep onset and sleep offset and aMT6s 
acrophase time and DLMO timing was assessed in postmenopausal women with 
self-reported sleep problem and postmenopausal women without sleep problems 
(Table 5.4).
There were no significant differences in the timing of aMT6s acrophase time, sleep 
onset and sleep offset between the two groups (Table 5.4a). Significantly earlier 
salivary DLMO was noted in subjects with self-reported sleep problems (Section 
5.4.4)(Table 5.4a).
However, there was a significant difference in the phase angle between the timing of 
DLMO and sleep onset between postmenopausal women without and those with 
self-reported sleep problems (2.3 h and 3.5 h, respectively, p < 0.05)(Table 5.4b). 
There was also a trend towards statistical significance between aMT6s acrophase 
timing and the timing of sleep offset (4.0 h and 2.6 h, respectively, p = 0.08)(Table 
5.4b). There was no significant difference between the two groups in aMT6s 
acrophase time and sleep onset phase angle. Similarly, no statistical difference was 
noted between the two groups in salivary DLMO and sleep offset phase angle 
(Table 5.4b)
Chapter 5
----------------------------------------------------------------------------------------------------------------------------------- 174
Table 5.4 aMT6s acrophase time, salivary DLMO, sleep onset and sleep offset (a) mean 
(± SEM) and (b) phase angle difference between postmenopausal women with and 
postmenopausal women with self-reported sleep problems.
(a)
Parameters 
(mean ± SEM, decimal h)
Postmenopausal 
Women without 
Sleep Problems
Postmenopausal 
Women with 
Sleep Problems
aMT6s Acrophase Time 3.3 ± 0 .5 4.1 ± 0 .4
DLMO 21.7 + 0.5 20.4 ± 0.2*
Sleep Onset 24.0 ± 0.2 23.9 ± 0.2
Sleep Offset 7.3 ± 0 .2 6.7 ±0 .1
M
Phase Angle Difference 
(decimal h)
Postmenopausal 
Women without 
Sleep Problems
Postmenopausal 
Women with 
Sleep Problems
aMT6s Acrophase Time - Sleep Onset 3.3 4.2
aMT6s Acrophase Time - Sleep Offset 4.0 2.6 (p=o.08)
DLMO - Sleep Onset 2.3 3.5*
DLMO - Sleep Offset 9.6 10.3
* d < 0.05, unDaired Student’s t-test
5.4.8 Light-Induced Melatonin Suppression
Individual light-induced melatonin suppression in postmenopausal women without 
and postmenopausal women with self-reported sleep problems is presented in 
appendix I.
There was no significant difference in the degree of melatonin suppression, between 
postmenopausal women with and without self-reported sleep problem, following 
administration of either short A,max456 nm (3.8 and 9.8 pW/cm2; F(i,ig) = 2.77, p > 
0.05) or medium A,max548 nm (28 and 62 pW/cm2; F(i,ig) = 1.01, p > 0.05, two-way 
repeated measures ANOVA) wavelengths of light (Fig. 5.10). A significant effect of 
light intensity was noted following 3.8 and 9.8 pW/cm2 of A,max 456 nm wavelength 
light (F(i,ig) = 15.90, p < 0.001) and 28 and 62 pW/cm2 of ^max548 nm light (F(i,i7) = 
4.18, p < 0.05). No statistically significant interaction between the group with self- 
reported sleep problems and the group without sleep problems was noted following 
m^ax 456 (F(i,ig) = 0.23, p > 0.05) and 548 nm (F(ii17) = 1.71, p > 0.05) light.
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Fig. 5.10 Average % melatonin suppression in postmenopausal women without 
sleep problems (□ , n=12) and postmenopausal women with self reported sleep 
problems (□ ,  n=9) across the 4 light treatments Amax456 nm: 3.8 and 9.8 pW/cm2 
and Amax548 nm: 28 and 62 pW/cm2
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5.5 DISCUSSION
In this chapter endogenous melatonin rhythm markers (aMT6s acrophase time, 
aMT6s production levels and salivary DLMO timing) were assessed as possible 
predictors of sleep problems in postmenopausal women. Relationships between 
these markers and subjectively and objectively analysed sleep and nap parameters 
were assessed in order to establish any correlations. Melatonin parameters were 
also compared between postmenopausal women without and postmenopausal 
women with self-reported sleep problems. Furthermore, the response of the 
circadian system, using light-induced nocturnal plasma melatonin suppression as a 
marker was investigated in two groups of postmenopausal women, those with and 
those without self-reported sleep problems.
It has been suggested that reduced melatonin levels in the elderly may underlie 
decreased sleep quality (Section 1.3.2.3.1). Reduced melatonin levels have been 
reported in elderly people with sleep problems (Section 1.3.2.3.1) compared to 
healthy elderly without sleep problems. However, these findings were not replicated 
in the present investigation. There was no significant difference in 24 h aMT6s 
production levels between elderly women without sleep problems and those with 
sleep problems. In addition, no relationship was seen between 24 h aMT6s 
production levels and the severity of self-reported sleep problems as assessed by 
the PSQI score. These findings, however, are consistent with earlier reports where 
total melatonin output was not reduced in self-reported insomniacs (Lushington et 
al., 1998; 1999). Lushington et al. (1998) studied 56 sleep maintenance insomniacs 
and 52 age-matched controls. No significant difference was observed in melatonin 
excretion during the 12 h night time period nor total 24 h between the two groups.
The discrepancies in the findings between the different research groups may be due 
to the selection criteria during subject recruitment. Garfinkel et al. (1995) recruited 
subjects that, apart from the sleep problems, suffered from a range of chronic 
diseases. Haimov et al. (1995) recruited both independently living and
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institutionalised subjects. Differences in the levels of light exposure during the day 
may also have affected the melatonin levels in these subjects.
The present study found no relationship between 24h aMT6s production levels and 
8 subjectively collected sleep parameters as recorded each day in the sleep diaries. 
These findings were supported by analysis of objectively recorded sleep using 
actigraphy, where no significant correlation was seen between 24h aMT6s 
production levels and 7 objectively recorded sleep parameters. Also, no association 
between aMT6s production levels and the number and duration of naps per day was 
observed. These findings support the Lushington et al. (1998) study that showed no 
correlation between self reported sleep and total melatonin production and the 
Lushington et al. (1999) study where no association between melatonin production 
and objectively measured sleep using polysomnography was demonstrated.
Kripke et al. (1998) reported a high prevalence of abnormal melatonin acrophases in 
a combined group of aged insomniacs and people suffering from depression 
compared to a young group. They reported a normal range aMT6s acrophase time 
(02.00 -  06.00 h) in less than 50% (37 out of 72 subjects) of subjects with either 
insomnia or depression. The authors suggested that this may reflect disturbed 
circadian timing in the elderly. However, inclusion of subjects suffering from 
depression may explain the abnormal circadian phases seen in the study (Reviewed 
in Wirz-Justice, 2006) or inclusion of subjects with circadian related sleep problems 
(Dahlitz et al., 1991).
The present study found no significant difference in aMT6s acrophase timing 
between subjects with self-reported sleep problems and those without sleep 
problems. No relationship was seen between aMT6s acrophase timing and the 
severity of the sleep problem as assessed by the PSQI score. The present study 
thus found no evidence of a relationship between melatonin phase and severity of 
sleep problems. Furthermore, no relationship between aMT6s acrophase timing and 
subjectively and objectively recorded sleep was demonstrated. Also no relationship 
between aMT6s acrophase timing and the number and duration of daytime napping
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was seen. This finding is in agreement with Lushington et al. (1999) who also 
addressed the possibility of melatonin phase playing a role in sleep and found no 
relationship.
Subjects with sleep problems had a significantly advanced salivary DLMO compared 
to those without sleep problems. This finding should be interpreted cautiously as the 
number of subjects with self-reported sleep problems was small (n=4). However, 
similar findings of advanced melatonin onset have been reported in elderly early 
morning awakening insomniacs (Lack et al., 1996). These authors associated this 
advance in melatonin onset with reduced sleep quality. In contrast, later melatonin 
onset (Haimov et al., 1994) and earlier melatonin offset (Hughes et al., 1998) have 
been linked with reduced sleep efficiency. The present data showed a significant 
relationship between DLMO and subjective sleep quality. Delayed melatonin onset 
in the present study was significantly linked with reduced sleep quality.
The present study, however, demonstrated no significant correlation between DLMO 
and 7 other subjectively collected sleep parameters in the elderly women. In 
addition, no relationship between DLMO and the number and duration of naps per 
day was observed. Furthermore, no association between DLMO and 7 objectively 
recorded sleep parameters was seen.
In addition, the present study shows a significant difference in the phase angle 
relationship between DLMO and sleep onset between postmenopausal women with 
and those without self-reported sleep problems. Compared to postmenopausal 
women without sleep problems, whose sleep onset was on average 2.3 h (± SEM) 
after DLMO, the phase angle was longer (3.5 h mean ± SEM) in postmenopausal 
women with sleep problems. There was also a significant trend to a shorter phase 
angle between the aMT6s acrophase time and sleep offset in subjects with self- 
reported sleep problems, compared to those without sleep problems. This is the first 
demonstration of an alteration in the phase relationship between melatonin and 
sleep timing in elderly women with sleep problems, compared to elderly women 
without sleep problems.
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Studies that looked at the phase relationship between sleep and circadian rhythms 
in young subjects show that a consolidated 8 h sleep can only be possible at one 
specific phase relationship between the sleep-wake cycle and endogenous circadian 
rhythmicity (Section 1.2.2.1). Only when sleep is initiated approximately 6 h before 
T min sleep remains uninterrupted for 8 h in young subjects (Section 1.2.2.1). Peak of 
the plasma melatonin rhythm occurs approximately 2 h before Tmjn so initiation of 
sleep 4 h before the plasma melatonin peak will result in a consolidated sleep 
episode. Sleep onset usually occurs approximately 2 h after DLMO. Sleep offset 
usually occurs approximately 2 h after T mjn, therefore 4 h after melatonin peak in 
young subjects (Reviewed in Burgess et al., 2002) showing a tight phase relationship 
between sleep and circadian rhythms. This tight relationship between melatonin and 
sleep is disrupted in elderly subject (Section 1.3.1.2), compared to young and, 
according to the data presented in this chapter, further disrupted in elderly subjects 
with sleep problems compared to those without sleep problems (Section 5.4.7).
In summary, consistent with some studies (Lushington et al., 1998) but not 
consistent with findings from other groups (Garfinkel et al., 1995; Haimov et al., 
1995), the present study showed no difference in melatonin production and the 
timing of the melatonin rhythm between subjects with self-reported sleep problems 
and those without sleep problems. In addition, no correlation was seen between 
melatonin production, the timing of the aMT6s rhythm and the timing of melatonin 
onset and subjectively and objectively assessed sleep.
There was no statistically significant difference in melatonin suppression following 
exposure to short and medium wavelength light between elderly women with and 
without self-reported sleep problems. If light-induced melatonin suppression can be 
assumed to be an indicator of the sensitivity of the circadian system, then this did 
not appear to differ in elderly women with sleep problems compared to elderly 
women without sleep problems.
The present study only assessed women with self-reported sleep problems. Further 
studies are needed to investigate the relationship between melatonin rhythm
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markers and. objectively and subjectively assessed sleep in a population with 
clinically diagnosed sleep problems, such as advanced sleep phase syndrome or 
restless legs syndrome. In addition light-induced melatonin suppression in subjects 
with clinically diagnosed sleep problems needs to be assessed. Further studies 
investigating more subjects using a range of light intensities and wavelengths need 
to be performed to above discussed preliminary findings.
Apart from physiological changes as a normal or pathological course of ageing it is 
also necessary to mention that sleep reflects roles and responsibilities of everyday 
life, especially in women who are trying to balance the demands of motherhood, work 
and relationship (Dzaja et al., 2005). A pattern of sleep disturbances in women may 
accumulate over the life course establishing a poor sleep patterns in later life. 
Therefore, age-related changes in sleep may be a combination of social factors and 
physiological changes.
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Chapter 6:
ENDOGENOUS MELATONIN RHYTHM AND LIGHT-INDUCED MELATONIN 
SUPPRESSION IN TYPE 1 DIABETES MELLITUS
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6.1 INTRODUCTION
Changes within the eye of elderly people and those suffering from type 1 diabetes 
mellitus have some similarities. In both of these groups an increase in the density of 
the crystalline lens occurs. In the elderly this is related to increasing age (Section 
1.3.2.1) while in the type 1 diabetic patients this is related to duration of the disease 
(Section 1.3.2.1.1). It has been shown that due to changes in the crystalline lens of 
type 1 diabetics, the transmission of light, especially in the short wavelength region, 
is reduced particularly in patients who have had the disease for 10 years or longer 
(Section 1.3.2.1.1). Furthermore, it has been shown that the rate of increase in the 
lens density of young type 1 diabetic patients is similar to that of elderly people over 
the age of 60 (Section 1.3.2.1.1).
Earlier it has been demonstrated that light-induced melatonin suppression following 
short wavelength light exposure is significantly reduced with ageing (Chapter 3). 
Furthermore, a negative correlation was found between the average lens density 
and melatonin suppression following short wavelength exposure (Section 3.4.6). 
Considering early onset of type 1 diabetes mellitus and the above mentioned 
reduction in the transmission of short wavelength light, it may be expected that the 
degree of melatonin suppression by short wavelength light would be altered in these 
patients, despite them being in their early twenties. This may have an impact on 
photic entrainment of their circadian system from an early age. To date, this has not 
been investigated.
To the author’s knowledge there have been only two studies that have investigated 
endogenous melatonin rhythms in sufferers of diabetes mellitus (Section 1.3.2.3.2). 
Only one study assessed endogenous melatonin levels over a 24 h period and 
found a significantly attenuated melatonin production in patients suffering from type 
2 diabetes mellitus (Section 1.3.2.3.2). There are no reports of melatonin production 
in patients with type 1 diabetes mellitus. Therefore, there is a need to assess 
endogenous melatonin rhythms in these patients and compare them to age and 
gender matched controls.
Chapter 6
-------------- 183
6.2 AIMS AND HYPOTHESES
The aim of the pilot study was to Investigate urinary aMT6s and plasma melatonin 
rhythms in young type 1 diabetics and age- and gender- matched controls. Null 
hypothesis stated that there would be no difference between young type 1 diabetics 
and age- and gender-matched controls in their urinary aMT6s and plasma melatonin 
rhythms. Alternative hypothesis stated that there would be a significant difference 
between young type 1 diabetics and age- and gender-matched controls in their 
urinary aMT6s and plasma melatonin rhythms (Section 1.5.3).
Second aim of this study was to adapt a protocol that was used in Chapter 3 to 
investigate the effectiveness of short wavelength light to suppress nocturnal 
melatonin production in type 1 diabetes mellitus sufferers was investigated and 
compared to healthy controls. Null hypothesis stated that there would be no 
difference between young type 1 diabetics and age- and gender-matched controls in 
their response to short wavelength light. Alternative hypothesis stated that there 
would be a significant difference between type 1 diabetics and age- and gender- 
matched controls in their response to short wavelength light (Section 1.5.3).
Chapter 6
-------------  184
6.3 METHODS
For this study the protocol used in Chapter 3 needed some modification. The 
protocol was redesigned to try to improve the repeatability of the melatonin rhythm 
observed in Section 3.3.5. The protocol also needed to be simplified so that it was 
suitable for studying diabetic patients. The schedule for blood collection, urine 
collection and light administration was modified and tested in this pilot study. The 
possibility of nocturnal hypoglycaemia needed to be considered and procedures 
were adapted to deal with this condition in the most appropriate way so that it had 
minimal effect on the study and the patient. The blood sampling schedule was also 
modified so that the endogenous melatonin rhythm could be assessed.
On the basis of the protocol used in chapter 3 (Section 3.3.5), a pilot study protocol 
was designed to assess subjects suffering from type 1 diabetes mellitus and age- 
and gender-matched controls. Ethical permission was obtained from the University 
of Surrey Ethics Committee (EC/2004/117/SB MS) and the South West Surrey Local 
Research Ethics Committee (04/Q1909/35). All subjects gave informed consent 
(Appendix J) after reading participants information sheet (Appendix K).
6.3.1 Subject Inclusion Criteria
• Suffering from type 1 diabetes mellitus for 10 years or longer (diabetic group 
only)
• Female or male aged 1 8 - 3 5  years old
• Female subjects must be taking oral contraceptives and not on a “break 
week” from the contraceptives during the study nights
• Haemoglobin Aic must be within the normal range (less than 10% - diabetic 
group only)
• Not taking medication that affects melatonin production (p-blockers, calcium 
channel blockers, a-blockers, NSAID, benzodiazepines, antidepressants, 
hypnotic drugs, antipsychotics, barbiturates, antiepileptic drugs)
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• Have a detectable aMT6s rhythm (> 5 jig/24 h)
• Pass an ophthalmological examination
6.3.2 Subject Exclusion Criteria
The subject exclusion criteria were the same as in Section 3.3.2. In addition, 
subjects with uncontrolled diabetes, where the haemoglobin Aic was out of range, 
were excluded.
6.3.3 Subjects Studied
Subjects were recruited from the Royal Surrey County Hospital out-patients diabetic 
clinic in Guildford. In a pilot study 4 subjects suffering from type 1 diabetes mellitus 
(24.3 ± 3.0 yrs, mean ± SD) and 4 age- and gender-matched controls (24.0 ± 2.6 
yrs) participated. One diabetic subject and one control were female (Table 1.1). One 
subject suffering from diabetes (DS01) and the age- and gender-matched control 
(CS01) participated in both legs of the study.
Table 1.1 Demographic details of subjects suffering from type 1 diabetes mellitus 
and the age- and gender-matched controls.
Subject Age Sex Duration of Disease
(years)
Hormonal Status PSQI H-o
DS01 21 M 12 5 34
CS01 21. M 4 53
DS02 25 M 13 4 54
CS02 25 M 3 58
DS03 28 F 20 Microgynon 30 1 57
CS03 27 F Microgynon 30 2 43
DS04 23 M 13 4 40
CS04 23 M 3 53
DS-diabetic subject; CS-control subject; PSQI - Pittsburgh sleep quality index score; H-0 
Home - Ostberg score (16-30: definitely evening type; 31-41: neither type; score 42-58: 
neither type; 59-69: moderately morning type; 70-86: definitely morning type)
Chapter 6
  186
6.3.4 Pre-Study Measurements
6.3.4.1 General Health and Sleep Screening
General health and sleep screening of all subjects was performed as described in 
Section 2.1.1. An additional medical history questionnaire was implemented in order 
to assess type 1 diabetes mellitus.
6.3.4.2 aMT6s Screening
All subjects collected urine as described in Section 2.2.2. Concentrations of urinary 
aMT6s were determined by RIA (Section 2.3.2). Analysis of aMT6s 24 h production 
levels and acrophase times were performed as described in Section 2.4.1.
6.3.4.3 Ophthalmology
All subjects underwent an ophthalmologic examination as described in Section
3.3.4.3.
6.3.4.4 Stability of Circadian Phase
To ensure the stability of circadian phase the same restrictions were imposed as 
described in section 3.3.4.5. Subjects were asked to maintain a regular sleep-wake 
schedule (23:00 - 07:00 h) 3 days before the study and to refrain from heavy 
exercise, alcohol, caffeine and bright light for 24 h before the study and during the 
study.
6.3.5 Experimental Protocol
The study design for study 1 is described below. Modifications to this were made in 
Study 2 (Section 6.4.4.2).
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6.3.5.1 Study Design
The study was conducted in the CIU, School of Biomedical and Molecular Sciences 
at the University of Surrey. The study was composed of 2 consecutive nights (Fig. 
6 .1).
Upon arrival at the CIU subjects had an indwelling cannula placed in one vein under 
local anaesthetic by a qualified nurse. N1 was a baseline night (19:00-07:00 h) with 
no light exposure. Half hourly blood samples for DLMO were collected on N1 and 
N2 (19:00 -  23:00 h). The light exposure night (N2) followed the baseline night (N1). 
Posture and environmental light were controlled throughout the study (N1 and N2 
19:00-23:00 h: < 5 lux at eye level in direction of gaze and 23:00-07:00 h: 0 lux, 
complete darkness with subjects wearing eye masks). The subjects’ pupils were 
dilated with one drop of a short acting pupil dilator, Tropicamide 0.5% (Chauvin 
Pharmaceuticals, UK) administered to each eye 90 mins before light exposure.
On each night of the study blood and saliva samples were taken at -150, -120,
-90, -15, 0, 15, 30, 45, 60, 75, 90 and 120 mins around the light exposure (0 is the 
start of the light exposure). Extra blood samples were also collected for blood 
glucose levels at the same time. Blood samples for plasma melatonin were collected 
into lithium heparin tubes, which were centrifuged for 10 mins at 3000 rpm at 4°C. 
Plasma was separated and stored at -20 °C until analysis (Section 2.3.3).
The protocol described in Section 3.3.5.1 was thus changed as follows:
• The protocol was reduced to 2 study nights
• Samples for DLMO were taken on both study nights (N1 and N2)
• Extra blood samples for DLMO were added at -150, -120 mins before the 
predicted light exposure
• Lighting and posture were controlled from 19:00 h on both study nights
• Blood glucose levels were also analysed
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6.3.5.2 Light Treatment
The baseline night (N1, no light exposure) was followed by a “light exposure” night
(N2) with each subject being exposed to 30 mins of short wavelength
2monochromatic light (Xmax 456 nm: 3.8 pW/cm ).
Medium wavelength monochromatic light (^max 548 nm) that was tested in Chapter 3 
was excluded from this study because no significant difference in light-induced 
melatonin suppression following medium wavelength light was observed between 
the group of young subjects and postmenopausal women (Section 3.4.4). In 
addition, only one intensity of light was tested. These changes were made in order 
to make the protocol as easy and convenient as possible for subjects suffering with 
type 1 diabetes mellitus.
6.3.5.3 Light Administration
Light was administered as described in Section 3.3.5.2. Light was administered for 
30 mins and it was timed to occur on the rising phase of the subjects’ melatonin 
rhythm determined as described in Section 3.3.4.2.
Interference filters were used to produce monochromatic light (Section 3.3.5.3). For 
this study a monochromatic filter with a A,max460 nm and Xm 10 nm was used. The 
equipment used in this study altered the transmission spectra from ?tmax 460 to Xmax 
456 nm, which were checked with a spectrometer (Spectrascan 650 portable, 
Photoresearch, Chadsworth, CA, USA) at eye level (Section 3.3.5.4).
Light measurements and calculations were performed as described in Section
3.3.5.4.
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6.3.6 Data Analysis
6.3.6.1 RIA of Urinary aMT6s
Urinary aMT6s levels were measured by RIA as described in Section 2.3.2. The limit 
of sensitivity for the assays was 0.5 ng/ml. The interassay CVs were 15% at 5 ng/ml 
(n=3), 3% at 12 ng/ml (n=3), and 12% at 23 ng/ml (n=3).
6.3.6.2 RIA of Plasma Melatonin
Plasma melatonin levels were measured by RIA as described in Section 2.3.3. All 
samples from each subject for each study night were measured in the same assay. 
The mean (± SEM) limit of detection for all assays was 2.5 ± 0.3 pg/ml. The 
interassay CVs were 9% at 5 pg/ml (n=4), 8% at 10 pg/ml (n=4), 9% at 32 pg/ml 
(n=7) and 10% at 83 pg/ml (n=7).
6.3.6.3 RIA of Salivary Melatonin
Salivary melatonin levels were measured by RIA as described in Section 2.3.4. The 
limit of sensitjvity for the assay was 0.8 pg/ml. The interassay CVs were 16% at 4 
pg/ml (n=10), 7% at 8 pg/ml (n=10), 19% at 16 pg/ml (n=10).
6.2.6.4 Glucose Analysis
Blood for glucose measurement was collected into yellow fluoride oxalate tubes. It 
was centrifuged for 10 mins at 3000 rpm at 4°C and the plasma was separated and 
frozen at - 20°C. Samples were analysed using the YSI 2300 StatPlus blood glucose 
analyzer (YSI Inc., Yellow Springs, Ohio, USA).
6.3.6.5 aMT6s and Melatonin Parameters
Urinary aMT6s parameters (aMT6s 24 h production and acrophase time) were 
calculated as described in Section 2.4.1.
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DLMO and melatonin suppression were calculated as described in sections 2.4.2.1 
and 2.4.2.2, respectively.
6.3.6.6 Statistical Analysis
Unpaired Student’s t-test was used to compare aMT6s acrophase times and aMT6s 
24 h production levels between diabetic subjects and age- and gender-matched 
controls. The same statistical method was also used to compare the DLMO in 
saliva and plasma between the two groups of subjects and the degree of light- 
induced melatonin suppression.
Repeated measures ANOVA was used to compare melatonin rhythms from N1 of 
the study between the two groups of subject with time and subject group as factors. 
The data were first normalised by z-scoring method (Section 2.4.6). The AUC of z- 
scored data were analysed. The AUC time intervals (19:00-20:30 h, 20:30-22:00 h, 
22:00-23:30 h, 23:30-00:15 h, 00:15-01:00 h and 01:00-02:15 h) adjusted to clock 
time were analysed. Furthermore, the AUC time intervals (-300 to -210 mins, -210 to 
-120 mins, -120 to -30 mins, -30 mins to 15 mins, 15 to 60 mins and 45 to 120 mins) 
normalised to the 0-time point (lights on) were also analysed.
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6.4 RESULTS
6.4.1 Urinary aMT6s Production and Acrophase Time
The aMT6s acrophase times and 24 h production for the subjects are shown in 
Table 6.2. Two subjects, DS01 and DS02, suffering from diabetes mellitus had late 
aMT6s acrophase times, 11.8 and 8.9 h, respectively. The other subjects had a 
aMT6s acrophase time within the normal range (Table 6.2). There was no 
statistically significant difference in acrophase timing between the diabetic group 
(8.0 ± 1.6 h, mean ± SEM) and the age- and gender-matched controls (5.1 ± 0.1 h). 
Mean aMT6s production for all subjects was 25.8 ±4 .1  pg/24h (mean ± SEM). 
There was no significant difference in aMT6s production levels between diabetic 
subjects (19.1 ± 2.1 pg/24h) and age- and gender-matched controls (32.5 ± 6.6 
pig/24h).
Table 6.2 aMT6s acrophase time (h) and production levels (jug/24 h) for the diabetic 
subjects and the matched control subjects
Subjects Age aMT6s Acrophase Time 
(h)
aMT6s Production Levels 
(pg/24 h)
DS01 21 11 .8* 23.4
CS01 21 g*** 26.4
DS02 25 8.9* 16.0
CS02 25 4.8** 44.4
DS03 28 4  g*** 22.1
CS03 27 0 2*** 42.3
DS04 23 6.7* 14.9
CS04 . 23 5.4** 16.8
DS-diabetic subjects; CS-control subjects; aMT6s acrophase times were calculated by 
cosinor analysis (*p < 0.05; ** p < 0.01; *** p < 0.001, (significant fit) cosinor analysis
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6.4.2 DLMO
The DLMO in both plasma and saliva were assessed in both groups of subjects 
(Tables 6.3 and 6.4). One diabetic subject (DS04) had a late DLMO in both plasma 
(23:32 h) and saliva (22:50 h). It was not possible to calculate the DLMO in one 
diabetic subject (DS02) because the melatonin levels were already too high in the 
first early samples.
A significantly delayed salivary DLMO was found in diabetic subjects (22:28 ± 00:25 
hh:mm, 22.47 ± 0.42 decimal h) compared to age- and gender-matched controls 
(21:05 ± 00:20 hh:mm, 21.09 ± 0.34 decimal h) (p = 0.04, unpaired Students t-test). 
Plasma DLMO data were not able to be statistically analysed since there were only 
two subjects in the diabetic group (Table 6.3).
Overall, there was a significant correlation between individual plasma DLMO (21:19 
± 0:24 hh:mm, 21.32 ± 0.40 decimal h) and salivary DLMO (21:41 ± 0:22 hh:mm, 
21.68 ± 0.36 decimal h) (r = 0.93, p > 0.05, linear regression).
Table 6.3 Plasma DLMO for diabetic and matched control subjects
Subject
Plasma DLMO
N1 N2 Mean
(decimal h)
Mean
(clock time)
DS01 21.07 NS 21.07 21:04
CS01 21.40 21.08 21.24 21:14
DS02 Baseline too high
CS02 20.17 20.35 20.26 20:16
DS03 NS NS
CS03 21.52 21.23 21.38 21:22
DS04 23.30 23.77 23.53 23:32
CS04 20.83 20.42 20.62 20:37
DS-diabetic subjects; CS-control subjects; NS-no blood sample
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Table 6.4 Saliva DLMO for diabetic and matched control subjects
Subject N1 N2
Salivary DLMO
Mean
(decimal h)
Mean
(clock time)
DS01 22.9 22.95 22.92 22:55
CS01 21.8 21.7 21.75 21:45
DS02 Baseline too high
CS02 20.72 20.94 20.83 21:50
DS03 21.98 21.28 21.63 21:38
CS03 21.4 21.33 21.37 21:22
DS04 23.17 22.52 22.84 22:50
CS04 20.28 20.55 20.41 20:25
DS-diabetic subjects; CS-control subjects
6.4.3 Melatonin Rhythms in Plasma and Saliva
Determination of the AUC of the z-scored plasma melatonin profile revealed no 
statistically significant difference between the diabetic subjects and age- and gender 
matched controls (F(i,3) = 2.32, p > 0.05, repeated measures ANOVA). The data 
were normalised to the 0-time point (lights on) and the areas under the melatonin 
curve were analysed. There was a significant effect of time (F^is) = 14.61, p < 
0.001) and a significant interaction (F(5,15) = 4.07, p < 0.05).
Analysis of AUC of melatonin rhythms in saliva also showed no difference between 
the diabetic and control groups (F(i,5)= 0.32, p > 0.05). There was a significant effect 
of time (F(5,25) = 51.08, p < 0.001) but no significant interaction (F^, 25) = 2.02, p > 
0.05). Analysis of AUC of the non-normalised data also showed no statistical 
difference in melatonin rhythms between diabetic and control groups in both plasma 
and saliva samples.
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6.4.4 Light-Induced Melatonin Suppression
6.4.4.1 Study 1
Individual plasma and salivary melatonin rhythms obtained during study 1 are shown 
in figures 6.2, 6.3 and 6.4. The graphs show the melatonin rhythms obtained on both 
N1 (no light) and N2 (light exposure).
Due to a mistake by the nurse, pupil dilator was not administered at the appropriate 
time (00:30 h) for scheduled light administration at 02:00 h in two diabetic subjects, 
DS01 and DS02. Instead, pupil dilator was administered at 01:40 h and light 
administration was postponed for 90 mins until 03:10 h. As a result of this delay light 
was administered at the peak of the melatonin rhythm in particular for subject DS01 
(Fig. 6.2). Light-induced melatonin suppression was still visible in these two 
subjects, especially in plasma.
There was no difference in light-induced melatonin suppression in plasma between 
diabetic (14.4 ±1 .0  %, mean ± SEM) and age- and gender-matched control (2.9 ±
6.7 %) subjects (p > 0.05, unpaired Student’s t-test). Light-induced melatonin 
suppression in saliva was only visible in one out of three diabetic subjects and 2 out 
of three control subjects. Melatonin suppression in saliva was not detectable in all 
subjects (DS01, CS02 and DS02). It was not possible to perform statistical analysis 
on these small numbers.
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6.4.4.1.1 Changes to the Protocol
A number of protocol changes were instigated following study 1. Firstly, due to the 
low amount of melatonin suppression following administration of 3.8 pW/cm2 short 
wavelength (456 nm) light, it was decided to increase the irradiance of light to 9.8 
jaW/cm2 in study 2.
Secondly, in study 1 some subjects (CS01; DS01 and DS02) received light too late 
occurring at the melatonin peak or on the falling phase of their melatonin rhythm. 
Subject errors during urine collections or a delayed excretion of aMT6s in diabetic 
subjects could have contributed to the incorrect timing of the light. For that reason it 
was decided to collect urine during the study night 1 (baseline, no light exposure 
night) so that it could be compared to the pre-study aMT6s results. Activity and light 
were also recorded using Actiwatch L during the urine collection before the study to 
clarify any delayed aMT6s rhythms detected in the pre-study samples.
Thirdly, additional blood samples were taken at earlier times (18:00 and 18:30 h) 
and blood sampling also occurred on an hourly basis throughout night 1 of the 
study.
6.4.4.2 Study 2
Individual plasma and salivary melatonin rhythms obtained during study 2 for control 
and diabetic subjects are shown in figures 6.5 and 6.6. Two subjects (CS01 and 
DS01) participated in both study 1 and study 2. Individual DLMO timing from the 
data collected in study 2 for these subjects is shown in Fig. 6.5. Individual DLMO for 
subjects CS04 and DS04 is presented in Fig. 6.6.
Light-induced melatonin suppression in plasma following exposure to 3.8 and 9.8 
fxW/cm2 456. nm light is summarised in Table 6.5. The amount of melatonin 
suppression increased with increasing light intensity in the subjects that received 
both intensities of light (DS01 and CS01). Light-induced suppression of melatonin 
was not clearly visible in the saliva data.
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Table 6.5 Light-induced suppression of plasma melatonin (%) in both groups of subjects 
following exposure to both intensities (3.8 and 9.8 pW/cm2) of short wavelength light (^max 
456 nm)
Subjects
% Melatonin Suppression
Plasma
3.8 pW/cm2 9.8 pW/cm2
DS01 13 24
DS02 16
DS03 NS
DS04 37
CS01 12 41
CS02 4
CS03 13
CS04 39
DS-diabetic subjects; CS-control subjects 
NS-no blood samples; not participated
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6.4.4.2.1 Urinary aMT6s
Only two out of the four subjects in study 2 agreed to do urine collections during the 
study since this was added onto the original study 1 protocol. The aMT6s rhythms of 
CS04 and DS04 are shown in Fig. 6.7. The diabetic subject (DS04) had an aMT6s 
acrophase time of 6.7 h (Table 6.2) in urine samples collected before the study and 
an acrophase of 4.6 h in urine collected during the study (determined by cosinor 
analysis). The midpoint peak occurring at 06:15 h in the field study in subject DS04, 
is likely to be due to the long 10.5 h collection period (01:30 -  12:00 h) and is thus 
unlikely to be incidence of a true delay in aMT6s excretion (Fig. 6.7b). The fact that 
this delay in the aMT6s acrophase time was not observed during the laboratory 
study supports this idea.
(a)
2500 -i CS04
aMT6s acrophase time: 
Before study: 5.4 h** 
During study: 2.6 h2000
1500
1000
500|
16:00 20:00 24:00 16:0004:00 08:00 12:00
t
5 2500 DS04
aMT6s acrophase time: 
Before study: 6.7 h* 
During study: 4.6 h*2000
1500
1000
500
16:00 20:00 24:00 04:00 08:00 12:00 16:00
Fig. 6.7 Midpoints of urinary aMT6s (ng/h) collected before (H )  and during night 1 (O) of 
study 2 in (a) control (CS04) and (b) diabetic (DS04) subject.
* p < 0.05, ** p < 0.01 -  cosinor analysis
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6.5 DISCUSSION
The aim of this pilot study was to adapt a pre-existing protocol in order for it to be 
used in subjects that suffer from type 1 insulin dependent diabetes mellitus. The 
protocol was previously used to assess light-induced melatonin suppression 
following exposure to short and medium wavelength light in young and 
postmenopausal women (Chapter 3).
Since there are very little data in the literature regarding melatonin rhythms in type 1 
diabetic patients this study also aimed to investigate whether there was any 
difference in the melatonin rhythms between control and diabetic subjects. AUC of 
the melatonin profiles in diabetic subjects and age- and gender-matched controls 
were analysed. Statistical analysis revealed no difference in the plasma and salivary 
melatonin rhythms between these two groups. Normalisation of the data prevented 
the amplitude, of the rhythms between the two groups to be assessed. The original 
protocol (Chapter 3) did not include assessment of the melatonin rhythm during the 
entire night but rather concentrated around the time of melatonin onset and around 
the predicted timing of the light exposure. With this original sampling schedule it was 
not possible to determine the amplitude of the melatonin rhythm or the melatonin 
offset. However, visual inspection of the raw data suggested a reduction of 
melatonin amplitude in diabetic subjects compared to control subjects. In order to 
investigate this further, additional blood sampling was introduced in study 2. This 
change included blood sampling on an hourly basis throughout the night in all 
subjects. However, with only four subjects recruited for the second study (two 
diabetics, two controls) and due to the technical problems with blood collections it 
was not possible to assess differences in melatonin amplitude. Recruitment of more 
subjects in future studies will allow any difference in amplitude between diabetic 
subjects and age- and gender-matched controls to be assessed.
The melatonin rhythms were normalised to the 0 time point (lights on) and the AUC 
of melatonin were analysed. There was no significant difference in the AUC of the 
melatonin rhythm between the diabetic and control groups. Protocol adaptation and
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introduction of overnight blood sampling will allow the melatonin rhythms to be 
analysed in more detail in future studies. Any differences in the melatonin rhythm 
parameters (e.g. melatonin onset/offset, midrange crossing, 25% rise and fall, peak 
time and duration of melatonin production) can be assessed by extending the blood 
sampling throughout the night (Section 1.2.1).
Analyses were also performed on the urinary samples that were collected before the 
study in order to determine 24 h aMT6s production levels and the aMT6s acrophase 
times. Two diabetic subjects had relatively delayed aMT6s acrophase times. 
However, there was no statistically significant difference in the timing of the aMT6s 
peak between the two groups, despite the 3 h delay in the aMT6s peak that was 
seen in the diabetic group of subjects compared to controls. This lack of statistical 
significance is most probably due to the small number of subjects. Whether this 
delay in aMT6s in diabetics is a consistent finding needs to be verified with 
increased subject numbers. However, there is also the possibility that subjects may 
have made errors during the collection of their urine. For that reason a change in the 
protocol was made in study 2. In study 2 urine was also collected during night 1 of 
the laboratory study and the aMT6s rhythm collected inhouse was compared to the 
aMT6s results obtained from urine collected in the subjects’ homes before the study.
Analysing aMT6s rhythms from the urine collected before and during the study 
allowed subject errors to be minimised and for any delay in aMT6s excretion to be 
confirmed. Use of the Actiwatch L to record activity and light exposure during the 
urine collections in the subjects’ homes was also implemented as a delay in aMT6s 
excretion could also be due to light exposure during the early part of the night. 
Actiwatch data would thus confirm whether subjects were following the pre-study 
conditions of a regular sleep-wake cycle before the laboratory study.
There was no statistically significant difference in aMT6s production (pg/24 h) 
between the diabetic and control group, despite lower aMT6s production seen in the 
diabetic subjects. As mentioned above, the number of study subjects in both groups 
needs to be increased to confirm this finding.
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The timing of salivary DLMO was significantly delayed (approximately 1.5 h) in 
diabetic subjects compared to the controls. This difference may be due to the timing 
of the saliva collection in the diabetic subjects. Since two diabetic subjects had late 
aMT6s acrophase times in urine that was collected before the study the blood and 
saliva sampling in the laboratory study was also scheduled late. By doing this 
unfortunately some baseline melatonin values were missed. As a result of this 
another change to the protocol was introduced, namely earlier timing for blood and 
saliva sampling for all subjects in order to try to capture the true baseline melatonin 
value needed for the accurate calculation of DLMO.
Light-induced melatonin suppression was clearly visible in the plasma melatonin 
profiles. There is some evidence that the degree of melatonin suppression was 
dependent on the light intensity. This finding supports earlier findings (Section
1.2.1.3.1). On the other hand the saliva data did not show clear melatonin 
suppression following light exposure. In saliva, light-induced suppression of 
melatonin was not visible in three out of four diabetic subjects and in one out of four 
control subjects. This was the case despite light-induced suppression of melatonin 
being observed in the plasma profiles. There is some evidence that salivettes used 
for saliva collection may interfere with the radioimmunoassay (Middleton, 
unpublished data). The saliva data in the present study should thus be treated with 
caution. Another reason may be that saliva melatonin levels are low in these 
subjects and thus it is difficult to see any light-induced melatonin suppression.
The poor repeatability in the melatonin rhythm between N1 and N2 of the laboratory 
study that was seen in young and postmenopausal women (Section 3.4.2) was 
largely rectified in this study. In the present study only 1 (CS02) out of 6 subjects 
showed a greater than 20% difference in plasma melatonin concentration (pg/ml) at 
the 0 time point between N1 and N2. Lights were dimmed in the CIU at 19:00 h on 
both nights of the study. This differs from the protocol in Chapter 3 where lights were 
dimmed at 21:00 h on the light exposure nights and at 19:00 h on the baseline night 
(Section 3.3.5.1).
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In order to simplify the protocol for this study and to increase the chances of 
recruitment of diabetic patients the 6 night study protocol originally used (Chapter 3) 
was reduced to a 2 night study protocol. Following exposure to low intensity (3.8 
nW/cm2) short wavelength light (^max 456 nm) little suppression of melatonin in both 
plasma and saliva was noted. In order to increase the amount of melatonin 
suppression and allow for any difference in melatonin suppression between the two 
groups to be observed higher intensity (9.8 (iW/cm2) light of the same wavelength 
(^ max 456 nm) was administered in study 2. This increase in light intensity resulted in 
greater melatonin suppression in both groups of subjects.
In summary, a number of adaptations to the original protocol used in Chapter 3 and 
to the protocol used in study 1 were implemented and evaluated in study 2. Blood 
sampling was extended to cover a longer period of time for better DLMO 
assessment and additional blood sampling was introduced throughout the night in 
order to obtain a more detailed melatonin profile. Collection of urine during the first 
24 h in the laboratory study was also introduced in order to confirm the aMT6s 
rhythm observed under field conditions. The intensity of the short wavelength light 
was also increased from 3.8 to 9.8 pW/cm2for greater melatonin suppression.
This modified protocol will be useful in future studies designed to assess both 
melatonin rhythms and light-induced melatonin suppression in diabetics and other 
patient groups compared to age- and gender-matched controls. Unfortunately the 
current data can only be considered as preliminary as too few subjects have been 
studied. Future studies of more subjects will clarify any differences between 
diabetics and controls in melatonin rhythmicity and its response to light.
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Chapter 7: 
GENERAL DISCUSSION
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7.1 INTRODUCTION
There are well described changes in the components of the circadian timing system 
with age (Section 1.3.2). In addition, light (Section 1.2.1.2) and melatonin (Section
1.4.2) can shift the timing of the circadian system. The studies reported in this thesis 
have the broad aim of investigating the response of the elderly to light and melatonin 
administration. Whether these responses differ between women with and without self- 
reported sleep problems has also been investigated. In addition, the melatonin and 
sleep rhythms were characterised in two groups of elderly women, those with and 
those without self-reported sleep problems.
7.2 EFFECT OF AGE ON THE RESPONSE TO SHORT WAVELENGTH LIGHT
A number of age-related changes in the eye have been reported that may be of 
relevance to the amount and spectral composition of light reaching the retina (Section
1.3.2.1). These alterations, in particular in the lens, would reduce the amount of light 
input to the circadian clock, thereby affecting photic entrainment and may, in part, 
explain some of the changes in circadian rhythmicity seen in the elderly.
Findings that short wavelength light was the most effective light in suppressing 
nocturnal plasma melatonin (Section 1.2.1.3.3) and reduction in transmission of these 
wavelengths through the ageing lens (Section 1.3.2.1) postulated a hypothesis where 
it might be expected that the melatonin response to short wavelength light would be 
reduced in elderly compared to young people. Therefore, a protocol, adapted from the 
earlier action spectrum study (Thapan et al., 2001) was set up to investigate this issue 
(Chapter 3). In this protocol subjects were exposed to two monochromatic 
wavelengths of light, short (^max 456 nm) and medium (Xmax 548 nm) wavelength light. 
The hypothesis was as follows: if the melatonin response was affected by age-related 
lens changes then a reduced response to short wavelength light would be expected in 
the elderly, whereas there would be no difference in the response to medium 
wavelength light between elderly and young subjects.
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This hypothesis has been confirmed by the present study (Chapter 3). The ability of 
short wavelength light to suppress nocturnal melatonin was significantly reduced in 
the older group of subjects while there was no significant difference in the response to 
medium wavelength light between the young and elderly groups. These findings 
suggest changes in the crystalline lens, since the age-related increase in lens density 
causes an alteration in the spectral absorption (Section 1.3.2.1). This results in a 
reduced amount of short wavelength light that reaches the retina. Ideally, individual 
lens density and lens transmittance measurements should have been performed to 
determine the amount of photons reaching the retina for both groups of subjects. 
Unfortunately, these measurements are not easy to perform and require specialised 
staff and equipment. As a surrogate, the average lens density for each subject was 
calculated using the two-factor non-linear lens density spectrum formula (Section 
3.3.6.3). In the present study, the average lens density calculated for each subject 
was significantly associated with the amount of nocturnal melatonin suppression 
following exposure to short wavelength light, where greater melatonin suppression 
was noted in young subjects with lower lens density.
These findings, however, do not exclude a role for other components of the circadian 
system in the reduced response to short wavelength light seen in the elderly. In order 
to investigate this it would be necessary to ensure that the same number of photons 
reach the retina in both groups of subjects. With this approach it would be possible to 
exclude the influence of pre-receptoral filtering effects.
Whether the reduced melatonin response to short wavelength light observed in the 
elderly was associated with self-reported sleep problems was also investigated 
(Section 5.4.8). Since no difference in the degree of melatonin suppression was noted 
between elderly women with and those without self-reported sleep problems it is 
unlikely that the age-related alteration in spectral sensitivity contributed to the 
observed sleep disturbances seen in the elderly group. Therefore, reduction in short 
wavelength sensitivity does not appear to be a major cause of the sleep problems 
when an individual is exposed to sufficient light levels at appropriate times of day. 
Subjects in the present study were healthy elderly subjects, that are mobile and
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probably receiving sufficient amounts of light in their daily lives. However, in other 
populations, for example, elderly housebound individuals or hospitalised patients who 
may not receive sufficient light exposure, it may not be possible to exclude the role 
that reduced spectral sensitivity to short wavelength light plays. In these groups, the 
age-related alteration in spectral sensitivity to short wavelength light may lead to 
insufficient light input necessary for photic entrainment causing disruption in circadian 
rhythmicity. Further studies need to test this hypothesis.
It is more likely that a combination of changes within each component of the circadian 
system contributes to the deterioration in sleep in healthy elderly women (Section
1.3.2). Global neurodegeneration with ageing including in the SCN have been 
reported (Section 1.3.2.2). Thus, combined with a weakened signal from the retina, 
age-related changes within other components of the circadian system may all affect 
photic entrainment of the circadian clock. In addition, reduced zeitgeber strength in 
the elderly (Section 1.3.2.1.2) may play a role in the age-related deterioration in sleep 
and disrupted circadian rhythmicity. Another test of the hypothesis would be to 
investigate whether exposure to short wavelength light can facilitate synchronisation 
of disrupted circadian rhythms and improve sleep in the elderly.
One of the limitations of the present study is the exclusion of male subjects. Looking 
at the literature there is some evidence showing greater sensitivity of females to a 
2000 lux light pulse compared to males (Section 1.2.1.3.5). In contrast, three other 
studies showed no gender difference in the light-induced melatonin suppression 
response across different light intensities (Section 1.2.1.3.5). Therefore, although not 
tested, we assume that older men would also show a reduced sensitivity to short 
wavelength light, as seen in older women. This remains to be demonstrated, however.
The protocol used in the present study was adapted and evaluated for the study of 
young patients suffering from type I diabetes mellitus. In relation to their circadian 
rhythmicity this group of subjects has not been widely investigated (Section 1.3.2.3.2). 
Changes within the eye of diabetic subjects, especially the crystalline lens, are 
reportedly very similar to that of elderly people (Section 1.3.2.1.1). Depending on the
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duration of their disease, the crystalline lens in young type I diabetic patients is 
reported to exhibit the same changes as that of a 60-year-old individual (Section 
■1.3.2.1.1). Whether a reduced melatonin response or reduced phase shifting 
response to short wavelength light would be seen in this group remains an 
outstanding question. Preliminary results from this thesis (Chapter 6) require follow up 
with more diabetic patients and age- and gender-matched controls.
7.2.1 Application of the Findings
These data suggest that the minimum amount of short wavelength light needed for 
daily circadian synchronisation may be different for older individuals compared to the 
young. Further studies are needed to define what these levels might be. Furthermore, 
on the basis of the current findings, it is possible that other circadian responses, such 
as light-induced phase shifting, is also reduced in the elderly following exposure to 
short wavelength light. This has not yet been tested. Therefore, further studies are 
needed to investigate any difference in the phase shifting response to different 
monochromatic wavelengths of light between young and elderly individuals. This may 
have important practical implications on the lighting needs in nursing homes and in 
the homes of housebound elderly individuals who are exposed to low lighting levels 
(Section 1.3.2.1.2). Reduced daytime light exposure has been linked to sleep 
disturbances in the elderly (Section 1.3.2.1.2). Furthermore, exposure to higher levels 
of light during the day has been shown to result in a reduced number of nighttime 
awakenings in the elderly (Section 1.3.2.1.2).
The present data also raise the question of elderly shift workers and time zone 
travellers who may require higher intensity short wavelength light, compared to 
younger colleagues, in order to aid adaptation to a new shift schedule. Alertness and 
performance are altered during the night shift, which is known to affect safety at work 
place (Reviewed in Burgess et al., 2002). Therefore, rapid adaptation of both young 
and older individuals to a new shift schedule is important in order to minimise human 
errors. Whether adaptation to a new shift schedule following appropriately timed short
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wavelength light of higher intensity would contribute to faster adjustment in the elderly, 
remains to be demonstrated in future studies.
7.2.2 Risk Factors of Blue Light Application
Before short wavelength light can be commercially used, a phenomenon known as 
“blue light hazard” needs to be considered. Blue light is defined as light within the 
wavelength range of 400 -  475 nm and it has been shown that over 88% of photo- 
oxidative damage to the retina from fluorescent lamps is due to light wavelengths in 
this region (ICNIRP, 1997). The blue light hazard peaks at 440 nm and falls to 80% at 
460 nm light.
The hazard from blue light may be of particular relevance in older people because the 
anti-oxidative mechanisms needed to protect the retina progressively deteriorate with 
age, particularly after the age of 40 (Reviewed in Terman and Terman, 2005). The 
susceptibility for age-related macular degeneration varies within the individual, as 
does the amount of light, especially in the blue region of the spectrum, reaching the 
retina (Reviewed in Terman and Terman, 2005). Since the conditions by which normal 
retinal deterioration from ageing becomes pathological deterioration known as age- 
related macular degeneration are not known, it is of importance to consider lowering 
blue light exposure to its minimum effective levels. The timing of light administration is 
also important. For example, the eye is much more sensitive to photic damage during 
the night or in the early morning hours, when the eye is still dark-adapted. Eye 
damage can be increased during this time.
Therefore, calibration of short wavelength light that is both effective and safe needs to 
be taken into consideration. Blue light therapy that may be effective and safe in older 
subjects whose ageing lens restricts most of the blue light reaching the retina may 
cause considerable photo-oxidative damage in a person of the same age, whose lens 
has high transmission of blue light, or in the individual who has had cataract surgery. 
Therefore, adjusting the amount of blue light exposure on the individual basis will not 
be a simple task. The present study used light intensities that were 10-fold lower than
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the average household illumination and suppression of melatonin occurred at these 
low intensities of light. A pupil dilator was used in the present studies, which would 
increase suppression of melatonin by abolishing the pupillary reflexes. There is thus a 
need to investigate a range of intensities of short wavelength light in subjects with non 
dilated pupils possibly in field situations in order to establish the minimum light 
intensity that is both effective and safe in real life conditions.
7.3 THERAPEUTIC POTENTIAL OF MELATONIN IN THE ELDERLY WITH SLEEP 
PROBLEMS
The response of the elderly with self-reported sleep problems to exogenous melatonin 
was another aim of this thesis. Therefore, the effectiveness of exogenous melatonin 
administration on sleep, alertness, mood and performance was investigated in elderly 
women with sleep complaints (Chapter 4).
Overall, findings from the present study showed that a fast release preparation of 
melatonin (5 mg) administered 30 mins before desired sleep failed to significantly 
improve any of the subjectively and actigraphically analysed sleep parameters 
compared to placebo. However, performing sleep analysis within each individual 
subject showed both improvements and worse sleep in some subjects following 
melatonin administration. Out of 11 subjects studied, one subject showed 
improvements in subjectively analysed sleep and another in objectively analysed 
sleep while taking melatonin compared to placebo. Worse subjectively analysed sleep 
was noted in one subject while two subjects showed worse objectively analysed sleep 
during melatonin administration. There was no clear relationship between the 
changes in sleep seen in these subjects and their endogenous aMT6s production or 
the aMT6s peak time. Therefore, it appears that a small number of postmenopausal 
women with self-reported sleep problems respond well to melatonin administration 
whereas some do not. Future studies including more subjects should aim to identify 
subgroups of people that could benefit from exogenous melatonin administration.
Chapter 7
_________  215
However, in the present study and previous studies (Section 1.4.3), large numbers of 
subjects did not report a positive response to melatonin administration, regardless of 
the methods used to analyse sleep. One of the explanations behind the lack of effect 
of melatonin on sleep in postmenopausal women may be due to already high 
endogenous melatonin levels. In one carefully controlled study where melatonin was 
administered at a range of circadian phases it was shown that melatonin was most 
effective outside the time window of its normal production (Wyatt et al., 1999). 
Exogenous melatonin administration during the daytime in normally entrained 
individuals elicits all the physiological effects, which occur in the evening during 
endogenous melatonin secretion (Reviewed in Cajochen et al., 2003) showing that 
melatonin is most effective when endogenous levels are low. In a study where these 
evening physiological changes (increase in sleepiness, heat loss, melatonin 
secretion) were blocked by light exposure, exogenous melatonin administration 
reversed this response (Cajochen et al., 1998). This may be one explanation why 
melatonin failed to improve sleep in the present study, since it was administered 30 
mins before sleep time when endogenous melatonin levels would be rising or high.
In the present study melatonin failed to significantly reduce sleep latency. Its soporific 
effect was therefore not demonstrated in contrast to some studies where melatonin 
showed soporific effects on sleep latency when administered close to the desired 
bedtime (Reviewed in Olde-Rikkert and Rigaud, 2001). Another explanation for the 
lack of effect of melatonin administration may be that exogenous melatonin is not a 
strong enough zeitgeber in sighted humans, under real life conditions, to override the 
effect of light, which is the most potent time cue. This may explain the effectiveness of 
melatonin to improve sleep in totally blind individuals (Section 1.4.3).
In the present study, most of the subjects had a problem maintaining sleep, bringing 
into question the formulation of melatonin that was used. The formulation used in the 
present study was fast acting which provides a rapid increase in the plasma melatonin 
concentration (Deacon and Arendt, 1995). It may be possible that this fast release 
formulation was not ideal for this group of subjects who may need more melatonin at 
a later stage of the night. The use of a surge-sustained release (Rajaratnam et al.,
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2004), slow release formulation (Shamir et al., 2000) or infusion of melatonin 
(Fourtillan et al., 2000) may have a more pronounced effect on sleep maintenance. 
Additional trials comparing different melatonin formulations should be conducted in 
future to define the optimum formulation for the different indications of melatonin. To 
date, infusion of melatonin has not yet been used to investigate its effectiveness on 
sleep in the elderly. Regardless of the formulation used, variable clearance rates of 
melatonin should also be considered since it may influence the results. Prior 
knowledge of the pharmacokinetics of melatonin in each individual should ensure 
appropriate dosage for each person. Even if melatonin is shown to be effective, there 
are very few reports on the effects of long-term use of melatonin. Although melatonin 
appears to be well tolerated, safety of its long-term use needs to be assessed. Until 
this is done melatonin is likely to remain unregistered. The recent registration of 
melatonin agonists, ramelteon (McGechan and Wellington, 2005) and agomelatine 
(Banasr et al., 2006) hold future promise that remains to be assessed in circadian 
rhythm sleep disorders.
Since epidemiological studies (Section 1.3.1.1) have shown that approximately 40- 
70% of the elderly population suffer from sleep problems and due to the increase in 
the ageing population, a number of studies have investigated the effects of melatonin 
on sleep in the elderly (Section 1.4.4). These studies have used different doses and 
preparations of melatonin given at different times with conflicting results (Section 
1.4.4). Some have found that melatonin is effective in the treatment of sleep problems 
while others have failed to see any improvement in sleep while taking melatonin 
(Section 1.4.4). These discrepancies may be due, in addition to the above mentioned 
diversity in dosage, preparation and timing of melatonin, to differences in the 
assessment of sleep where different methods have been used, ranging from 
subjective measurements to objectively assessed sleep. Selection of the subjects and 
the type of sleep problems has also been different across the studies. For example, 
while some studies have selected subjects with diagnosed sleep problems that were 
secondary to other medical conditions such as renal problems or heart conditions, 
other studies have been stricter in selecting subjects without any health problems 
other than sleep disturbances (Section 1.4.4).
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In the present study sleep problems were identified using different validated 
questionnaires (Sections 2.1) and all subjects were otherwise healthy 
postmenopausal women, as assessed by a medical health questionnaire (Appendix 
A). One of the limitations of the present study was that the sleep problems reported by 
the subjects were not clinically diagnosed. However, the present study confirmed the 
findings from Baskett et al. (2003) where elderly subjects with clinically diagnosed 
sleep problems were used in a similarly designed protocol. These researchers also 
showed no improvement in sleep during administration of fast release melatonin (5 
mg) taken 30 mins before desired sleep time for the same length of time (4 weeks). 
The present study differs from Baskett et al. (2003) and other studies (Section 1.4.4) 
in that it also investigated the effects of melatonin administration on daytime alertness, 
mood and performance in the elderly with self-reported sleep problems. This had not 
been done before. This assessment was performed because of the slow clearance 
rate of exogenous melatonin (over 24 h) and its possible hangover effect on daytime 
activities. Analysis of the data showed no effect of melatonin administration on self- 
rated alertness, mood and performance the following morning upon wakening nor was 
there any effect of melatonin on these parameters during the awake period of the day. 
Melatonin administration therefore does not appear to affect daytime mood or 
performance. This lack of a hangover effect may be considered an advantage for the 
treatment of sleep problems.
7.3.1 Application of the Findings and Future Work
The present study showed that some postmenopausal women may benefit from 
melatonin administration although overall there were not significant improvements in 
the study group. The underlying reasons behind both improvements and worse sleep 
seen in some individuals should be investigated further and these subgroups 
identified in future studies.
It appears that melatonin may be more effective when it is used for its chronobiotic 
properties, as seen in the blind, DSPS and shift workers. Individuals whose sleep 
timing is out of phase with conventional, 24 h, society have been shown to benefit
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from appropriately timed melatonin (Reviewed in Arendt and Skene, 2005). However, 
while the effectiveness of melatonin to adjust misalignment of sleep with the 
environment have been well characterised in some circadian rhythm sleep disorders, 
such as non 24 h sleep wake syndrome seen in the blind or DSPS, there are no 
reports on the effectiveness of melatonin in ASPS and there are very few reports of 
melatonin administration in patients suffering from Alzheimer’s disease. Furthermore, 
there is a need to investigate whether elderly people that are housebound or 
institutionalised and do not receive enough light for everyday photic entrainment may 
benefit from melatonin administration.
In addition, as mentioned above, there is a need to optimise the dose, preparation, 
time and duration of melatonin administration taking into consideration different 
groups of people that have different types of sleep problems. Investigation into the 
effectiveness of melatonin as a therapeutic agent may help to understand, in more 
detail, the relationship between melatonin and sleep. Targeting specific groups of 
individuals that suffer from sleep problems will result in a better understanding of the 
physiological role of melatonin and its therapeutic potential in humans.
7.4 ENDOGENOUS MELATONIN RHYTHMICITY AND ITS RELATIONSHIP TO 
SLEEP
The final aims of this thesis were to characterise endogenous melatonin rhythms and 
their relationship to sleep in elderly women with and without sleep problems. 
Differences in aMT6s production levels, aMT6s acrophase time and salivary DLMO in 
elderly women with and without self-reported sleep problems were investigated. In 
addition, the relationship between melatonin rhythm markers and subjective and 
objective sleep parameters was investigated in the elderly women and phase angle 
differences were assessed between melatonin rhythm markers and sleep onset and 
sleep offset in elderly women with and without sleep problems.
The findings from the present study (Chapter 5) showed no differences in the timing 
and production of aMT6s between elderly women with and without self-reported sleep
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problems. In addition, there was no significant relationship between the melatonin 
rhythm markers (aMT6s production, aMT6s acrophase time and salivary DLMO) and 
sleep and nap parameters measured both subjectively and objectively. A significantly 
earlier salivary DLMO was seen in elderly women with sleep problems compared to 
elderly women without sleep problems. However, these results should be taken with 
caution since only 4 subjects without sleep problems were included in the analysis. 
More subjects without sleep problems need to be studied in order to confirm these 
results.
In addition, the findings presented in Chapter 5 showed that the phase angle between 
the aMT6s peak and sleep offset was shorter in women with self-reported sleep 
problems, compared to those without sleep problems. Although there was a statistical 
trend towards this difference, it was not statistically significant (p=0.08). However, the 
phase angle between DLMO and sleep onset was significantly longer in women with 
sleep problems compared to those without sleep problems. No statistically significant 
difference was noted in the phase angle between the aMT6s peak time and sleep 
onset and DLMO and sleep offset in women with and without self-reported sleep 
problems. However, a larger (non significant) phase angle difference was noted 
between aMT6s and sleep onset in postmenopausal women with sleep problems (4.2 
h) compared to women without sleep problems (3.3 h). These changes in the phase 
angle between sleep and melatonin rhythm markers may indicate an alteration in the 
intrinsic phase relationship between sleep and melatonin in women with sleep 
problems, compared to those without sleep problems. This is the first demonstration 
of this.
A tight relationship between the timing of sleep and circadian rhythms has been 
demonstrated in young subjects (Fig 7.1a)(Section 1.2.2.1). Compared to young 
people, circadian rhythms of melatonin, CBT, aMT6s, Tmin and sleep onset and offset 
occur approximately 1 h earlier in elderly people without sleep complaints (Fig. 7.1 
b)(Section 1.3.1.2). Earlier timing of the aMT6s peak by approximately 1 h (Chapter 3, 
Section 3.4.1), and earlier timing of DLMO by approximately 40 mins (Chapter 3, 
Section 3.4.3) in the elderly women, compared to young women, has also been
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demonstrated in this thesis. In previous studies the internal phase relationship 
between sleep offset and Tmjn (Duffy et al., 1998) and sleep offset and the plasma 
melatonin peak (Duffy et al., 2002) were shown to be significantly shorter in the 
elderly compared to a young group of subjects (Fig. 7.1b). In the present thesis this 
could not be assessed in the young subjects that took part in the Chapter 3 study 
since they were instructed to keep a regular sleep wake cycle (23:00 -  07:00 h) in 
order to ensure the stability of melatonin/aMT6s rhythm prior to the laboratory study
As mentioned above, no differences in the production and timing of the aMT6s 
rhythms were noted between elderly with self-reported sleep problems and those 
without sleep problems, suggesting that these factors alone are unlikely to contribute 
to the sleep disturbances reported by the elderly people. Therefore, according to the 
present findings, an alteration in the phase relationship between melatonin markers 
and sleep in the elderly with sleep problems (Fig. 7.1c), compared to elderly without 
sleep problems (Fig. 7.1b), may in part underlie the sleep problems reported by 
elderly women. Further investigation of the phase relationship between melatonin and 
sleep in the young, elderly and elderly with sleep problems in field conditions may 
help to understand this more clearly. Furthermore, the phase angle relationship 
between sleep and other markers of the circadian system such as plasma melatonin 
and Tmjn should also be investigated, both in the field and laboratory conditions in all 
three groups of subjects.
The alteration in the phase relationship between sleep offset and circadian phase 
markers of T mjn (Duffy et al., 1998) and melatonin (Duffy et al., 2002) suggest that 
elderly are not only waking up at an earlier clock time but are also waking at a 
different circadian time. Findings from the present study (Chapter 5) indicate that the 
elderly with sleep problems are waking up at an even earlier circadian time than the 
healthy elderly who, in turn, wake up at an earlier circadian time compared to the 
young.
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Chapter 5 Chapter 5
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Clock Time (h)
Fig. 7.1 Phase relationship changes (<--►) between sleep onset and offset (UU) and 
circadian rhythms of plasma melatonin, DLMO, aMT6s and T m jn in (a) young (Adapted 
from Burgess.et al., 2002), (b) elderly (Duffy et al., 1998; Duffy et al., 2002) and (c) 
elderly with self-reported sleep problems (Chapter 5).
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Waking up at this particular time when endogenous melatonin levels may still be 
elevated in the elderly subjects and being exposed to light at this earlier circadian time 
may, in part, explain the phase advances in sleep and other circadian rhythms seen in 
the elderly, rather than changes in the periodicity of the circadian clock as previously 
thought (Section 1.3.1.2). These findings indicate that the general effects of ageing in 
the brain and on the SCN and its regulation may play a role in the age-related 
alteration in circadian rhythmicity. Further understanding of these causes may help in 
improving sleep in the elderly population.
7.5 CONCLUSIONS
The results presented in this thesis may in part contribute towards an understanding 
of the effects of light and melatonin on circadian physiology in the elderly. An age- 
related reduction in the melatonin suppression response to short wavelength light was 
first demonstrated in this thesis (Chapter 3). Furthermore, it appears that changes 
within the crystalline lens with age may, in part, contribute to this reduced sensitivity. 
Further work should aim to investigate whether other non-visual light responses, such 
as circadian phase shifting differs in the elderly compared to the young. In addition, 
housebound or hospitalised individuals should be studied since they may be exposed 
to insufficient light cues, which may result in disruption of circadian rhythmicity and 
sleep. Possibly these groups may benefit from light therapy that is enriched with blue 
light.
According to the findings described in Chapter 4, it appears that otherwise healthy 
elderly people with complaints of sleep problems derive little benefit from exogenous 
melatonin administration given as a nightly dose (5 mg fast release). Future work 
should concentrate on assessing different formulations, dosage and timing of 
melatonin administration together with its long-term safety.
Melatonin production and the timing of the melatonin rhythm per se do not appear to 
be associated with the sleep problems reported by elderly women (Chapter 5). The 
phase relationship between the circadian timing system (as assessed by melatonin)
Chapter 7
_________ 223
and the timing of sleep seen in healthy elderly subjects, however, was significantly 
different to elderly subjects with sleep problems (Chapter 5). Understanding the 
causes of these changes may prove to be the key in the treatment of age-related 
sleep problems.
Endogenous melatonin has been proposed as the signal that weakens the circadian 
opposition to increasing homeostatic drive for sleep, promoting heat loss, decrease in 
body temperature and sleepiness (Reviewed in Cajochen et al, 2003). In the elderly 
the amplitude of this signal is reduced (Chapter 3), advanced (Chapter 3) and its 
phase relationship with sleep is altered (Chapter 5). These findings suggest that the 
interaction between the homeostatic and circadian sleep controlling mechanisms is 
disturbed. Understanding the underlying cause behind this disruption may aid in the 
development of therapeutic methods that would improve sleep quality in the elderly 
population.
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Appendix A
Medical Health Questionnaire
Name: D.O.B.
Address: Age
Sex
Females Pre/post menopausal ?
Tel:
(post menopausal no period for 1 year)
GP’s Name 
GP’s Address
Any known eve conditions (glaucoma, cataract)
Visual Acuity Left Eve Right Eve
Eve Colour 
Ishihara Test score
Do you take any medication? (Please specify)
HRT
Oral contraceptive pill 
Anti depressants(Prozac)
Beta-blockers (Atenolol)
Tranquillisers(Benzodiazepines, Valium)
Sleeping tablets (Tamazepam)
Do you have any major helath problems?
Psychiatric conditions
Migraine (Conditions suffered by subject or relative)
Epilepsy
Blood Pressure 
Endocrine disorders
Smoker/Non Smoker
Do you suffer from a sleep disorders
PSQI Score
Have you given more than 400ml blood in past 3 months
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Appendix B
GENERAL SLEEP QUESTIONNAIRE
Identification Number: Date:
1. Date of Birth: 2. Age (years):
3 Male Female
4. Are you on any regular medication? Yes / No
Yes / NoAnti-depressants 
Yes / No
Major tranquillisers 
Yes /  No
Yes / No
Minor T ranquillisers Yes / No
Corticosteroids Yes /  No
Other medication..........................................
Beta Blockers 
Sleeping Tablets
5. How much alcohol do you drink on average per week (units per week)? 
(1 pint = 2 units; 1 measure of alcohol = 1 unit)
None 1-4 units
How many cups of tea/coffee do you drink a day?
5-14 15 or more
7. Are you a smoker/non-smoker? Yes /  No
How many cigarettes do you smoke per day?
8. On a normal day how many times do you go outside?
< 1/day 1/day
9. Would you regard you mobility as:
good fair
10 What time do you normally go to bed (h:min)?
11 How many hours per night do you sleep on average?
12 How long does it take you to fall asleep?
<10min  10-30 min
> 1/day
poor
> 30 min
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13. How often do you wake up during the night?
14 How often do you get up during the night?
15 Why do you get up during the night?
16 What time do you normally wake up (h:min)?
17 Do you go through phases of getting to sleep earlier and earlier or later and later 
each night?
18 Do you have any difficulty getting up in the morning? Y/N  
If yes, What kind of difficulty?
19 Do you fall asleep during the day? Y/N  
If yes, How often and for how long?
20 Do you feel you have any problems sleeping? Y/N
21 If yes - What kind of problems?
22 Does it occur regularly?
23 Do you do anything to try and overcome this problem?
(I.e. sleeping pills, relaxation techniques, herbal remedies, routine)
24 Are these strategies effective?
25 How long have you had this sleep problem?
< 6 months 6-12 months >12 months
26 Do you ever skip a night’s sleep?
27 Is your sleep pattern different during work free periods (e.g. holidays, weekends)?
If yes, how is it different?
28 Does your sleep pattern affect your social or occupational life? Y/N If yes, how?
If yes, in what way?
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Appendix C
Mood Test - Visual Analogue Scale (VAS)
IDENTIFICATION No: Date:
I am ecstatically 
happy
I feel extremely 
withdrawn
I am extremely 
relaxed
tense physically
I am extremely 
aggressive
I am mentally 
very dulled
I have no ability 
to concentrate
I am extremely 
wide awake
I feel absolutely 
carefree
I am absolutely 
calm
I am extremely 
energetic
With regard to carrying out general duties
I feel that I am
extremely
efficient
I am extremely 
irritable
Time:
in the depths of 
depression
extremely
sociable
absolutely
physically
extremely
passive
extremely
alert
complete ability 
to concentrate
extremely
sleepy
extremely
anxious
extremely
agitated
extremely
lethargic
absolutely
useless
not at all
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Appendix D
OSST 
Work Period Nol
Subject  Session No j  , Dot e. .   Time . . . . . . .
1 2 3 4 5 6 7 8 9 0
H n X A X *"V”* H A H K
0 8 4 6 9 3 1 2 5 9 6 1 8 7 5 3 0 2 4
2 7 0 5 1 9 8 4 6 3 5 9 4 1 3 8 0 6 7 2
5 3 7 9 8 2 6 1 4 0 2 4 3 0 5 1 6 7 9 8
6 1 9 2 4 7 5 3 0 8 4 7 0 6 1 3 2 9 8 5
-
8 5 3 7 2 0 4 9 1
CO 0 2 5 3
CO CD 7 8 4 1
1 4 6 0 3 5 2 8 7 9 1 8 2 5 9 6 4 3 0 7
,
CD 2 1 4 0 6 3 5 8 *7 6 1 9 2 4 7 8 5 3 0
3 6 2 1 5 8 7 0 9 4 3 5 8 7 0 4 1 2 6 9
4 9 5 8 7 1 0 6 3 2 8 3 7 9 2 0 5 4 1 6
7 0 8 3 6 4 9 2 5 1 7 0
CD 4 8 2 9 1 5 3
J
Note: this is only one example, symbol and number order change for each separate test
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Appendix E
INFORMED CONSENT FORM
Study Title:_______________________________________________
Participants Name:_________________________________________
Investigators: M. Herljevic, Dr. B. Middleton, Dr. D. Skene and Dr. J. Wright.
The nature of this trial and treatment have been fully explained and understood by me and a copy of 
the written explanation given to me is attached. I am aware that there could also be unforeseen risks 
and I must assume that if I suffer injury I will only receive compensation which I am entitled to receive 
under the law. In other words, I shall be in the same position I would be in if I were receiving normal 
clinical management.
I agree to participate in the trial investigating____________________________________________________.
I understand that I must inform the investigators of my involvement in any other trials or projects.
I have informed the investigators of all the medication I am taking.
I agree to allow the investigators to write to my GP requesting relevant details regarding medications 
or medical disorders that may affect the study.
I understand that all information about me will remain confidential.
I understand that I am free to withdraw from the study at anytime without explanation.
Participant’s Signature........................  Date.................
The full explanation of the trial has been given and all questions completely answered
Witness (who may be a friend witnessing a signing of this document) 
Witness Signature................................................................Date.................
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Appendix F 
PARTICIPANT INFORMATION SHEET
LIGHT SUPPRESSION OF MELATONIN IN SIGHTED, COLOUR BLIND AND BLIND SUBJECTS.
Melatonin is a natural hormone produced by the pineal gland in the brain. It is only produced in the 
dark at night and its production is immediately stopped by light perceived through the eyes. W e are 
currently investigating the effects of various wavelengths (colours) and intensities (strengthens) of 
light on the suppression of night-time melatonin levels in sighted, colour blind and blind subjects. 
Light is essential for ensuring that our internal body clock runs in parallel with the environment. This 
is achieved by the daily light/dark cycle which daily resets the internal body clock to run to a 24 hour 
day. Melatonin is thought to be an excellent reflection of the timing of the body clock because of its 
sensitivity to light.
The melatonin suppression test attempts to determine which wavelengths of light are responsible for 
the suppression of melatonin. Subjects will be exposed to different wavelengths of light at different 
intensities during times of peak melatonin production (around 02:00h) measurements of melatonin 
will be made in order to determine whether melatonin production is inhibited by this light.
The study will be conducted in the Clinical Investigation Unit at the University of Surrey Guildford and 
consists of legs .lasting 3 consecutive days. You will be asked to attend the Unit in the evening of 
each of the three study days and remain there until at least 7 a.m. The Unit has full toilet and shower 
facilities, a television, video recorder and a telephone will be available if necessary. You will need to 
bring any equipment that you need for the day (for example, personal stereo, Braille machine).
Drops of a pupil dilator will be placed into each eye by a qualified nurse at the beginning of the study. 
You should not feel any discomfort from the dilator and should not have any difficulties with vision as 
you will be asked to remain in the dark and wear eye masks as soon as the dilator has been placed 
in each eye. The effects of the dilator will have worn off by the next morning before you leave the 
Unit, so you will be able to resume any usual activity. You will be asked to remain in a sedentary 
(sitting up) or semi-recumbent (lying down at an angle) position throughout the sampling around the 
light treatment period. Blood and saliva samples will be taken every 1 5 - 6 0  minutes around the light 
treatment (Blood samples each day totalling 50 ml and 150 ml blood over the three days). The total 
amount of blood taken for the 2 legs will be 300 ml) by an indwelling cannula inserted into a forearm 
vein under local anaesthetic on the study day by a qualified nurse. Saliva samples (approximately 3 
mis) will be collected into small plastic vials. Both Plasma and saliva samples will be used to measure 
levels of melatonin.
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Light Exposure will consist of 30 minutes of light of various intensities and wavelengths. You will be 
required to keep your eyes open during the exposure and face the light source. Light levels in the 
Unit outside the exposure period will be constant dim light. To minimise effects of environmental light,
you will be asked to sleep at night in darkness (wearing masks), avoid bright light during the day and
to wear sunglasses if you go outside between 0700-1200 hours. The light exposure has been 
extensively used before both at the University of Surrey and elsewhere. Any side-effects or 
discomfort you experience MUST be reported immediately to the investigators. You will be free to 
leave the study at any time without explanation.
You MUST inform the investigators of any medication you are taking or any involvement in other trials 
or projects. W e will write to your GP to ask whether he/she considers you suitable for the study and 
to request information about medications or medical disorders that may affect the study. If your GP 
considers that you should not, for whatever reason, participate in the study, we will be obliged to 
accept this advice. Any information obtained about you will remain confidential.
You will be reimbursed for your time and inconvenience.
Contact numbers:
Mrs Mirela Herljevic (H) 020 8673 0417  
(W) 01483 259712  
Professor Debra Skene (W ) 01483 259706  
Dr Benita Middleton (W ) 01483 259712
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Appendix G
PARTICIPANT INFORMATION SHEET
MELATONIN ADMINISTRATION STUDY
This study forms part of a project to investigate sleep disturbances in both sighted and visually 
impaired adult men and women from 18-75 years of age.
Traditionally, biomedical research has used males as participants. In sleep research, only 1 in 7 
publications during the last ten years have addressed female specific sleep problems. Whilst a 
number of health problems are common to both men and women, there are specific conditions in 
female physiology that contribute to health problems. Previous studies have shown that sleep in 
healthy women is modulated during the menstrual cycle and pregnancy.
In this study we are interested in studying both men and women in their own homes to record their 
normal sleep-wake patterns and the timing of the internal body clock and to assess the effect of daily 
administration of 5.0 mg melatonin on sleep quality and timing.
To take part in this study there are specific inclusion and exclusion criteria. These are:
1. You must be aged 18-75.
2. Ideally you should not be taking any regular medications.
3. If female, you must not be pregnant.
4. You may not take part if you, or a close blood relative suffer from psychiatric disease or migraine.
5. You must not have undertaken shift-work or night-work less than 3 weeks prior to the study 
period and refrain from this during the study period.
6. You must not have travelled across more than 3 time zones less than 3 weeks prior to the study 
period and refrain from this during the study period.
7. Completion of screening questionnaires. These include a general health questionnaire, a Lark- 
Owl questionnaire which measures whether you are an extreme morning or evening type or 
neither, a general sleep questionnaire and two sleep disorders questionnaires which determine 
whether you should be considered as having a particular sleep problem or not.
8. You must give informed and written consent
9. Your GP must give approval for you to participate in the study
Study requirements
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The study involves the following procedures.
1. A continuous eight week period for study. This can be timed to suit you.
2. The study can be completed entirely in your own home and equipment can be sent to you, and 
returned to us, by post. W e will pay for all postal charges.
3. Completion of a daily sleep and nap diary, single mood assessment and lifestyle record every 
day during the 8 week study. Completed diaries to be returned to us by post.
4. Wearing of a wrist mounted activity and light monitor called an Actiwatch. This is about the size 
of a wristwatch and should be worn at all times, including during sleep. As it is not waterproof it 
must be removed when showering or bathing. The Actiwatch should be worn outside clothing as 
it measures light levels as well as movement. The Actiwatch will record data for up to 21 days so 
a replacement will be sent to you by post at 14 day intervals and you will be asked to post the 
used monitor back to us.
5. A single capsule containing either placebo (lactose filler) or 0.5-5.0 mg melatonin each night 30 
minutes before going to bed. The actual time the capsule was taken to be recorded in the sleep 
diary.
6. Collection of 4 hourly urine samples (plus an 8h overnight sample) over a 48 hour period each 
week. This must be 2 consecutive days and ideally should be the same days each week e.g. 
Monday/Tuesday. All equipment for the collection of urine samples will be provided. A sheet 
detailing the urine collection procedure and record sheet is enclosed. Please note that it is very 
important that all urine passed during the 48h period is collected in the urine container and the 
volumes measured. The timing need not be precisely as indicated on the form but a accurate 
record must be kept of the actual time period covered by each sample.
7. During the 48 hour period when urine samples are collected you will be asked to complete a 
mood scale .assessment and two simple paper based or auditory performance tests every two 
hours whilst you are awake. Taking a maximum of 5 minutes each time.
8. On one occasion you may also be requested to collect half-hourly saliva samples from 17:00h to 
bedtime whilst remaining seated in dim light. If necessary an investigator can visit you on this 
occasion to help with the saliva collection and storage.
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Please note: Melatonin is a natural hormone produced by the pineal gland. It is normally made at 
night and is considered to signal darkness to the body. It appears to serve similar functions in all life 
forms so far studied, these being to act as a time signal for the organisation of daily and annual 
rhythms.
In mammals it appears to re-enforce behaviour associated with darkness, for example sleep in 
humans. It has rapid, transient mild sleep inducing effects and lowers alertness and body 
temperature during the 3-4 hours following low doses. It is able to shift the timing of the internal "body 
clock" both to later and earlier times when administration is appropriately timed.
Melatonin can induce transient sleepiness in sensitive individuals. You are advised not to participate 
in activities that may be affected by sleepiness for 4-5 hours after taking your pill. If you, or a close 
blood relative, suffers from psychiatric disease or migraine you are advised not to take part in this 
experiment. If you wish to drink alcohol you are advised not to consume more than 2 units per day 
during the experiment.
The other possible side-effects of melatonin are headaches, nausea and dizziness). ANY side-effects 
must be recorded and reported to the researchers immediately.
All information collected will be treated with the strictest confidence and will comply with the Data 
Protection Act 1998.
If you have any queries or questions, or require further information please contact:
Mirela Herljevic (01483 689712) 
m.herlievic@surrev.ac.uk
Dr Benita Middleton (01483 689712) 
b.middleton@surrev.ac.uk
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Appendix H
PARTICIPANT INFORMATION SHEET
FOUR WEEK FIELD STUDY
This study forms part of a project funded by the European Union to investigate Sleep disorders in 
menopausal and post menopausal ageing women.
Traditionally, biomedical research has used males as participants. In sleep research, 1 in 7 
publications during the last ten years have addressed female specific sleep problems. Whilst a 
number of health problems are common to both men and women, there are specific conditions in 
female physiology that contribute to health problems. Previous studies have shown that sleep in 
healthy women is modulated during the oestrous cycle and pregnancy.
In this study we are interested in studying women in their own home to record their normal sleep- 
wake patterns and the timing of the internal body clock over a four week period. Women with and 
without sleep problems are to be included.
To take part in this study there are specific inclusion and exclusion criteria. These are:
10. You must be female.
11. You must not be receiving hormone replacement therapy or regularly taking sleeping tablets.
12. Ideally you should not be taking any regular medications.
13. You must not have undertaken shift-work or night-work during the two months prior to the study 
period.
14. You must not have travelled across more than 3 time zones in the two months prior to the study 
period.
15. Completion of screening questionnaires. These include a general health questionnaire, a Lark- 
Owl questionnaire which measures whether you are an extreme morning or evening type or 
neither and two sleep disorders questionnaires which determine whether you should be 
considered as having a sleep problem or not.
Study requirements
The study involves the following procedures.
9. A continuous four week period for study. This can be timed to suit you.
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10. The study can be completed entirely in your own home and equipment can be sent to you, and 
returned to us, by post. All postage costs incurred will be paid by us.
11. Completion of a daily sleep and nap diary every day during this 4 weeks. An example is 
enclosed. Completed diaries to be returned to us by post.
12. Wearing of a wrist mounted activity and light monitor called an Actiwatch. This is about the size 
of a wristwatch and should be worn at all times, including during sleep. As it is not waterproof it 
must be removed when showering or bathing. The Actiwatch should be worn outside clothing if 
possible as it measures light levels as well as movement. The Actiwatch will record data for up to 
21 days so a replacement will be sent to you by post after 14 days and you will be asked to post 
the initial monitor back to us. The second Actiwatch should be returned at the end of the 4 week 
study period.
13. Collection of urine samples over a 48 hour period each week. This must be 2 consecutive days 
and should be the same days each week e.g. Monday/Tuesday. All equipment for the collection 
of urine samples will be provided. A sheet detailing the urine collection procedure and record 
sheet is enclosed. Please note that it is very important that all urine passed during the 48h 
period is collected and the volumes measured. The timing need not be precisely as indicated on 
the form but a record must be kept of the actual time period covered by each sample.
14. You may also be requested to collect half-hourly saliva samples from 18:00h to bedtime on one 
occasion during the 4 week study period whilst remaining seated in dim light. If necessary an 
investigator can visit you on this occasion to help with the saliva collection and storage.
All information collected will be treated with the strictest confidence and will comply with the Data 
Protection Act 1998.
If you have any queries or questions, or require further information please contact:
Mirela Herljevic
School of Biomedical & Life Sciences 
University of Surrey 
Guildford 
Surrey GU2 7XH
Telephone: 01483 689712
Fax: 01483 689712
e-mail: m.herljevic@surrey.ac.uk
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Appendix 1
Individual melatonin suppression (%) in postmenopausal women without sleep problems following 
exposure to kmax 456 and 548 nm light.
Subjects Age PSQI
Melatonin suooression (%)
■^max 456 nm Xmax 548 nm
3.8
pW/cm2
9.8
pW/cm2
28
pW/cm2
62
pW/cm2
EULSS-08 62 1 -7.9 4.2 15.4 43.8
EULSS-34 60 1 24.3 37.8 44.8 53.6
EULSS-37 55 1 26.1 23.5 49.3 31.9
EULSS-40 54 2 -20.5 9.7 2.9 33.7
EULSS-20 64 3 -26.5 -5.9 -59.1 33.3
EULSS-32 56 3 12.2 21.3 13.8 48.9
EULSS-39 56 3 -7.0 14.7 20.1 24.0
EULSS-41 58 3 -0.7 -2.3 1.8 5.4
EULSS-01 54 4 -39.4 0.7 0.7 28.6
EULSS-22 60 4 2.6 -12.5 -58.3 2.1
EULSS-29 54 4 -48.5 -8.0 -50.0 0.0
EULSS-36 52 4 11.0 44.2 35.4 —
mean -6.2 10.6 1.4 27.8
SD 22.8 17.4 36.4 17.6
SEM 6.6 5.0 10.5 5.3
Individual melatonin suppression (%) in postmenopausal women with self reported sleep problems 
following exposure to A,max 456 and 548 nm light.
Subjects Age PSQI
Melatonin suDDression (%)
■^max 456 nm Xmax 548 nm
3.8
pW/cm2
9.8
pW/cm2
28
pW/cm2
62
pW/cm2
EULSS-23 63 6 28.0 51.7 21.1 —
EULSS-26 51 6 20.5 29.7 43.8 37.7
EULSS-31 53 6 34.1 47.4 46.2 52.5
EULSS-35 54 6 -30.0 12.5 15.5 -25.0
EULSS-38 59 8 10.4 25.0 33.9 48.1
EULSS-15 63 10 10.0 11.4 31.7 11.6
EULSS-24 54 13 4.6 10.4 19.9 25.4
EULSS-28 70 13 -5.7 -20.7 -14.7 -14.0
EULSS-21 55 15 15.5 38.9 42.5 44.2
mean 9.7 22.9 26.7 22.6
SD 19.1 22.5 19.1 29.2
SEM 6.4 7.5 6.4 10.3
—  missing sample
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Appendix J 
INFORMED CONSENT FORM
Participants Name:_________________________________________
Study Number___________________________ Identification Number________ ________
Title of Project: LIGHT SUPPRESSION OF MELATONIN IN DIABETES MELLITUS SUFFERERS. 
Name of Researchers: M. Herljevic, Dr. B. Middleton, Prof. D. Skene and Dr. J. Wright.
Please indicate your willingness to take part by ticking the boxes below.
1. I confirm that I have read and understand the information sheet for the 
above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals from the University of Surrey and the Royal Surrey County Hospital or from 
authorities where it is relevant to my taking part in research. I give permission for these 
individuals to have access to my records.
4. I agree to take part in the above study
Name of Patient Date Signature
Name of person taking consent Date Signature
(If different from researcher)
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Appendix K 
PARTICIPANTS INFORMATION SHEET
LIGHT SUPPRESSION OF MELATONIN IN SUFFERERS FROM DIABETES MELLITUS
You are being invited to take part in a research study entitled “Light Suppression of Melatonin in 
Sufferers from Diabetes Mellitus”, which lasts for only 2 nights. Before you decide whether you would 
like to participate in this study, it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and discuss it with others 
if you wish. Please ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.
1. What is the purpose of the study?
Background of the study
Melatonin is a natural hormone produced by the pineal gland in the brain. In most individuals it is 
produced during the night and its production is immediately stopped by light. Light is essential for 
ensuring that our internal body clock runs in parallel with the environment. This is achieved by the 
daily light/dark cycle, which resets the internal body clock to run to a 24 hour rhythm. Melatonin is an 
excellent reflection of the timing of the body clock and the integrity of the pathway from the eye to the 
clock and its output. In diabetic patients some of these routes can be impaired.
Short wavelength light (blue) is most effective in suppressing melatonin. Changes in the lens 
density of the eye can alter the amount of short wavelength light reaching the body clock as 
we have recently shown in older people. As a consequence the resetting of the internal body 
clock may be affected which could influence the circadian rhythms of glucose metabolism, 
hormones and possibly the sleep\wake cycle. It is well known that changes in the lens density 
are not only seen as people get older but are also a feature of diabetes mellitus. The lens 
density of diabetes mellitus sufferers increases at the same rate as in older people (> 60 yrs). 
However, it is not yet known whether these changes in the eye of diabetes mellitus sufferers 
have an effect on the internal body clock.
Aim of the study
The aim of this study is to investigate the ability of light of different wavelengths to suppress 
night time melatonin levels in type 1 (insulin dependent) diabetes mellitus sufferers.
2. Why have I been chosen?
You have been chosen because you are over 18 and under 35 years of age and have been 
suffering from type 1 diabetes mellitus for at least ten years.
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In order to take part you have to fulfil and number of conditions:
•  You will need to give us informed written and oral consent after the study has been fully 
explained to you.,
•  You will need to give us permission to contact your GP so that they can give their 
agreement for you to take part.,
•  Pre-study questionnaires must be completed,
•  We must be able to measure a rhythm in aMT6s (major melatonin metabolite in urine),
•  You must be willing to refrain from alcohol and caffeine consumption 24 h before the 
study and during the study,
•  You must be willing to avoid heavy exercise and bright light for 24 h before and during 
the study.
•  You will need to keep a regular sleep-wake cycle (23:00h-07:00h) for three days before 
coming to the laboratory. You will be asked to complete a daily sleep/nap diary and wear 
an activity and light monitor called an ActiwatchL (AWL).
You will not be able to take part if:
•  You have a history of psychiatric, neurological or cardiovascular disease,
•  You suffer from drug or alcohol abuse,
•  You are taking any drugs that affect the melatonin rhythm
■ Antihypertensive drugs, non-steroidal anti-inflammatory drugs, 
hypnotics, benzodiazepines, antidepressants, barbiturates or 
antiepileptic drug,
•  You have given over 400 mis of blood within 4 months of the study,
•  You are working night shifts or have travelled across more than 2 time zones in the 3 
weeks before the study,
•  If you are already taking part in another research programme.
In total, 15 individuals suffering from type 1 diabetes mellitus and 15 age and gender matched 
controls (not suffering from diabetes mellitus) will be studied.
3. Do I have to take part?
No you do not have to take part. It is up to you to decide whether or not you wish to take part should 
you satisfy all our criteria. If you decide to take part you will be given a copy of this information sheet 
to keep and be asked to sign a consent form. Should you be willing to take part you are still free to 
withdraw at any time and without giving a reason. Should you decide not to join the study or 
withdraw at any time this will not affect the standard of care you receive.
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4. What will happen to me if I take part?
Before you are accepted to take part in the study you will need to:
•  Complete 1 general health questionnaire and 4 sleep related questionnaires,
• Collect urine samples over a 48 h period to allow us to measure your melatonin rhythm,
• Have a complete ophthalmological examination,
• Sign an informed consent form.
•  Allow us to contact your GP to ensure he/she has no reservations about you taking part on health 
grounds.
The Study
Before taking part in the laboratory based part of the study you will need to:
•  W ear an Actiwatch, which will record your activity and light levels (3 days before the study and 
throughout the study)
• Complete daily sleep/nap diaries (3 days before the study and through the study)
The study will be conducted in the Clinical Investigation Unit at the University of Surrey Guildford 
lasting 2 consecutive nights. You will be asked to attend the Unit from 17:00 h of each of 2 study 
days and remain there until at least 8 a.m. The Unit has full toilet and shower facilities, a television, 
video recorder and a telephone will be available should you need it. You may bring any personal 
items you need during the study (for example, personal stereo, lap top computer).
A drop of a pupil dilator will be placed into each eye by a qualified nurse each evening at the 
beginning of the study period. You should not feel any discomfort from the dilator and should not 
have any difficulties with vision as you will be asked to remain in the dark and wear eye masks as 
soon as the dilator has been administered. The effects of the dilator will wear off by the next morning 
before you leave the Unit, so you will be able to resume your usual activities. You will be asked to 
remain in a semi-recumbent (lying down at an angle) position throughout the sampling around the 
light treatment period. Blood and saliva samples will be taken every 1 5 - 6 0  minutes during the night 
(Each blood sample is 5 mis and in total 280 mis will be taken during the study). The total amount of 
blood taken is much less than a blood donating. Blood will be sampled via an indwelling cannula 
inserted into a forearm vein under local anaesthetic on each study day by a qualified nurse. Saliva 
samples (approximately 3 mis) will be collected into small plastic vials at the same time as the blood 
samples. Both plasma and saliva samples will be used to measure levels of melatonin.
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Light exposure will consist of 30 minutes of light on one night only. You will be required to keep your 
eyes open during the light exposure and face the light source. Light levels in the Unit outside the 
exposure period will be constant dim light (< 5lux). To minimise the effects of environmental light, you 
will be asked to sleep at night in darkness (wearing masks), avoid bright light during the day and to 
wear sunglasses if you go outside between 0700-1200 hours. The light exposure has been 
extensively used before both at the University of Surrey and elsewhere. Any side-effects or 
discomfort you experience MUST be reported immediately to the investigators.
5. What are possible disadvantages for taking part?
Some minor discomfort may be experienced due to blood collection and staying awak. During this 
period you will stay in a comfortable semi-recumbent position reclining on a bed. You will not be 
allowed to eat between 23:00h and the end of sample collection. There will be constant medical and 
nursing supervision throughout the time spent in the Clinical Investigation Unit. If required transport 
will be provided in the mornings.
6. What are the possible benefits of taking part?
Participation in this study will not benefit you as an individual directly. However, your participation will 
help us to understand circadian control in conditions such as diabetes mellitus.
7. What if something goes wrong?
The University of Surrey holds insurance policies (liability and no-fault), which cover involvement in 
clinical trials. The no-fault cover is intended to provide compensation to participants in the study in 
the event of their suffering a significant and enduring injury, which on the balance of probabilities is 
directly attributed to their involvement in the study.
8. Will my taking part in the study be kept confidential?
If you consent to take part in the research, those carrying out the study may inspect your medical 
records but all the information found will be strictly confidential. W e will write to your GP to ask 
whether he/she considers you suitable for the study and to request information about medication or 
medical disorders that may affect the study. If your GP considers that you should not, for whatever 
reason, participate in the study, we will be obliged to accept this advice. Each person taking part will 
be given a unique identification number and all samples/data collected will be stored under that 
number only. All information will be kept according to the Data Protection Act 1998.
9. What will happen to the results of the research study?
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It is anticipated that the results will be published in a relevant scientific journal within 2 years. If you 
wish you can obtain a copy of the results in due course. You will not be identified in any report or 
publication.
10. Will I be compensated for taking part in this study?
Yes, you will be fully compensated for your time and inconvenience by receiving £200 for completing 
2 days of the study.
11. Who has reviewed this study?
Ethical approval for the study has been granted by the South West Surrey Local Research Ethics 
Committee (LREC) and University of Surrey Ethics Committee.
12. Contact for further information:
Mrs Mireia Herljevic (W ) 01483 683341 m.herljevic@surrey.ac.uk 
Professor Debra Skene (W ) 01483 689706
Dr Benita Middleton (W ) 01483 689712
